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Abstract 
Innate and adaptive immunity are regulated by complex signalling pathways that 
require the assembly and activation of apoptotic and inflammatory signalling 
complexes, which ultimately induce gene expression and alter cellular behaviour. Key 
players in regulating the assembly of many of these signalling complexes are 
CARD-containing proteins that are members of the death domain superfamily. 
However, the molecular mechanisms that underline the function and regulation of 
CARDs remain unclear. 
 This project was aimed to investigate the biochemical and biophysical 
characteristics of CARD-CARD interactions to gain insights into the binding specificity 
and/or stoichiometry of CARD-mediated protein complexes and specifically, to 
elucidate if there is a common mode of interaction within this protein subfamily. 
 It was known that CARDs have a tendency to aggregate when purified 
individually, therefore all human CARDs were prepared for small scale expression and 
solubility screening with the aim to perform co-expression and pull-down studies. 
These screens identified the highly soluble, yet structurally and biophysically 
uncharacterised CARMA1-CARD. Consequently, one focus was set on the signalling 
complexes involving CARMA1 and CARD9, both of which bind BCL10 via CARD-CARD 
interactions.  
 Preliminary work had been performed in the group focusing on NOD2 and RIP2, 
therefore, these two proteins were taken as a second system for further investigations 
with the aim to describe the intramolecular interaction between the tandem CARDs of 
NOD2 and its intermolecular interaction with the CARD of RIP2 in molecular detail. 
Further insights into the binding surfaces involved in these interactions were gained 
using mutagenesis combined with biophysical assays. 
 To follow up on the newest development in the field concerning CARDs forming 
filamentous assemblies, this work tested both, RIP2- and BCL10-CARD for their ability 
to polymerise using fluorescence polymerisation assays. However, no polymerisation 
could be detected in this work, questioning the relevance of filament formation as a 
general behaviour of CARDs. 
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1.1 The immune system - Innate and adaptive immunity 
Multicellular organisms are living in an environment surrounded by a high number of 
potentially harmful pathogens, such as bacteria, viruses, fungi and parasites. The first 
line of defence against invading microbial pathogens is the innate immune response; 
an evolutionary conserved mechanism shared by all multicellular organisms to rapidly 
initiate a host defence response within minutes. A secondary line of defence, a system 
developed just by vertebrates, is the adaptive immune response. The response is more 
delayed, but includes the benefit of an immunological memory to enable a faster 
secondary response in the future [1]. 
 The innate immune response relies on a limited number of germline-encoded 
pattern-recognition receptors (PRRs) that belong to several distinct protein families. 
PRRs detect pathogen-associated molecular patterns (PAMPs). PAMPs are conserved 
products of microbial metabolism, which are essential for the survival of the 
microorganism, including viral nucleic acids, components of bacterial and fungal cell 
walls or flagellar proteins [2, 3]. 
 Adaptive immune responses are carried out by two different classes of 
lymphocytes called B-cells and T-cells. Molecules capable of mounting an adaptive 
immune response are collectively called antibody generators, or simply antigens. The 
great diversity of receptor variants is generated by mechanisms involving 
rearrangement of receptor gene segments. Unlike the PRRs in the innate immune 
system, which detect molecular patterns, antigen-receptor binding involves 
recognition of specific features of biological molecules [1, 4]. 
 Signal transduction plays a major role in both the innate and the adaptive 
immune system. The following sections will mainly focus on the innate immune system 
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with its PRR protein families followed by their downstream signalling pathways. An 
overview of selected pathways, which are relevant to this work can, be found in 
Figure 1-1. Signalling pathways relevant to acquired immunity will be briefly described 
and will focus mainly on the CARMA1-BCL10-MALT1 complex in lymphocytes.  
 
1.2 Transmembrane pattern recognition receptors 
Transmembrane PPRs enable signal transduction from the extracellular matrix to the 
cytoplasm for the activation of intracellular signalling pathways [5]. Transmembrane 
PRRs of innate immunity are foremost represented by the Toll-like receptors (TLRs) 
and the C-type-lectin receptors (CLRs). The following sections will concentrate on 
those signalling pathways that are important for the understanding of this thesis.   
 
1.2.1 Toll-like receptors 
Toll-like receptors are a family of evolutionarily conserved receptors that have a crucial 
role in early host defence against invading pathogens. The first TLR in human was 
reported in 1994 by Nomura et al. [6]. Since then, 10 TLRs have been identified which 
has driven forward the research of innate immunity. TLR members are type I 
transmembrane glycoproteins either expressed on the cell surface (TLR 1, 2, 4, 5, 6 and 
10) or endosomal/lysosomal cell compartments (TLR 3, 7, 8 and 9) with molecular 
weights ranging between 90-115 kilodalton (kDa) [7]. 
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Figure 1-1 Overview of innate immune signalling pathways.  Shown are the basic mechanisms 
after the activation of several signalling pathways of the innate immune system, divided into 
their pattern recognition receptor families. Details are provided in the text. Figure based on Yin 
et al. 2015, Kersse et al. 2011 and Ruland et al. 2008 [8-10]. 
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TLRs are characterised by extracellular domains containing leucine-rich-repeat (LRR) 
motifs, thought to be directly involved in ligand binding, followed by a single, 
membrane-spanning α-helix and a cytoplasmic signalling domain called Toll/IL-1R 
homology (TIR) domain. The TIR domain is essential for the recruitment of 
downstream signalling molecules, ultimately leading to the induction of genes involved 
in the antimicrobial host defence response i.e. the production of inflammatory 
mediators [7]. 
 
1.2.1.1 TLR signalling pathways 
Although LRRs are highly conserved, the human TLRs recognise a wide variety of 
PAMPs including viral nucleic acids and various types of bacterial and fungal ligands. 
Interestingly, individual TLRs interact with several structurally unrelated ligands such 
as lipopolysaccharides, RNA or proteins [11].  Upon ligand binding, TLRs are believed to 
dimerise and undergo conformational changes [12]. These conformational changes 
may affect the cytoplasmic TIR domain, required to recruit downstream signalling 
molecules with other TIR domains (primarily MyD88, MAL, TRIF and TRAM). The use of 
these adapter molecules varies between TLRs, which results in different signalling 
outcomes depending on the specific TLR activated. All TLRs except TLR3 recruit 
myeloid differentiation primary-response protein 88 (MyD88), which has an N-terminal 
death domain (DD), and a C-terminal TIR domain only separated by a short linker. 
MyD88 exists as homodimers in solution, where dimerisation is mediated by its death 
domain [13]. Ligand-induces dimerisation of TLRs leads to the recruitment of MyD88 to 
the receptors through homotypic TIR-TIR interactions. Although structures of both 
receptor and adaptor TIR domains are available (example protein data bank (PDB) 
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code: 2Z5V [14], 2J67 [15]), there is currently no structure of a 
TIR(receptor)-TIR(adaptor) complex, possibly due to difficulty in obtaining stable 
complexes in solution [16]. On the other hand, there is structural insight available into 
the recruitment of the downstream effector domain IL-1R-associated kinase (IRAK) by 
the dimeric MyD88 via DD-DD interactions [17] (Figure 1-2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-2 Model showing the TLR induced assembly of the MyDDosome. Ligand-induced 
dimerisation of TLRs leads to the recruitment of MyD88 (coloured as red or orange): 
Intracellular TLR-TIR domains (dark-red) form homotypic interactions with MyD88-TIRs. MyD88 
linkers are shown as dashed lines. MyD88-DDs interacting with each other to recruit DDs of 
IRAK4 and IRAK1 or IRAK2 (pink and violet) for the assembly of a signalosome called 
MyDDosome. The MyDDosome interacts with TRAF6, an L-shaped E3-ligase, which can form a 
two dimensional lattice by forming dimers and trimers.  TRAF6 enables the recruitment and 
activation of IKK and therefore the activation of NF-κB. Figure reprinted from Berke et al. 2013 
[18] with permission from  John Wiley & Sons Inc. 
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IRAKs contain an N-terminal DD and a central serine/threonine-kinase domain. The 
crystal structure of a MyD88–IRAK4–IRAK2 death domain complex revealed an 
arrangement of six MyD88-DDs and four IRAK4-DD as well as four IRAK2-DDs into a 
left-handed helical tower. IRAKs phosphorylate and activate downstream substrates 
leading to the activation of NF-κB. This MyD88–IRAK signalling platform was later 
named ‘the MyDDosome’. More structural details about the MyDDosome assembly 
will be provided in section 1.6.2.1. 
 DDs are members of the death domain superfamily, which includes death 
effector domains (DED), caspase recruitment domains (CARDs) and pyrin domains 
(PYDs). Effector domains in innate immune signalling are often members of this family.  
This protein superfamily will be explained in more details in section 1.6.  
 
1.2.2 C-type lectin receptors 
Other transmembrane PRRs are members of the C-type lectin receptors. The C-type 
lectins are the largest and most diverse of glycan binding receptors. Sugars are 
recognised by CLRs through their carbohydrate-recognition domain (CRD) in which 
ligand binding occurs in a Ca2+-dependent manner [19]. Fungal PAMPs consist primarily 
of cell wall carbohydrate structures, therefore, CLRs are mostly known for their role in 
anti-fungal immunity [20]. For the purpose of this thesis, I will mainly focus on the 
signalling pathway of Dectin-1, a type II transmembrane enzyme that is expressed in 
myeloid cells including macrophages, dendritic cells and neutrophils [21].  
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1.2.2.1 Dectin-1 signalling pathway 
The ectodomain of Dectin-1 recognises β1-3 and β1-6 linked β-glucans, which are 
categorised as fungal PAMPs [22]. Fungal recognition by Dectin-1 triggers phagocytosis 
and - more relevant here - it also induces signals mediated by CARD-containing 
proteins for the production of cytokines and chemokines as well as the activation of 
antigen presenting cells [10, 23]. Upon ligand binding, signalling is induced through 
tyrosine phosphorylation of the tyrosine-based activation motif (ITAM; YxxL) located 
within the cytoplasmic tail of these receptors. This is followed by the recruitment and 
activation of SYK kinase via its phosphotyrosine specific SH2 domain. This leads to the 
formation of a trimolecular complex composed of CARD9, BCL10, and MALT1, which 
will be referred from now on as the CBM-M complex, where ‘-M’ stands for myeloid. 
The CBM-M complex ultimately leads to NF-κB activation [10]. 
 
Role of CARD9 in the CBM-M signalling pathway 
CARD9 is an adaptor protein containing an N-terminal CARD followed by a long 
coiled-coil domain, which functions as an oligomerisation domain. CARD9 plays a 
crucial role in the Dectin-1 signalling pathway to link signals from the ITAM receptor to 
the canonical NF-κB pathway. CARD9 recruits the downstream adaptor protein B cell 
lymphoma 10 (BCL10) via a homotypic CARD-CARD interaction [24]. BCL10 is a 233 
amino acid long protein containing an N-terminal CARD and a Ser/Thr-rich C-terminus 
of unknown function. The CARD9-BCL10 complex associates with the paracaspase 
MALT1 to complete the CBM signalosome [25]. An overview of the functional domains 
and known interactions is given in Figure 1-3. It has recently been shown that protein 
kinase C δ (PKCδ) is responsible for the phosphorylation of CARD9 at Thr231, a residue 
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located in the coiled-coil domain [26]. This phosphorylation was proven to be crucial to 
allow CARD9-BCL10 complex assembly. It is known, that the CMB-M is required for the 
activation of transforming-growth-factor-β-activated kinase 1 (TAK1) [26]. However, 
the molecular details of the signalosome activation remain unclear, as does the 
question of how exactly the CBM-M complex transduces signals to downstream 
effector molecules including TAK1, which finally leads to NF-κB activation [10]. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-3 The functional domains of CARD9, BCL10 and MALT1. 1: In 2000, Bertin et al. 
showed via mammalian two-hybrid and co-immunoprecipitation assays that CARD9 associates 
with BCL10 through its CARD motif [24]. 2: In 2001, studies of Lucas et al. showed that MALT1 
binds to BCL10 through its immunoglobulin domains [25]. CARD: caspase recruitment domain, 
DD: death domain, S/T -rich: Serine/Threonine rich region, Ig: immunoglobulin-like domain. 
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The role of CARD9 in this conserved CLR-triggered pathway has been shown to be 
essential in host protection. Patients who showed a point mutation from C to T in exon 
6 at codon 295, resulting in a premature termination codon (Q295X) showed 
proneness to fungal infections as evidenced by chronic mucocutaneous candidiasis. In 
vitro reconstitution using CARD9 -/- cells suggested that the truncated CARD9 Q295X is 
a loss of function mutation as it failed to correct signalling defect observed in the 
CARD9 knock-out cells [27]. Further roles of CARD9 will be described in section 1.3.1 
and 1.3.2. 
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1.3 Intracellular pattern recognition receptors 
Once infectious agents have successfully invaded the cytosol, there are two families of 
cytoplasmic PRRs to detect pathogens and activate an innate immune response - the 
retinoic-acid-inducible gene-I (RIG-I)-like receptors (RLRs) and the NOD-like receptors 
(NLRs). RLRs recognise viral PAMPs such as dsRNA and NLRs can detect bacterial and 
endogenous ligands [28]. Recent structural insights into ligand detection and signal 
transduction revealed that intracellular PRRs assemble into multimeric protein 
complexes with their signalling adaptors upon ligand binding, as is the case for the 
transmembrane PRRs, which promotes recruitment of effector proteins and ultimately 
leads to inflammatory responses, principally through NF-κB activation, type 1 
interferons or Caspase-1 [8]. 
 
1.3.1 RIG-I like receptor signalling pathway 
Members of the RLR family detect viral RNA present in the cytoplasm and initiate 
anti-viral immune responses [29]. The RLRs belong to the RNA helicase family and 
consist of only three members: retinoic acid inducible gene-I (RIG-I), melanoma 
differentiation gene-5 (MDA5) and laboratory of genetics and physiology-2 (LGP2) [30]. 
The proteins contain a central RNA helicase domain (DExD/H-box helicase), which is 
flanked by a so-called C-terminal domain (CTD), while on their N-terminus, RIG-I and 
MDA5 contain tandem CARDs. It has been shown in vitro that RIG-I recognises short 
double stranded RNA (dsRNA) as well as single stranded RNA (ssRNA) with 
5’-triphosphatate (5’-ppp) [31, 32]. Crystal structures revealed that RIG-I adopts an 
inactive state in absence of viral RNA, with its two CARDs interacting with the helicase 
domain [33]. RNA and ATP (adenosine triphosphate) binding induces a conformational 
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change to the helicase and CTD domain, which causes its two CARDs to disengage 
(Figure 1-4) [34, 35]. In the signalling pathway of RIG-I, both covalently attached and 
unanchored poly-ubiquitin chains were shown to play important roles: Back in 2007, 
Gack et al. [36] demonstrated via in vivo pull-down experiments and immunoblotting 
that the RIG-I tandem CARDs become ubiquitinated. They further identified the E3 
ligase TRIM25 to interact with the N-terminal CARDs of RIG-I and catalyse their 
modification with Lys 63-linked ubiquitin chains, a process important for signalling 
activity. Subsequent studies indicated the importance of unanchored ubiquitin chains 
in RIG-I activation: The tandem CARDs of RIG-I assemble into a helical tetramer in 
complex with uncovalently bound Lys 63-linked di-ubiquitin molecules [37, 38]. 
 
 
 
 
Figure 1-4 Structural model of the auto-inhibited and activated dsRNA-bound states of duck 
RIG-I (dRIG-I). Left: Model of the auto-inhibited dRIG-I with the tandem CARDs (grey), helicase 
domain (blue) and the flexible CTD (purple) (PDB: 4A2Q). Right: A model of the activated dRIG-I 
bound to dsRNA (orange) as well as the ATP transition state analogue ADP-AlF3 (red) 
(PDB: 4A36, 4A2X) with the tandem CARDs attached to a flexible linker but disengaged from 
the helicase domain.  Figure based on Kowalinski et al. (2011) [33] and redrawn in PyMOL. 
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Following RIG-I activation, it is proposed that the RIG-I assembly nucleates the 
oligomerisation of the adaptor protein mitochondrial antiviral-signalling protein 
(MAVS, also called IPS-I) to promote formation of its active form. This nucleation leads 
to the polymerisation of MAVS-CARDs to form helical filaments similar to the death 
domains of MyD88 [39]. Interestingly, MAVS, which is located on the mitochondrial 
and peroxisomal membranes, was associated with self-propagating, prion-like 
properties to amplify signalling, drawing inactive monomers into functional aggregates 
[40]. In summary, the current model of RIG-I signalling as indicated in Figure 1-1 
involves the oligomeric assembly of RIG-I upon RNA and ubiquitin binding / 
ubiquitination to initiate the oligomerisation and activation of MAVS. RLR signalling 
through MAVS oligomerisation ultimately leads to NF-κB and IRF3 (Interferon 
regulatory factor 3) activation, inducing type-1 interferon production and other 
antiviral functions. More structural insights are given in section 1.6.5.2. 
In contrast, comparison of the structures of MDA5 and RIG-I indicate significant 
differences in their conformations: MDA5, unlike RIG-I, doesn’t seem to take on an 
auto-inhibited state in which the tandem CARDs are interacting with the helicase 
domain. Additionally, MDA5 has been shown to favour the binding of longer dsRNA 
(> 1 kbp) and to cooperatively assemble into ATP sensitive filaments on dsRNA [41, 42]. 
The MDA5-CTD was suggested to be required for cooperative filament formation 
rather than dsRNA binding [42]. This was further underlined with an EM study showing 
MDA5 forming a helical filament bound to dsRNA with the CTD forming contacts to 
adjacent MDA5 molecules [43]. An independent study showed similar results where 
the MDA5/dsRNA model was built using a 1:1 MDA5/dsRNA crystal structure and 
cross-linking experiments [44]. Rig-I has been also shown to assemble into helical 
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filaments and the current model suggests that RIG-I and MDA5 filament formation on 
dsRNA brings their CARDs into proximity to nucleate MAVS filament formation to 
initiate downstream signalling in an ubiquitin independent manner [42, 45].  
 
1.3.2 NOD-like receptor signalling pathways 
The NLR family contains 23 members in humans and is also known as NACHT-LRR, 
NOD-LRR or Caterpiller, all names which refer to the domains present in this family: 
Proteins of the NLR family are characterised by a tripartite domain structure. Similar to 
the TLRs, NLRs have a C-terminal receptor domain, which consists of a variable number 
of LRR motifs. Adjacent to this, NLRs have a nucleotide binding and ligand induced 
oligomerisation domain termed either NACHT (NAIP, CIITA, HET-E and TP1) or 
nucleotide-binding oligomerisation domain (NOD). Additionally, NLR family members 
have an N-terminal effector-binding domain, which is in most cases a member of the 
death domain superfamily that recruit and activate downstream effector molecules for 
signal transduction. NLRs are divided into the following subgroups according to their 
N-terminal domain: NLRA [A=acidic activation domain], NLRB; also called NAIP 
[B=baculovirus inhibitor of apoptosis repeat (BIR)], NLRC [C=Caspase recruiting 
domain] and NRLP [P=Pyrin domain] [46]. 
 The ligand-induced oligomerisation of NLRs is followed by the recruitment of 
effector proteins to form large signalling assemblies that rely on homotypic 
interactions between members of the death domain family (Figure 1-5). Nowadays, 
NLRs are mostly known for their ability to initiate the formation of inflammasomes, 
supramolecular assemblies that mediate the activation of Caspase-1, which promotes 
maturation and secretion of the proinflammatory cytokines interleukin 1β (IL-1β) and 
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IL-18. The protein ‘apoptosis-associated speck-like protein containing a CARD’ (ASC) 
contains an N-terminal pyrin domain followed by a CARD and serves as the adaptor 
protein to bridge caspase recruitment to selected inflammasomes. Inflammasomes 
form in cells after sensing a diverse range of microbial, stress and damage signals. It is 
important that inflammasomes are tightly regulated as malfunctions can be linked to 
auto-inflammatory diseases (e.g. ulcerative colitis), Alzheimer’s disease and Crohn’s 
disease [47-49]. Therefore, regulation is complex and occurs at transcriptional and 
post-transcriptional levels.  
 
 
Figure 1-5 Examples of activating platforms. Shown are examples of signalling platforms with 
receptors of the NLR family and – for comparison – APAF1 from the wider nucleotide-
oligomerisation domain (NOD) family. Proteins are divided into their role of sensors/receptors, 
adaptors or effectors. Figure based on Martinon et al. 2004 and Rathinam et al. 2012 [50, 51]. 
APAF1; Apoptotic protease-activating factor 1, NOD2; Nucleotide-binding oligomerization 
domain-containing protein 2, LRR; leucine-rich repeat, WD40; beta-transducin repeat, CARD; 
caspase-recruitment domain, PYD; pyrin domain, NACHT; NAIP/CIITA/HET-E/TP1 domain, ROS; 
reactive oxygen species, MDP; MurNAc-L-Ala-d-isoGln (peptidoglycan), Flagellin-NAIP; bacterial 
flagellin bound to baculoviral IAP repeat-containing protein 1 (NAIP). 
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1.3.2.1 The apoptosome 
In the literature, NLRs are sometimes referred to as members of the wider NOD family. 
Another important member of the NOD family is the apoptotic protease activating 
factor 1 (APAF1). The main difference between NLRs and APAF1 is the type of ligand 
binding domain: whereas NLR proteins contain LRRs, APAF1 has WD-40 repeats 
(Figure 1-5). WD-40 is a structural motif of approximately 40 amino acids, often 
terminating in a tryptophan/aspartic acid (W-D) [52]. APAF1 exists in solution as an 
inactive monomer in which the WD-40 repeats are folded back onto the NOD thereby 
supressing oligomerisation [53]. In presence of cytochrome c and ATP, APAF1 
undergoes oligomerisation via its nucleotide binding domain. The EM structure of 
APAF1 bound to cytochrome c shows a heptameric disc, the so-called apoptosome 
(Figure 1-6) [54, 55].  
 
 
 
 
 
 
 
 
Figure 1-6 A structural insight into the apoptosome. The apoptosome is a multiprotein 
complex formed by APAF1 upon cytochrome c binding. In the shown cryo EM structure, the 
different APAF-1 molecules are highlighted  in various colours and are lacking the CARD. 
WD-40 repeats of APAF1 bind to cytochrome c (red). In presence of ATP, the APAF-1-
cytochrome-c complex forms a heptameric hub via it’s nucleotide oligomerisation domain 
(NOD). This Figure was prepared in PyMOL using PDB 3J3B. 
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The goal of APAF1 assembly is to form a platform that can recruit and activate the 
downstream effector Procaspase-9 to further activate caspases which ultimately 
mediate apoptosis. In the current model, APAF1 recruits Procaspase-9 via CARD-CARD 
interactions by assembling a ring-like CARD-platform. However, the precise mechanism 
is still unknown as the EM analysis only shows a low resolution disk sitting on the 
central heptameric APAF1 hub containing the APAF-1 and Procaspase-9 CARDs [54]. 
With no further structural insights, it is still under debate if activation of Procaspase-9 
depends on the formation of a CARD-CARD disk. 
 
1.3.2.2 The NLRP3 inflammasome 
Out of the 23 human NLRs, six have been reported to assemble into inflammasomes: 
(NLRP1 [56], NLRP3 [57, 58], NLRP6 [48], NLRP7 [59], NLRP12 [60]and the NAIP/NLRC4 
complex [61]). The NLRP3 inflammasome is the best-studied family member and for 
this reason, signalling via NLRP3 will be discussed in more detail (Figure 1-1). NLRP3 is 
activated by a wide range of stimuli from bacterial, viral, and fungal pathogens, as well 
as by endogenous danger signals indicating tissue damage (e.g. extracellular ATP, 
amyloid-β fibrils and uric acid crystals). However, with such a wide range of agents, it is 
believed that the interactions between the activators and the receptor are not direct 
[47]. Originally, the assembly model of NLRs was based on the heptameric hub formed 
by APAF1 (as seen in Figure 1-6), due to its similar domain organisation. Therefore, EM 
images of negatively stained specimens of NLRP1 revealing a low-resolution structure 
with a ring-like organisation were not surprising [56].  
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In addition to the initial receptor assembly of inflammasomes, in the last two years, 
more insight could be gained on ternary inflammasome complexes. In the NLRC3 
pathway, it has been suggested, that there is a two-step nucleation-polymerisation 
mechanism: As shown in Figure 1-5, ASC is bridging NLRP3 and Caspase-1 by forming 
homotypic PYD-PYD with NLRP3 and CARD-CARD interactions with Capsase-1. Via EM 
and fluorescence polymerisation assays, it was shown that a sub-stoichiometric 
amount of NLRP3 nucleates ASC-PYD filament formation, which then further forms a 
platform for Caspase-1-CARD filaments. This leads to proximity driven dimerisation of 
Capsase-1, thereby inducing allosteric changes necessary for Caspase-1 auto-cleavage 
and activation. This allows Caspase-1 to process cytokine substrates pro-interleukin 
(IL)–1β and pro–IL-18 [62]. Regulation of these cytokines is essential, whereas for 
example low concentration of IL-1β is needed in local inflammation, higher 
concentrations can lead to fever and raised blood pressure and can in some cases be 
lethal [63]. 
 
1.3.2.3 The NOD2-RIP2 signalling pathway 
NOD1 and NOD2 
The first two NLRs identified were the nucleotide-binding and oligomerization-domain 
containing 1 and 2 (NOD1, NOD2) members of the NLRC subgroup [64]. Like the other 
NLRs described so far, NOD1 and NOD2 contain a tripartite domain structure with a 
C-terminal leucine-rich repeat (LRR) domain, a central NACHT domain and an 
N-terminal effector domain. Whereas this N-terminal effector region of NOD1 consists 
of one CARD motif, NOD2 contains two CARDs, referred to as tandem CARDs. Their LRR 
motif recognises fragments of bacterial peptidoglycan, more specifically, NOD1 
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recognises γ-d-glutamyl-meso-diaminopimelic acid (ieDAP) and NOD2 
MurNAc L-Ala-d-isoGln (MDP) [65, 66]. Recent in vitro biochemical and biophysical 
studies have shown that the interaction with MDP happens in a direct fashion by 
immunoprecipitation and surface plasmon resonance assays [67, 68]. Similar to other 
NLRs, NOD1 and NOD2 undergo ligand-induced oligomerisation through their NACHT 
domains, which subsequently leads to the recruitment of receptor-interaction protein 
kinase 2 (RIP2) through CARD-CARD interactions [69].  
 
RIP2 
RIP2 is a 61 kDa serine/threonine kinase consisting of an N-terminal kinase domain and 
a C-terminal CARD (Figure 1-5). Serine/threonine kinases together with tyrosine 
kinases constitute one of the largest protein families in eukaryotes and 
phosphorylation is the most common post-translational modification in signal 
transduction [70]. Structural information on RIP2 is currently only available for the 
kinase domain in complex with an inhibitor (PDB: 4C8B) [71]. RIP2 mediates the 
activation of the NF-κB [72, 73] and MAPK (mitogen-activated protein kinase) 
pathways [74] downstream of NOD1/NOD2.  
 
Signalling pathway mediated by NOD2 and RIP2 
There is currently no structural information available for activated forms of NOD2. 
Considering the similarity of the NOD2 domain structure with APAF1 and other NLRs, 
there is the possibility NOD2 may also form a disk-like hub as seen for the 
apoptosome. Another point of debate is whether both NOD2-CARDs are necessary for 
RIP2 recruitment. Studies available are contradictory and will be further discusses in 
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Chapter 6. Once the NOD2-RIP2 complex is formed, RIP2 becomes poly-ubiquitinated, 
currently assumed by the E3 ligase Pellino3 [75], to allow the recruitment of kinase 
TAK1 to the RIP2 kinase domain [76]. Signalling via NOD2 and RIP2 ultimately leads to 
NF-κB activation to enhance transcription of inflammatory cytokines.  
 
Regulation of NOD2 via CARD9 and association with Crohn's disease 
It was discovered that invasion of epithelial cells by pathogenic bacteria responded not 
only with the activation of the transcription factor NF-κB but also with the initiation of 
different MAPK pathways [77]. In 2007, Hsu et al. reported that this parallel pathway 
downstream of NOD2 is regulated by CARD9 (Figure 1-7) [78]. This is particularly 
interesting, because the genes for both of these proteins contain polymorphisms 
enhancing susceptibility to the inflammatory bowel condition Crohn’s Disease in 
humans [79]. It was believed that CARD9 can form a tripartite complex with RIP2 and 
NOD2 via its CARD, which activates the JNK (C-jun N-terminal kinase) and p38 
signalling pathways. These pathways upregulate expression of proinflammatory 
cytokines important for mounting appropriate immune responses. However, a recent 
biochemical and biophysical analysis showed that the interaction between NOD2 and 
CARD9 is mediated by two interaction sites in NOD2 outside the CARDs; one in the 
CARD-NACHT linker and one in the NACHT itself [80].  
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Figure 1-7 The parallel downstream pathways of NOD2 signalling. Whereas RIP2 is crucial for 
the activation of NF-κB signalling pathway, it is CARD9 which regulates the NOD2 induced 
activation of kinases p38 and JNK upon MDP recognition. LRR: Leucine-rich repeat, CC: coiled-
coil, JNK: C-jun N-terminal kinase, MDP: MurNAc L-Ala-d-isoGln. Figure adapted from Roth and 
Ruland (2013) [81]. 
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1.4 Activation of transcription factors NF-κB and IRF3/IRF7 
1.4.1 Nuclear factor-kappaB (NF-κB) - the canonical pathway 
NF-κB is a transcription factor that forms either homo- or heterodimers. Subunits are 
members of the Rel-family, a family of structurally-related eukaryotic transcription 
factors. Mammalian NF-κB includes five members; p50, p52, RelA, RelB, and c-Rel, 
which mediate activation of a large number of target genes by binding to an enhancer 
element called κB. In unstimulated cells, NF-κB dimers are retained in the cytoplasm by 
inhibitory proteins called inhibitors of κB (IκBs) (Figure 1-8 A). Activation of NF-κB 
occurs via two major pathways, the canonical and non-canonical pathway. The 
canonical pathway will be described here in more detail. As mentioned in previous 
paragraphs, transmembrane as well as intracellular PRR signalling pathways lead to the 
activation of the transcription factor NF-κB. This happens usually through the 
recruitment of IκB kinase (IKK) complex via adaptor proteins such as TAK1 kinases 
and/or TRAF (TNF receptor associated factors) ligases. The IKK consists of two kinases, 
IKKα and IKKβ, and a regulatory subunit called IKKγ or NF-κB essential modulator 
(NEMO). Upon recruitment, NEMO becomes ubiquitinated, which in turn activates the 
kinase activity of IKKα and IKKβ. This allows the IKKα and IKKβ subunits to 
phosphorylate IkBα, which receives Lys48‑linked ubiquitination by the E3 ubiquitin 
ligase TRCP, which means marking the subunit for proteasomal degradation. 
Subsequently, this unmasks the nuclear localisation sequence of NF-κB and allows its 
translocation to the nucleus to initiate the expression of target genes [82-84]. 
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1.4.2 Interferon regulatory factors 
Interferon regulatory factors (IRFs) are, similar to NF-κB, a family of transcription 
factors. In mammals, the IRFs have nine family members numbered as IRF1 to IRF9, 
which all of them contain a conserved N-terminal DNA binding domain (DBD) of 
about 120 amino acids.  IRFs were originally thought to function mainly as crucial 
regulators of immune responses, however, recent studies suggest IRFs have additional 
critical functions such as in the regulation of oncogenesis or metabolism for example 
[85, 86]. In the regulation of innate immune responses, IRFs are acting, similar to 
NF-κB, downstream of the PRRs and have the role of transmitting the signals of 
intracellular signalling cascades to chromatin to alter gene regulation.  
Following detection of viral RNA via TLRs or RLRs, signalling cascades evoke in  
most cases type I IFN responses via activation of IRFs, particularly IRF3 and IRF7 
(Figure 1-1). Activation of IRFs generally happens through phosphorylation by kinases 
such as TANK-binding kinase 1 (TBK1). TBK1 then phosphorylates IRF3 and IRF7, 
resulting in their homo- or hetero-dimerisation (Figure 1-8 B). This allows the 
translocation to the nucleus to induce expression of type I IFN genes [87, 88]. 
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Figure 1-8 Activation of NF-κB and IRF transcription factors. A: TAK1 kinases and/or TRAF 
ligases recruit the IKK complex, which is followed by the ubiquitination of NEMO. This activates 
the kinase activity of IKKα and IKKβ, which phosphorylate IkBα for proteasomal degradation. 
Subsequently, this allows NF-κB to translocate into the cell nucleus to initiate the expression of 
target genes. B: Kinases such as TBK1 phosphorylate IRF3 and IRF7, resulting in their homo- or 
hetero-dimerisation. This allows the translocation to the nucleus to induce expression of type I 
IFN genes. 
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1.5 Antigen receptors (AgR) 
The key players of the adaptive immune system are two different types of 
lymphocytes: B-cells and T-cells. For successful antigen detection and signal 
transduction to the cytoplasm, the cells require a number of antigen-specific cell 
surface receptors. The subunits for antigen binding and signal initiation differ between 
the two cell types [1]. 
 
1.5.1 B-cell receptors (BCR) 
B-cells, originally formed in the bone marrow, are able to produce immunoglobulins, 
which can be either secreted into the blood stream or expressed as membrane-bound 
proteins functioning as cell surface antigen recognition units. As the membrane-bound 
immunoglobulin is lacking any intracellular signalling motive, it is linked to 
receptor-associated transmembrane accessory proteins: a heterodimer consisting of 
Igα and Igβ [1, 89]. Igα and Igβ have a cytoplasmic C-terminal region containing 
immune-receptor tyrosine-based activation motifs (ITAM), which are responsible for 
coupling signals from the extracellular matrix to the cell interior and activate 
downstream signalling pathways. ITAMs contain a conserved sequence of four amino 
acids in which a tyrosine is separated from a leucine or isoleucine by any two amino 
acids (YxxL/I). These sequence is generally repeated twice in the cytoplasmic domain of 
ITAM-containing proteins [90]. Activation of these intracellular signalling pathways 
alters gene expression, which ultimately leads to the neutralization and elimination of 
the antigen as well as B-cell differentiation to memory- or immunoglobulin secreting 
plasma cells.  
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1.5.2 T-cell receptors (TCR) 
 T-cells, developed in the thymus, contain antigen receptors, which are structurally 
similar to the BCRs. However, just a small number is able to recognise soluble antigens 
directly and therefore need antigen presenting cells, such as dendritic cells or 
macrophages. Antigen presenting cells load antigen peptides to major 
histocompatibility complex (MHC) molecules, which will then be transported to the cell 
surface and become accessible to TCRs [1, 91]. 
 TCRs are composed of two disulfide-linked, immunoglobulin-like chains α and β 
(αβTCR) or γ and δ (γδTCR). Similar to BCRs, these chains lack a functional cytoplasmic 
tail for signal transduction and interact therefore with accessory molecules which 
contain ITAM motives; the CD3 chains (γ,δ,ε and ζ) [92, 93], which enable inducing 
downstream signalling cascades regulating the activity, proliferation and survival of the 
lymphocyte.  
 
1.5.3 Antigen receptor mediated activation and regulation of NF-κB 
AgRs are key receptors to initiate signalling cascades, which regulate the proliferation 
and cell survival of lymphocytes. One way this is regulated, is through signalling 
cascades leading to NF-κB activation. This signalling pathway is initiated by the 
activation of the SRC family of protein tyrosine kinases, which phosphorylate ITAMs 
within AgR signalling chains [94, 95]. Many factors downstream remain still unclear, 
but it has been shown that a trimolecular protein complex, involving the two CARD 
containing proteins CARMA1 and BCL10, is responsible for IKK complex activation. This 
complex, called CBM-L signalosome (CARMA1-BCL10-MALT1 in lymphoid cells), is 
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regulated by protein kinase C θ (PKC θ) in T-cells and PKCβ in B-cells, respectively 
(Figure 1-9) [4, 96].  
 
1.5.3.1 CARMA1 activation 
CARD-containing MAGUK protein 1 (CARMA1), also referred as CARD11, is a 133 kDa 
scaffold protein and contains several domains, including CARD, coiled-coil, SH3, GUK, 
and PDZ domains (Figure 1-10) [97]. All of these domains apart from the PDZ domain 
have been shown to be required for the function of CARMA1 in mediating NF-κB 
activation [98].  The structural arrangement of PDZ, SH3, and GUK domains is called 
the MAGUK (Membrane-associated guanylate kinase) domain. MAGUK family proteins 
bind directly to the cytoplasmic termini of transmembrane proteins and to other signal 
transduction proteins [99]. Additionally, in both, T and B cells, clustering of CARMA1 
through its SH3-GUK domain is essential for NF-κB activation [100]. CARMA1 appears 
to be regulated by a range of phosphorylation events; It contains phosphorylation sites 
within the linker region between the coiled coil and the PDZ domains, which are 
targets of PKCθ and PKCβ, suggesting CARMA1 to adopt an inactive conformation that 
is stabilized by an intramolecular interaction between the CARD and the linker region 
[101, 102]. Hence, it is believed that these phosphorylation events trigger a 
conformational change, which enables BCL10-MALT1 recruitment, as the CARD domain 
and the coiled-coil of CARMA1 become accessible [102]. 
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Figure 1-9 Simplified model of early signalling events in AgR mediated NF-κB activation. TCRs 
with co-receptor/stimulator CD28 and BCRs are triggering the activation of protein kinase C 
isoforms (PKCθ and PKCβ, respectively), which phosphorylate CARMA1 to enable recruitment 
of BCL10 via its CARD domain. It was recently suggested that in BCR signalling, CAMRA1 form 
clusters which nucleate the filamentous assembly of BCL10. If this applies to T-cells needs to 
be investigated. MALT1 interacts with the Serine-/Threonine-rich domain of BCL10 to connect 
the activated CARMA1 with the ubiquitin ligase TRAF6. Poly-ubiquitination events and TRAF6 
are recruiting and activating the IKK complex. This leads to NF-κB translocation to the nucleus 
to induce transcription of genes involved in regulation of proliferation and cell survival. Figure 
based on Thome et al. (2010) and Qiao et al. (2013) [96, 103]. 
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Figure 1-10 Cartoon of the domain structure of CARMA1, BCL10, and MALT1. Interaction 1: In 
2001, Bertin et al. demonstrated the interaction between CARMA1-CARD and BCL10-CARD via 
co-immunoprecipitation and in vitro binding assays [97]. Interaction 2: Che et al. showed in 
2004 with a two-hybrid approach that MALT1 directly binds to the coiled-coil domain of 
CARMA1 [104]. Interaction 3: In 2001, studies of Lucas et al. have shown that MALT1 binds to 
BCL10 through its immunoglobulin domains [25]. CARD: caspase recruitment domain, 
DD: death domain, S/T -rich: Serine/Threonine rich region, Ig: immunoglobulin-like domain, 
PDZ: post synaptic density protein (PSD95) - Drosophila disc large tumor suppressor (Dlg1) - 
zonula occludens-1 protein (zo-1), SH3: Sarcoma homology 3, GUK: guanylate kinase. 
 
 
1.5.3.2 CBM-L complex formation and downstream signalling  
After activation, CARMA1 recruits the adaptor protein BCL10 via CARD-CARD 
interaction. Similar to the CBM-M signalosome described in section 1.2.2.1, MALT1 is 
recruited to the CARMA1-BCL10 complex where the Ser/Thr-rich C-terminal part of 
BCL10 associates with the immunoglobulin-like domain of MALT1  [25]. Previous study 
has revealed that overexpression of BCL10 induces formation of cytoplasmic filaments 
shown by fluorescence microscopy in lymphomas, which are necessary for the 
recruitment of downstream effector molecules [105]. Qiao et al. (2014) recently 
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revealed the EM analysis of a helical filamentous BCL10 assembly. They also indicate 
that CARMA1 is forming clusters, which are nucleating BCL10 filament formation [103]. 
If this filament formation applies to TCRs as well, need to be investigated. So far, TCR 
signalling also was related to the formation of punctate structures named ‘polkadots’, 
which contain CBM molecules and appear to be critical for NF-kB activation. [106]. 
Regarding downstream signalling of the CBM signalosome, MALT1 contains a 
binding site for the ubiquitin ligase TRAF6, which is required for IKK recruitment: The 
association of MALT1 with TRAF6 results in the addition of Lys63-linked 
(non-degradative) ubiquitin chains to a multitude of proteins, including BCL10 and 
MALT1, which can provide a docking surface for the recruitment of the IKK regulatory 
subunit NEMO. However, the mechanism for the subsequent activation of the IKK 
complex is still unclear [107]. It is possible that TRAF6 recruits the kinase TAK1, which 
activates IKK by phosphorylation [108]. IKK activation leads to NF-κB activation, 
resulting in gene transcription to express proteins essential for proliferation and cell 
survival.  
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1.6 The death domain superfamily 
In the above paragraphs, we have come across a variety of proteins controlling 
immunity, inflammation or apoptosis. This variation which includes receptors, 
adaptors, scaffold and effector proteins, often carry a motif belonging to the death 
domain superfamily. Members of death domain superfamily are responsible for the 
transmission of extracellular signals or form subcellular compartments to specific 
multiprotein platforms in signalling pathways of both, the innate (inflammasomes, 
apoptosomes, MyDDosomes etc.) and the adaptive (CBM complexes) immune system. 
They are key players in mediating protein-protein interactions important for 
transducing signals leading to apoptosis and inflammation, which has given them the 
this sinister name ‘death domain’. Both, apoptosis and inflammation, are associated 
with many human diseases, which give studies of the death domains their ultimate 
biological importance. The members of this family can be categorised into four 
subfamilies: the death domains (DDs), the death effector domains (DEDs), the pyrin 
domains (PYDs) and the caspase recruitment domains (CARDs). These four types of 
domains are evolutionary conserved in organisms from mammals to C. elegans and 
Drosophila. Even viral proteins contain sequences that show high homology with the  
death domain superfamily, enabling them to interfere with host signalling pathways 
and suppress the apoptotic programme [109]. In humans, 102 family members have 
been discovered so far; 39 DDs, 8 DEDs, 33 CARDs and 22 PYD, which makes them one 
of the largest domain superfamilies [110, 111].  Proteins of the death domain 
superfamily contain a structurally conserved domain, comprising six amphipathic 
α-helices, arranged in an antiparallel α-helical bundle with Greek key topology, forming 
a hydrophobic core containing nearly all the conserved residues of this  
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superfamily [112-115]. However, there are small structural differences between the 
four subfamilies resulting in a change of the orientation of the helices as well as the 
electrostatic potential of their surface or the distribution of hydrophobic residues. 
Representative structures of the four subfamilies are shown in Figure 1-11. A structural 
comparison between the subfamilies show distinct characteristics including a more 
flexible helix 3 in DDs, whereas DEDs have conserved surface-exposed hydrophobic 
patches, CARDs contain a kink in their first helix and PYDs contain a small helix 3 with 
an extended loop serving as linker between helix 2 and 3.  
Studies have shown that members of the death domain family are difficult to 
work with because they have a tendency to aggregate. Only recently, we have gained 
more structural insights: Several death-fold structures have been solved, a number of 
them by using non-physiological conditions, solubility enhancement tags or by 
co-expressing them with another domain [110]. 
Interactions within the superfamily are almost all homotypic, which means 
interaction partners belong to the same subfamily. Compared to the number of 
structures available of isolated death domains, the number of complex structures 
solved is still very limited and it remains under debate if there is a common mode of 
interaction within the superfamily or the subfamilies. This debate has taken a 
significant turn over the time of this study, which will be discussed in the following 
sections. 
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Figure 1-11 Tertiary structures of the four death-fold subfamilies. The death domain 
superfamily comprises four subfamilies: Death domains (DD), death effector domains (DED), 
caspase recruiting domains (CARD) and pyrin domains (PYD). Highlighted are the structural 
characteristics of the individual subfamilies. Figure reprinted from Kersse et al. 2011 [9] with 
permission from Elsevier. PDB code for DD: 2OF5, DED: 2BBR, CARD: 3YGS, PYD: 1UCP. 
 
 
 
1.6.1 Complex formation within death domain subfamilies 
Back in 2001, only ten structures of the death domain superfamily with two complex 
structures were known: the 1:1 complex of APAF1-CARD and Procaspase-9-CARD [116] 
as well as the DD complex of the proteins Pelle and Tube. Weber and Vincenz (2001) 
[117] analysed and compared them, with the suggestion that the homotypic 
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interactions (DD-DD, DED-DED, CARD-CARD, PYD-PYD) of death-fold domains engage in 
three distinct types of asymmetric interactions to enable the formation of higher order 
complexes: A type 1 would be formed when residues from helices 1 and 4 of one 
death-fold domain interact with residues from helices 2 and 3 of another. This 
interaction was already represented by the CARD-CARD interaction between APAF1 
and Procaspase-9 (Figure 1-12), where an acidic patch on APAF1 (helices α2 and α3) 
and a basic patch on Procaspase-9 (helices α1 and α4) are forming a 1:1 complex.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-12 Structure of Procaspase9-CARD in complex with APAF1-CARD. Top: Crystal 
structure of the homotypic CARD-CARD interaction between Procaspase-9- and APAF1-CARD. 
Residues involved in complex formation are highlighted to demonstrate the interface between 
the two molecules. Bottom: Electrostatic representation of the binding interface. Procaspase-9 
uses a positively charged surface (blue) to interact with a negatively charged surface (red) of 
APAF1-CARD. Prepared in PyMOL using PDB 3YGS. 
Procaspase-9-CARD APAF1-CARD 
N 
C 
C 
N 
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The type 2 interaction was predicted to involve helix 4 and the loop between helices 4 
and 5 of one death-fold domain interact with residues of the loop between helices 5 
and 6. A type 3 interaction would be formed when residues from helix 3 of one 
death-fold domain interact with residues located on the loops between helices 1 and 2 
and between helices 3 and 4 of the other death-fold domain. With these three 
interaction surfaces, a death-fold domain can potentially engage up to six binding 
partners. Since the prediction that the death domain superfamily may form these 
interactions, experimental data involving higher-order complexes and filamentous 
structures have confirmed that several subfamilies are capable of all three types of 
interactions, providing six interfaces per molecule. In the following sections, these 
structures will be presented in more detail. 
 
1.6.2 The death domain (DD) subfamily 
Members of the death domain subfamily earned their name for being involved in 
signalling pathways leading to caspase activation which ultimately results in apoptosis. 
However, nowadays it is well-known that DDs are just as important in other signalling 
cascades, such as those leading to NF-κB activation during an inflammatory response. 
15 out of 37 isolated DD structures have been solved up so far. Because of their 
tendency to aggregate, several structures had to be solved using extreme pH and/or by 
inserting de-aggregating mutations [118, 119] 
 
1.6.2.1 Intermolecular interaction 
Detailed molecular insight into how death-fold proteins mediate the formation of 
higher-order complexes has been first gained from crystal structures containing DD 
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proteins forming signalling platforms. One of these DD signalling platforms is the 
MyDDosome, a TLR induced assembly consisting of the adaptor molecule MyD88 as 
well as IRAK2 and IRAK4, that mediates the activation of NF-κB. More details about the 
TLR signalling cascade can be found above in Figure 1-1 and section 1.2.1. In 2010, Lin 
et al. [17] published the crystal structure of the MyDDosome assembly at a resolution 
of 3.4 Å, which includes the death domains of six MyD88, four IRAK-4 and four IRAK-2 
molecules (Figure 1-13). 
 
 
 
 
 
 
 
 
 
Figure 1-13 Ternary structure of the MyDDosome. Shown is a ribbon diagram of the 
MyDDosome, containing the molecules MyD88, IRAK2 and IRAK4. Schematic diagram on the 
right shows the three types of interactions in the complex (top). Given are the 
superimpositions of the three type 1 interactions, the three type 2 interactions and the five 
type 3 interactions in the ternary complex (bottom). Figure based on Lin et al. 2010 [17] and 
redrawn with PDB 3MOP in PyMOL. 
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The subunits of the complex are arranged in a left-handed helix with 3.7 subunits per 
turn, with type 1 and type 2 interactions mostly mediating the contacts between the 
layers, whereas type 3 interaction form contacts between adjacent DD molecules in 
the helical spiral. Based on the structure, it has been suggested that the assembly is 
nucleated by the MyD88 complex, that recruits the four IRAK4 molecules, followed by 
four IRAK-2 subunits. As the bottom surface of IRAK2 finds its best match in the top 
surface of IRAK4, IRAK2 is only recruited when IRAK4 is present on the top surfaces of 
MyD88. This is a cooperative process with every DD recruited increasing stability. 
 The MyDDosome is not the only higher-order complex formed by DDs. Another 
DD signalling platform is the PIDDosome, a p54-induced multiprotein complex formed 
upon DNA damage, comprising PIDD and RAIDD, which recruit and activate Caspase-2 
resulting in apoptosis, DNA repair or NF-κB activation [120]. Additionally, a further 
apoptosis inducing DD platform is called DISC (Death-Inducing Signalling Complex), 
which is formed upon activation of transmembrane death receptors such as FAS and 
TNFR (tumor necrosis factor receptor), which recruit the adaptor protein FADD (FAS-
associated protein with death domain) via DD-DD interaction. FADD also contains a 
DED domain additionally to its DD. Activation leads to the recruitment of Procaspase-8 
via DED-DED interactions, which completes the DISC assembly.  
 
1.6.3 The death effector domain (DED) subfamily 
In contrast to the death domains, no multiprotein assemblies of DEDs have been 
identified yet. On the other hand, whereas DDs are found as single copies in single- or 
multi-domain proteins, tandem DEDs exist in proteins such as Caspase-8 and -10, and 
viral Caspase-8/FLICE-inhibitory protein (vFLIP) MC159. The tandem DED containing 
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FLIPs are regulating DISC assembly and caspase activation. Similarly, MC159, a protein 
from poxvirus, is able to interact with FADD and Caspase-8 to inhibit apoptosis [121]. 
Currently, six DED structures are available. This includes the isolated domains of the 
above mentioned FADD-DED [113], the tandem DEDs of MC159 [121], PEA-15-DED 
[122] and the newest addition: the two Caspase-8-DEDs [123]. The structures of the 
isolated domains have revealed the specific characteristics of this subfamily: A 
conserved E/D-RxDLΦ (x=any amino acid, Φ=any hydrophobic amino acid) motif in 
helix 6 and the preceding loop (Figure 1-11 b) form a hydrogen-bonded charged triad 
with an acidic residue in helix 2.  This feature is essential for DISC formation as it allows 
FADD self-association and MC159 binding. Additionally, another DED specific feature 
are conserved residues forming a hydrophobic patch on helix 2. This hydrophobic 
patch facilitates the FADD-Caspase-8 DED-DED interaction as well as the MC159 DED1-
DED2 interaction [124]. 
 
1.6.3.1 MC159 
The mechanism by which MC159 is inhibiting apoptosis is by interacting with FADD, 
therefore blocking FADD self-association, which prevents Caspase-8 to dock and 
induce downstream signalling.  The DEDs of MC159 are locked in a compact, 
dumbbell-shaped structure, covering an extensive interface (Figure 1-14 A). This 
intramolecular interaction is mainly composed of hydrophobic interactions, involving 
helices α2 and α5 of DED1 and α1 and α4 of DED2. Therefore, this cannot be 
categorised as either a type 1, 2 or 3 interaction usually found in the death-fold 
superfamily. The reason for this difference is  that DED1 is highly divergent from a 
typical DED fold; the topologically equivalent helix α3 is missing and is replaced by a 
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short loop connecting helices α2 and α4. Additionally, DED1 contains a short helix α0 
at the N-terminus and helix α7, which helps to bury the hydrophobic core of the 
domain. The DED-DED intramolecular interaction involves the conserved hydrophobic 
patch on DED1, whereas the corresponding hydrophobic patch on DED2, as well as the 
charged triads on both DED1 and DED2, are free to interact with other DED-containing 
proteins [121, 124] 
 
1.6.3.2 Caspase-8 
The most recent crystal structure of a member of the death domain superfamily 
contains the tandem DEDs of Caspase-8 (Figure 1-14 B). Mutations F122A and I128D 
needed to be introduced to obtain soluble proteins. Similar to MC159, intramolecular 
interaction between DED1 and DED2 are mainly formed by hydrophobic residues from 
helices α2 and α5 of DED1 and the helices α1 and α4 of DED2. Whereas the overall 
structures of MC159 and caspase-8 are similar, there are variations which potentially 
define their individual function. An overlay of both tandem domains is provided and 
explained in Figure 1-14 C [123]. 
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Figure 1-14 Structure of tandem death effector domains. A: Intramolecular interaction of the 
MC159 tandem DEDs. Helices α2 and α5 of DED1 interact with helices α1 and α4 of DED2. 
B: Tandem DEDs of Caspase-8 with helices α2 and α5 of DED1 and the helices α1 and α4 of 
DED2 forming an intramolecular interaction. C: Overlay of MC159-DEDs (blue) and Caspase-8-
DEDs (cyan). Differences include such as helix α0 is missing in Caspase-8 (box 1) or a single turn 
helix in DED1 of Caspase-8 (box 2) whereas helix α3 in MC159 is replaced by a loop in DED2 of 
Caspase-8 (box 3). Figures were prepared in PyMOL using PDB code 2BBR for MC159 and 
4ZBW for Caspase-8. 
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1.6.4 The pyrin domain (PYD) subfamily 
The pyrin domains are the latest addition to the death-fold superfamily [125]. Their 
strongest characteristic feature is an altered helix α3. It can vary from being replaced 
by a long, exposed loop in NALP1 [114] to a short helix as seen in ASC [126]. So far, 9 of 
the 22 isolated pyrin structures have been solved. However, PYD-PYD interactions are 
not very well characterised and no complex structure is available at present. Helix α3 
has been demonstrated to be essential in DD interactions, therefore α3 in pyrins may 
significantly alter the way PYDs undergo complex formation [117]. Proteins comprising 
a PYD as an effector domain define the NLRP (NALP) subclass of NLR proteins, which 
form inflammasomes. These proteins have been described in detail in section 1.3.2. 
 
1.6.5 The caspase recruitment domain (CARD) subfamily 
CARDs are playing important roles in innate and adaptive immunity and are involved in 
a wide range of interactions to form complexes, that are required for intracellular 
signal transduction. The 33 identified human CARDs are present in a large variety of 
proteins, including over 100 kDa scaffold and receptor proteins to 10 kDa regulator 
proteins containing just the single CARD (Table 1-1). As described in previous 
paragraphs, CARD containing proteins are involved in signalling cascades downstream 
of NLRs, RLRs as well as the TCR and BCR, often contributing to the formation of large 
oligomeric complexes that are important in regulating apoptosis as well as NF-κB 
activation. The function of specific CARDs is summarised in Table 1-1. In the last 5 
years, the interest in these domains has significantly increased resulting in the 
structures of many individual CARDs being solved by NMR or X-ray crystallography. A 
full list of available CARD structures is provided in Table 1-2. This list highlights that, 
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similar to the other subfamilies of the death domain superfamily, CARDs tend to 
aggregate and a number of structures have been solved using solubilising mutations, 
non-physiological conditions or fusion tags. Apart from the typical six-helical 
death-fold, CARDs are characterised by a kink in helix α1 (Figure 1-11). As CARDs are 
crucial for many different signalling pathways, it is important to know more about the 
molecular features and determinants of specificity of the interactions CARDs are 
involved in.  
Table 1-1 Classification of CARD proteins. Shorthair and longhair CARD proteins don’t contain 
another domain, although can contain an additional sequence or motif. An example is BCL10, 
which has a Serine-/Threonine rich motif following its CARD. Proteins containing an additional 
> 500 amino acids long sequence without an obvious functional domain are categorised as 
‘longhair-CARD’. Table reprinted from Kao et al. 2015 [127] with permission from Springer 
Science and Business Media. 
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Protein/Complex Method Species Residues
Purification and crystallization 
conditions
PDB ID Year
ASC NMR human full-length pH 3.8 to increase solubility 2KN6 2009
ICEBERG NMR human full-length pH 3.8 to increase solubility 1DGN 2000
NLRP1 X-ray human 1379-1462 crystallized at pH 7.5 3KAT N/A
5-108
in complex with Ubiquitin, 
crystallized at pH 8.6
4JQW 2014
16-108 crystallized at pH 4.7 2NSN 2007
14-106 crystallized at pH 6 2NZ7 2008
NMR human 15-138
residues 107-138 added to 
increase stability
2B1W 2007
RAIDD NMR human 1-136
residues 118-136 added to 
increase solubility
3CRD 1999
APAF1: 1-97
domains individually expressed in 
E. coli  and mixed.
Caspase-9: 1-112 crystallized at pH 4.6.
full-length CED4
domains individually expressed in 
E. coli  and mixed.
full-length CED3
crystallization-pH was not 
indicated.
no apparent electron density for 
CED3 in the crystals.
APAF1: 1-97
Caspase-9: 1-108
1-97 crystallized at pH 8 1CY5 1999
1-97 crystallized at pH 4.6 2YGS 1999
1-97 crystallized at pH 6.1 2P1H 2007
full-length crystallized at pH 7.1 1Z6T 2005
1-97 1CWW 1999
1-97 1C15 1999
CED-4 (complexed to CED-9) X-ray c.elegans full-length co-expressed and co-purified 2A5Y 2005
cIAP1 NMR human 435-562 2L9M/3T6P 2011
CARD8 X-ray human full-length crystallized at pH 5.2 4IKM 2013
BINCARD X-ray human 1-99 crystallized at pH 7 4DWN 2013
ARC X-ray human 1-95 crystallized at pH 8.2 4UZ0 2015
21-108 mutation: E24D, dimer, at pH 6.5 4JUP 2013
18-110 mutations: E18A, E20A, at pH 6.5 4I16 2012
14-110 crystallized at pH 6.5 4LWD 2013
BCL10 NMR human 1-115 mutation: E53R, at pH 6.5 2MB9 2013
90-190 pH 7.5 2LWD 2012
90-190 mutation: T170E, at pH 7.5 2LWE 2012
duck full-length crystallized at pH 8.5 4A2W 2011
human 1-188 tetramer with ubiquitin, pH 7 4NQK 2014
human 3-93
N-terminally fused to MBP to 
increase solubility
2VGQ 2008
1-94 mutation: E26R 4O9L 2014
1-94 mutation: R64C 4O9F 2014
1-93 9.6 Å - cryo EM (pH 7.5) 3J6C 2014
1-97 3.6 Å - cryo EM  (pH 7.5) 3J6J 2014
RIG-I: 1-188
MAVS: 1-97
human
human
X-ray
NOD1
2014crystallized at pH 5.5
CARMA1 X-ray human
pH 6.5
1999
2010
4RHW
3YGS
3LQQ and 
3LQR
Apoptosome X-ray
human
c.elegans
APAF1
X-ray human
NMR human
2014
X-ray
RIG-I 
MAVS/RIG-I X-ray humn pH 7.5 4P4H
MAVS (IPS-1) X-ray
horse
EM humanMAVS filament
humanNMR
 
Table 1-2 CARD structures available as up to October 2015. Information collected from 
http://www.rcsb.org/pdb/. 
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1.6.5.1 Tandem CARDs and their intramolecular interactions 
CARDs and death effector domains are the only subfamilies with protein members 
containing tandem domains. Tandem CARDs are found in three different proteins:  
RIG-I [128], MDA5 [129] and NOD2 [64].  
 
RIG-I and MDA5 
RIG-I and MDA-5 are both members of the RLR family of PRRs and viral RNA sensor 
proteins. More information on their function can be found in section 1.3.1. The crystal 
structure of full length duck RIG-I (which shares 53% sequence identity with human 
RIG-I) has been solved in 2011 by Kowalinski et al. (Figure 1-15, cyan) [33]. This was 
followed by the crystal structure of the human tandem CARDs of RIG-I (overlaid in 
Figure 1-15, grey) in 2014 by Peisley et al.[37]. In these complex structures, the loop 
between helices 5 and 6 in CARDa and the loop between helices 4 and 5 of CARDb 
form an intramolecular interaction, which corresponds to a type 2 interaction. These 
two CARDs form a rigid unit and adopt a head-to-tail conformation, where the 
C-terminus of CARDa and the N-terminal helix of CARDb are linked together to form 
one long single helix. The interaction is based on both hydrophobic and polar 
interactions with Y24 and Y81 in CARDa and I130, S160 and K163 in CARDb as the main 
contributors. This structure underlines the finding that both CARDs serve as one 
functional unit and are both required for downstream signalling shown by Zang et al. in 
2010 using IRF3 dimerisation as a read out.  
 So far, there is no crystal structure available for the tandem CARDs of MDA5. 
However, SAXS data shows a compact structure and suggests that they might interact 
with each other as seen in RIG-I [42]. 
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Figure 1-15 Structure of RIG-I tandem CARDs. Duck RIG-I is showed in cyan with the main 
residues of the interface highlighted in blue. As comparison, human RIG-I is overlaid and 
shown in grey (root mean square deviation: 1.0). PDB 4A2Q for duck and 4NQK for human 
RIG-I were processed in PyMOL. 
 
 
NOD2  
The third protein containing tandem CARDs is NOD2. Wagner et al. [130] first 
demonstrated that there is an interaction between the two NOD2 CARDs using 
yeast-two hybrid assays. Previous work in our lab has confirmed these results using 
purified proteins: ITC and pull-down studies have been performed to characterise the 
binding stoichiometry and thermodynamic properties of this interaction. ITC studies by 
titrating CARDa into CARDb resulted in a KD of ~1 µM at 25 °C with a 1:1 stoichiometry. 
In addition, thermal unfolding experiments monitored by CD spectroscopy indicate 
that the two CARDs stabilise each other, which is shown in Figure 1-16. However, 
despite these studies, the exact binding surface involved in the intermolecular 
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interaction could not be identified and further studies are necessary to characterise 
the interaction.  
 
 
 
 
 
 
 
 
 
Figure 1-16 CD analysis of the NOD2 CARDa-CARDb complex. Thermal unfolding of the 
complex revealed a stabilising effect between CARDa and CARDb of NOD2. The complex 
(green) unfolded at a higher temperature (than the computed mean value (grey) of the 
individual curves. Figure from Fridh et al.(2012) [131]. 
 
 
NOD2 - preliminary work 
The tandem CARDs of human NOD2 are well expressed and soluble. However, 
extensive crystallisation trials of the NOD2 tandem CARDs have been performed but 
did not result in any diffracting crystals. Therefore, the focus was set on the individual 
CARDs. In contrast to the tandem construct, expression and purification of each 
individual CARD has not been possible in quantities required for biochemical studies. 
Consequently, a specific protocol allowing the purification of the individual CARDs has 
been developed in the group [131].  A Glutathione S-transferase (GST)-fusion construct 
(pGEX-6P1; GE Healthcare) containing the native sequence of NOD2 aa 28-218 was 
- Tm: 55.6 °C / 80.8 °C 
- Tm: 66.2 °C 
- Tm: 38 °C 
                - Tm: 52 °C 
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modified to contain a thrombin cleavage site (VPRGS) between residues leucine 119 
and histidine 120. Following affinity chromatography, the GST-fusion protein was 
cleaved on-column with thrombin (Merck Millipore) to elute CARDb. With GST-CARDa 
and a large portion of cleaved CARDb remaining on the column, another on-column 
cleavage was performed using PreScission protease (GE Healthcare) to yield CARDa. An 
anion-exchange step (Hi Trap Q FF; GE Healthcare) was conducted with the eluted 
CARDa/CARDb mixture to eliminate CARDb contamination prior to Gel filtration 
(Superdex 75 16/60; GE Healthcare).  
 As the extensive crystallisation trials of the NOD2 CARDs (tandem and 
individual) have not resulted in any diffracting crystals, it was decided to use NMR 
spectroscopy to gain structural insights. While the tandem CARD construct was not 
amenable to NMR studies due to a tendency to dimerise at higher concentrations, the 
structure of NOD2-CARDa could be determined by Dr Kovilen Sawmynaden, shortly 
before leaving the group (Figure 1-17). The calculated ensemble of 10 lowest energy 
and water-refined structures show good convergence with an all-atom root mean 
square deviation (RMSD) of 0.34 Å. CARDa is comprised of five alpha-helices, which 
come together to form the familiar alpha-helical bundle. However, unlike all other 
structures of isolated CARDs determined to date, the sixth alpha helix is absent. 
 In order to investigate the interaction of CARDa with CARDb, NMR saturation 
transfer difference experiments were completed. This experiment is a popular tool, 
which allows the identification of ligand regions/residues important for binding. This 
method is based on the nuclear Overhauser effect between bound ligand protons and 
all protein protons. This experiment involves the comparison of protein-ligand complex 
spectra measured under on-resonance (Ion) and off-resonance (Ioff) irradiation [132].  
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Figure 1-17 Solution structure of NOD2 CARDa. An average is shown of the calculated 
ensemble of 10 lowest energy and water-refined structures of CARDa (unpublished data; 
Rittinger Group). 
 
 
In Figure 1-18, the off-resonance spectrum (light blue) is shown as the reference 
spectrum and superimposed with the difference ΔI = Ioff - Ion (dark blue). Using this 
method, two tryptophan residues have been identified to be involved in CARDb 
binding. Following this result, titration experiments were performed, with the focus at 
the tryptophan region on the superimposed 15N-HSQC spectra of CARDa alone and 
CARDa bound to CARDb (Figure 1-19). Full spectra can be found in Appendix A 1-1. This 
experiment suggested that W59, W63 or W68 are the most likely tryptophans to be 
located at the binding site. These experiments were the basis of this part of my 
project, which was aimed at investigating the potential role of these tryptophan 
residues in CARDb binding and further characterisation of the CARDa-CARDb interface. 
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Figure 1-18 NMR Saturation transfer difference spectra. This experiment shows a sample of 
CARDa bound to CARDb. The reference spectrum (Ioff) is shown in light blue and is 
superimposed with the difference ΔI = Ioff - Ion presented in dark blue.  
 
 
 
 
 
 
 
 
 
Figure 1-19 Tryptophans of NOD2. A section of the 15N-1H TROSY-HSQC spectra of CARDa (red) 
and CARDa+CARDb (blue) show clear chemical shift changes in the tryptophan region 
(unpublished data; Rittinger Group).  
1H 
15N 
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1.6.5.2 Intermolecular interactions 
In 1999, when the structure of the 1:1 complex of APAF1-CARD and 
Procaspase-9-CARD was published (Figure 1-12), probably nobody expected that this 
will remain the only real structural insight into intermolecular CARD-CARD interactions 
for the next 14 years. The discovery of the multi-protein death domain signalling 
platforms such as the PIDDosome or MyDDosome established the new idea that the 
formation of higher-order assemblies could apply to all the death-fold subfamilies. This 
idea was supported by the a cryo EM structure of the apoptosome in 2010 by Yuan et 
al. [54] (Figure 1-6) although the CARD-CARD interactions are not defined in this 
structure. However, apart from the 1:1 interaction and the higher-order assemblies, a 
third mode of interaction has recently become part of the discussed models: the 
formation of filaments. 
 
CBM-L complex 
Considering the structural similarities of CARDs and DDs, the idea that CARDs may also 
form multimeric protein complexes, seemed only logical. It was in 2013, when finally a 
structure showed type 1 and type 2 interactions involving CARDs: Qiao et al. [103] 
demonstrated the filament formation of BCL10 CARDs downstream of BCR in the NF-
κB signalling pathway via the CBM-L complex (Figure 1-20, more information about this 
pathway can be found in section 1.5.3). The solution structure of BCL10 (E53R) was 
solved before the BCL10 subunits were fitted into an EM density map at a ~20 Å 
resolution, which resulted in a modelled structure of a CARD filament (Figure 1-20). Via 
EM analysis of streptavidin gold-labelled biotinylated CARMA1 together with the 
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BCL10 filament, CARMA1 was determined to be only located at the tip of the filament, 
and was therefore suggested to nucleate the CARMA1/Bcl10 filament.   
 
 
Figure 1-20 EM model of a BCL10 filament. A: Shown is the symmetry of the BCL10 filament 
forming a left-handed “four-start” helical strand. B-D: A closer look is given on the involved 
residues in the type 1 and type 2 interactions. E: EM density map is shown with the fitted 
BCL10-CARDs in cyan. Figure reprinted from Qiao et al. (2013) [103] with permission from 
Elsevier. 
 
 
MAVS signalosome 
The BCL10 filament structure was soon followed by other filamentous assemblies: the 
MAVS-CARD filament. EM analysis of MAVS-CARD by Hu et al. (2014) [133] resulted in 
a model at 3.6 Å resolution of a single-stranded left-handed helical arrangement. More 
importantly, the first crystal structure of a multi-domain CARD complex was revealed 
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by the same group. MAVS filament formation was limited by inserting mutations in 
either RIG-I and MAVS CARDs (Figure 1-21). This complex  includes four RIG-I tandem 
CARDs, which are tightly joined together through the type 2 interaction, whereas type 
1 and type 3 interactions were observed between the adjacent RIG-I units. Additionally 
a MAVS-CARD tetramer is stacked on top of the RIG-I tetramer through type 2 
interactions. To underline these findings, this RIG-I/MAVS complex is arranged in the 
same way as the individually solved EM MAVS filament, which can be superimposed 
well with the RIG-I tetramer proposing a model of RIG-I nucleating MAVS-CARD 
filament formation. 
 
NODosome 
The tandem CARDs of NOD2 and their binding partner RIP2-CARD have previously 
been co-expressed in E.coli in order to carry out binding studies by pull-down 
experiments. These studies provided evidence for a direct interaction between NOD2 
and RIP2. The two residues R38 and R86 in CARDa of NOD2 have been identified to 
play a crucial role in RIP2-CARD binding. The exact binding surface has yet to be 
determined and due to only a limited amount of mutants tested so far, it is still unclear 
whether CARDb participates directly, indirectly or not at all in the binding of RIP2. 
Further work will be explained in Chapter 4. 
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Figure 1-21 RIG-I-CARDab/MAVS-CARD complex. A: Mutational engineering allowed the 
crystallisation of a RIG-I-CARDab tetramer with four MAVS-CARD molecules stacked against the 
CARDb domains of RIG-I. B: 2D representation of the RIG-I-CARDab/MAVS-CARD complex 
represented with the mutations. Type 1 and type 3 interactions were observed between the 
adjacent tandem RIG-I units, whereas type 2 interactions were formed between MAVS and 
RIG-I CARDs. This is also highlighted in the schematic diagram on the right. Figure based on Wu 
et al. (2014) [133] with PDB 4P4H processed in PyMOL.  
A 
B 
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1.7 Project aims 
CARDs are important protein interaction domains of the innate and the adaptive 
immune system. However, our understanding of the molecular details underlying 
CARD-mediated protein-protein complex formation is limited and we do not 
understand if there is a general mechanism by which CARDs interact and if their 
mechanism of complex formation is similar to other members of the death domain 
superfamily. 
 The overall aim of this thesis was to investigate the biochemical and biophysical 
characteristics of CARD-CARD interactions, to gain insights into the binding specificity 
and/or stoichiometry of CARD-mediated protein complexes and to elucidate if there is 
a common mode of interaction within this protein subfamily. The aim was to identify 
interacting CARD pairs that can be expressed and purified to then further investigate 
their binding characteristics. Specifically, we want to determine if CARDs form 1:1 
protein complexes, or if CARDs are able to interact with up to six partners to form a 
signalling platform as seen with other members of the death domain subfamily, or if an 
additional oligomerisation domain is required to bring CARDs into close proximity to be 
able to interact in a similar manner as observed in the apoptosome. The ultimate goal 
was to gain structural insight by either crystallography or NMR spectroscopy but also 
to investigate biochemical and biophysical binding properties with available techniques 
including NMR spectroscopy, ITC, CD and fluorescence spectroscopy.  
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2.1 Materials 
Chemicals and reagents used in this study were purchased from Agilent Technologies, 
Cambridge Isotope Laboratories, Expedeon, GE Healthcare, Generon, Merck, New 
England BioLabs (NEB), Novagen, Qiagen, Roche, Sartorius, Sigma Aldrich, Source 
Bioscience and Thermo Fisher Scientific (Thermo Scientific). Specific chemicals and 
reagents are detailed throughout this chapter, in their relevant sections. 
Oligonucleotide primers were obtained from either Eurogentec or MWG.  
 
2.2 Molecular biology 
2.2.1 Bioinformatics 
Nucleotide sequences of target genes were downloaded from the European 
Nucleotide Archive website (http://www.ebi.ac.uk/ena). Protein domain boundaries 
were designed based on domain prediction and secondary structure prediction using 
the following websites: SMART (http://smart.embl-heidelberg.de), ScanProsite 
(www.expasy.ch/tools/scanprosite), JPred (www.compbio.dundee.ac.uk/wwwjpred/) 
and Uniprot (http://www.uniprot.org/). The Double Digest Finder from the New 
England BioLabs (NEB) website (http://www.neb.com/nebecomm/DoubleDigest 
Calculator.asp) was used to select correct buffers and conditions for DNA 
(deoxyribonucleic acid) restriction digests. The LIC primers were designed with the aid 
of the Protein Crystallization Construct Designer (Protein CCD) tool 
(http://xtal.nki.nl/ccd/Welcome.html). Mutagenesis primers have been designed using 
the QuikChange Primer Design (http://www.genomics.agilent.com/ 
primerDesignProgram.jsp). Emboss needle (http://www.ebi.ac.uk/Tools/psa/ 
emboss_needle/nucleotide.html) was used to verify results of cloning/mutagenesis 
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experiments by aligning sequenced DNA with template DNA. Biophysical parameters of 
cloned proteins such as isoelectric point (pI), extinction coefficient (ε) and molecular 
weight (MW) were determined using the PROTParam calculator on the Expasy server 
(www.expasy.ch). Protein sequence alignments were generated using Clustal Omega 
(http://www.ebi.ac.uk/Tools/ msa/clustalo/). Protein sequence alignments were 
visualised and edited and processed using JalView (http://www.jalview.org/) Pairwise 
protein sequence identities/similarities were calculated using Emboss align 
(www.ebi.ac.uk/tools/emboss/align/). SWISS-MODEL server (http://swissmodel. 
expasy.org/) was used for protein structure homology modelling.  
 
2.2.2 Construction of expression plasmids 
Details of cloned and purified proteins used in this study can be found in the relevant 
results sections. Plasmids for E.coli expression of recombinant proteins were 
generated by PCR amplification of the target gene followed by ligation independent 
cloning (LIC) or infusion cloning. Human cDNAs of CARD-containing proteins served as 
templates for polymerase chain reaction (PCR) and were obtained from 
Pascal Meier (ICR, UK), Margot Thome (UNIL, CH) or Life Technologies 
(https://www.lifetechnologies.com). Primer design was carried out taking into account 
the following parameters: 40-60 % GC content, ~30 bases in length and melting 
temperature similar for both forward and reverse primer between 55-72 °C (TM = 2 x 
(A+T) + 4 x (G+C)). The nucleotide sequence ‘CAGGGACCCGGT’ (forward) and 
‘GGCACCAGAGCGTTA’ (reverse) or ‘CTTTCAGGGACCCGGT’ (forward) and 
‘CAGAATTCGGATCCTGTTA’ (reverse) were added to the primers for LIC cloning or 
infusion cloning, respectively. Primers for site-directed mutagenesis were designed 
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using the Agilent Technologies’ QuikChange® Primer Design Program (see section 2.2.1 
for website). Primers were ordered from either Eurofins or Sigma Aldrich. The DNA 
fragments have been cloned in three different LIC vectors: pET52-47, designed by 
Vangelis Christodoulou (The Francis Crick Institute), which contains an ampicillin 
resistance and generates N-terminally His6-tagged proteins. pET49b (Novagen), a 
vector containing kanamycin resistance that generates His6-GST-fusion proteins. pGST 
(Vangelis Christodoulou), which contains a kanamycin resistance and generates 
GST-fusion proteins. For infusion cloning, pHMBP (Vangelis Christodoulou) was used to 
generate a N-terminally His6-tagged MBP (maltose binding protein) fusion proteins. All 
vectors include a 3C-protease cleavage site for tag removal. Plasmid vector maps can 
be found in Appendix A 2-1. 
 
2.2.3 Polymerase chain reaction (PCR). 
Template DNA was amplified using an Eppendorf Mastercycler® DNA Engine Thermal 
Cycler. The reaction was performed using the KOD Hot Start DNA polymerase kit 
(Merck) with a 50 μL reaction volume (Table 2-1). The PCR protocol consisted of 40 
cycles of strand separation, primer hybridisation and DNA synthesis (Table 2-2). The 
PCR purification was performed using QIAquick PCR purification kit (Qiagen) as per 
manufacturer’s instructions. DNA was eluted using 50 μL of distilled water. 
Reagent Volume (μL) 
2x KOD Hot Start master mix 25 
dsDNA template (20ng/uL) 1 
Forward primer (10uM) 1 
Reverse Primer (10uM) 1 
ddH2O 22 
Total Volume 50 
 
Table 2-1 Typical PCR reaction mixture for cloning.  
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Step Temperature (°C) Time (sec) 
1. Polymerase activation 95 120 
2. Denaturation 95 20 
3. Annealing 55 10 
4. Extension 70 20/kb 
Repeat steps 2-4 39 times   
5. Final extension 70 120 
6. Cooling 10 300 
 
Table 2-2 Typical PCR cycling protocol for cloning. 
 
 
2.2.4   Agarose gel electrophoresis  
DNA fragment size of the PCR product was determined by agarose gel electrophoresis 
and compared with known DNA size markers such as 1 kb or 100 bp DNA Ladders 
(NEB). Gels were prepared by dissolving 0.8% (w/v) agarose (Thermo Scientific) in 1X 
TAE buffer (40 mM Tris Acetate pH 7.7, 1 mM EDTA), whereas SYBR® Safe DNA Gel 
Stain (Thermo Scientific) was added to the gels to allow visualization of DNA bands by 
ultraviolet (UV) light at 254 nm.  
 
2.2.5   Determination of DNA concentration 
The NanoDrop® ND-1000 spectrophotometer (Thermo Scientific) was used to 
determine Plasmid DNA concentrations by UV spectrophotometry with 1 A260 = 
50 μg/mL. Alternatively, the intensity of visualized DNA bands was used to estimate 
concentration by comparison with DNA markers of known concentration.    
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2.2.6 Restriction enzyme digestion 
In preparation for ligation with the desired DNA fragment, LIC vectors have been 
digested using the compatible restriction enzymes KpnI and SacI (NEB), which was 
performed at 37 °C for 2 hours (Table 2-3). On the other hand, the vectors for infusion 
cloning were digested using only KpnI. Following restriction digestion, the 20 μL 
reaction sample was mixed with 5 μL 5x Loading Buffer (Qiagen) and run on a 0.8 % 
agarose gel. The DNA band was cut out from the gel and extracted using the QIAquick 
Gel Extraction kit (Qiagen) following manufacturer’s instructions and eluted with 35 μL 
dH2O. 
 
Reagent Volume (μL) 
Purified plasmid 10 
10X BSA (if required) 2 
10X reaction buffer 2 
Restriction enzyme 1 (10U/μL) 1 
Restriction enzyme 2 (10U/μL) 1 
ddH2O 4 
Total volume 20 
 
Table 2-3 Typical digestion protocol. 
 
 
2.2.7 Ligation independent cloning 
An overview is provided in Figure 2-1. The purified PCR products containing the LIC 
sites were treated with T4 DNA polymerase (Thermo Scientific) adding dATP to 
produce sticky overhangs (Table 2-4). Reaction as carried out at 37 °C for 30 min, 
followed by heat inactivation at 70 °C for 20 min. Cut and purified vectors were treated 
similarly, although the T4 treatment was carried out in the presence of dTTP instead of 
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dATP (Thermo Scientific), followed by gel extraction purification. LIC ready DNA 
fragment and vector were mixed together (3:1, [insert]:[vector]) and incubated for 5 
minutes at room temperature, followed by adding 1 µl of EDTA. An overview of the 
single steps is provided in Figure 2.1. 
 
Reagent Volume (μL) 
Purified DNA fragment 3 
dATP  2 
NEB Buffer 2.1 2 
ddH2O 12 
T4 polymerase 1 
Total volume 20 
 
Table 2-4 Typical T4 treatment protocol. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-1 Ligation-independent cloning steps. Diagram illustrating the steps involved in 
ligation-independent cloning. Figure adapted from Aslanidis (1990) [134]. 
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2.2.8 Infusion cloning 
Infusion cloning was carried out using the In-fusion®HD cloning kit (Clontech® 
Laboratories) (Table 2-5). Purified PCR products containing the infusion cloning sites do 
not need any further treatment. Vector and insert quantity was calculated using the 
Clontech Laboratories’ Molar Ratio Calculator (http://bioinfo.clontech.com/infusion/ 
molarRatio.do). The reaction was carried out at 50 °C for 15 min. 
 
Reagent Volume (μL) 
5X In-Fusion HD Enzyme Premix 2 
Linearized Vector (200ng/μL) 1 
Purified DNA fragment (50ng/μL) 1 
ddH2O 6 
Total volume 10 
 
Table 2-5 Typical Infusion cloning reaction. 
 
 
2.2.9 Transformation of cloning products 
LIC and Infusion products were transformed into competent NovaBlue GigaSinglesTM 
E.coli cells (Novagen) by heat-shock treatment at 42 °C for 30 seconds followed by an 
incubation time on ice for 60 seconds. After incubating the cells at 37 °C for an hour, 
they were plated on LB-agar, containing the appropriate antibiotic resistance 
(50 μg/mL kanamycin, 50 μg/mL carbenicillin and/or 34 μg/mL chloramphenicol), 
followed by a further incubation over night at 37 °C (Table 2-6).  
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Step Protocol 
1 Thaw competent cells on ice (50 μL/tube) 
2 Add 3 μL LIC / infusion reaction mix to each tube  
3 Incubate on ice for 30 minutes 
4 Heat shock cells for 45 seconds at 42 °C  
5 Incubate on ice for 60 seconds 
6 Add 500 μL SOC to each tube. 
7 Incubate at 37 °C for 1 hour 
8 Plate 250 μL on LB-agar plates supplemented with appropriate antibiotics 
9 Incubate plates at 37°C over night 
10 Pick 2-5 single colonies for colony PCR 
 
Table 2-6 Transformation protocol using heat shock. 
 
2.2.10 Identification of positive plasmids and purification 
Colony PCR using the Kapa2G PCR ready mix kit (Kapa Biosystems) was performed to 
screen for plasmids containing the desired insert. The reaction mixture of 25 μL each 
contained the appropriate primers: T7/T7-reverse for pET52-47, pGEX-
forward/T7-reverse for pET49b as well as pGEX-6P1 and construct specific primers for 
pHMBP plasmids. Two to five single colonies were picked from the plate and dipped 
into individual tubes containing the reaction mixture before a PCR was run. PCR 
products were analysed by agarose gel electrophoresis.  
 
2.2.11 Plasmid DNA purification, storage and sequencing 
Single colonies with the correct size of inserts were used to inoculate LB (Luria-Bertani 
broth) media supplemented with the appropriate antibiotics.  5 mL media for miniprep 
or 200 mL for Maxiprep was used to grow over night at 37 °C shaking at 200 rpm.  The 
QIAprep Spin Miniprep or the HiSpeed Maxiprep Kit (both Qiagen) respectively was 
used for plasmid purification following manufactur’s protocol and verified by 
sequencing (Source BioScience, LifeSciences or GATC Biotech). DNA was stored 
at -20 °C.  
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2.2.12 Site-directed mutagenesis 
Primers have been designed containing the desired mutation to generate altered 
synthesized plasmids via PCR. Site-directed mutagenesis was performed using the 
QuikChange II site-directed mutagenesis kit (Agilent Technologies) including the 
PfuUltra High-Fidelity DNA polymerase (Table 2-7 and 2-8). This method is based on 
the fact that DNA isolated from almost all E. coli strains is methylated whereas the 
PCR-synthesized plasmids are not. Following thermal cycling, the parental DNA is 
digested using the endonuclease Dpn I, which specifically targets methylated DNA, 
leaving the mutation-containing synthesized DNA. 1 μL of Dpn I-treated DNA was taken 
for transformation into XL1-Blue supercompetent cells (Agilent Technologies). All 
plasmids were verified by DNA sequencing as detailed above.  
 
Reagent Volume (μL) 
10x reaction buffer 5 
dsDNA template (50ng/uL) 1 
Forward primer (125ng/uL) 1 
Reverse Primer (125ng/uL) 1 
dNTP mix 1 
ddH2O 40 
PfuUltra HF polymerase 1 
Total Volume 50 
 
Table 2-7 PCR reaction mixture for site-directed mutagenesis.  
 
Step Temperature (°C) Time (sec) 
1. Initial denaturation 95 30 
2. Denaturation 95 30 
3. Annealing 55 60 
4. Extension 65 60/kb 
Repeat steps 2-4 16 times   
5. Final extension 65 120 
6. Cooling 10 300 
 
Table 2-8 PCR cycling protocol for site-directed mutagenesis. 
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2.3 Protein expression and purification 
2.3.1 Bacterial expression strains 
For recombinant protein expressions, the plasmids were transformed into the widely 
used E.coli host strain BL21, with advantage of its Lon and ompT proteases deficiency 
that otherwise can cause protein degradation. Commercially available modified BL21 
strains are often used depending on specific requirements for protein expression. 
Throughout this project, two specific strains were used: Rosetta2 (DE3) (Merk) and 
BL21 (DE3) gold (Agilent Technologies). The DE3 designation indicates that the 
bacterial strain contains a λDE3 lysogen, which carries a chromosomal copy of the T7 
RNA (ribonucleic acid) polymerase gene under control of the lacUV5 promoter and is 
inducible with lactose or the non-hydrolysable lactose analogue isopropyl 
β-D-1-thiogalactopyranoside (IPTG) (Generon). These strains are suitable for protein 
expression from target genes cloned into the T7 promoter containing pET vectors. 
Further, Rosetta2 (DE3) is modified with an additional chloramphenicol-resistant 
plasmid (pRARE2), which can enhance protein expression by supplying tRNAs for seven 
rarely used codons in E.coli: AGA, AGG, and CGA for arginine, GGA for glycine, AUA for 
isoleucine, CUA for leucine and CCC for proline.  BL21 (DE3) gold strain on the other 
hand features the high transformation efficiency phenotype (Hte) and have the gene 
encoding endonuclease I (endA) inactivated, which otherwise degrades isolated mini-
prep plasmid DNA. 
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2.3.2 Overexpression 
2.3.2.1 Small-scale expression 
Newly generated and purified plasmids were transformed into bacteria strains as 
mentioned above and usually first expressed on a small scale: A single colony was 
picked to inoculate a starter culture of 0.5 ml LB medium, containing the appropriate 
antibiotic resistance: 50 μg/mL kanamycin for pET49b and pHMBP, 50 μg/mL 
carbenicillin for pET52-47 and pGEX-6P1, 34 μg/mL chloramphenicol when using the 
Rosetta2 (DE3) strain.   10 μL starter culture was used to inoculate the main culture of 
1 ml ZYM505 rich medium in sterile 48-deep well plates. The cultures were grown at 
37 °C and 800 rpm to a mid log-phase OD600 of about 6 and, if not stated otherwise, 
cooled down to 18 °C before inducing them with 1 mM IPTG, followed by an 
incubation time of about 16 h. Cells were harvested by centrifugation at 4000 rpm at 
4 °C for 15 min, supernatant discarded and pellets stored at -80 °C. Novel constructs 
usually also included a screen for induction temperatures and induction time. 20 μL 
samples before and after induction were collected for Sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) analysis. 
 
2.3.2.2 Large-scale expression 
If not stated otherwise, the growth media used was LB supplemented with the 
appropriate antibiotics. Starter cultures of 10 - 25 mL growth media and inoculation of 
the main cultures was performed equally to small-scale expressions. Large-scale 
expressions varied between 0.75 and 12 L and were grown as 750 mL or 1 L cultures in 
sterile 2 L flasks in a shaking incubator at 37 °C, 210 rpm. The cultures were grown to a 
mid-log phase OD600 of about 0.6-0.8 and cooled down to 18 °C before inducing them 
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with 1 mM IPTG, followed by an incubation over-night. Cells were harvested by 
centrifugation at 4000 rpm at 4 °C for 30 min, supernatant discarded and pellets stored 
at -20 °C. 
 
2.3.3 Buffers and reducing agents 
Buffers throughout this work were made with deionised water (MilliQ), filtered 
through a 0.22 μm membrane filter. Buffers for chromatography were also degassed. 
The pH of buffers was adjusted to keep it at ± 1 pH unit from the protein’s pI 
(isoelectric point) to increase the charge on the protein and favour its interaction with 
the solvent. Depending on purification methods and experiments selected, the 
reducing agents DTT (dithiothreitol) (Thermo Scientific) or TCEP (tris(2-carboxyethyl) 
phosphine hydrochloride) (Thermo Scientific) were added to the buffers to prevent 
oxidation of cysteine residues. TCEP, compared to DTT, has the advantage to be 
resistant to air oxidation, is compatible with Ni-affinity chromatography and interferes 
less in UV spectroscopy applications. 
 
2.3.4 Small-scale solubility screen 
The protocol for small-scale protein expression and solubility screens has been 
developed by Vangelis Christodoulou (The Francis Crick Institute). The whole lysis 
process is carried out using the 48-well plate the pellets are stored in. The buffers used 
are listed in Table 2-9 for either His6-tagged or GST-fusion proteins. Cell pellets were 
re-suspended in 0.5 mL re-suspension buffer by shaking the 48-deep well plate at 10 °C 
and 650 rpm for 15 min. 0.5 mL lysozyme containing lysis buffer 1 was added, followed 
by incubation on the shaker for another 15 min. A hypotonic shock was then induced 
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by adding 1 mL of H2O (4 °C). After further 15 min, the plate was removed from the 
shaker and 1 mL of lysis buffer 2 was added. The deep-well plate was sealed with clear 
tape and the solution was mixed by just inverting 3 to 4 times. To complete the lysis 
process, the samples were incubated for 15 min at 4 °C before centrifugation at 
5900 rpm for 1 h at 4 °C. 20 μL samples of the cleared lysate were taken for SDS-PAGE 
gel analysis, and the remaining lysate (approx. 3 mL) was loaded on a 96-deep well 
receiver plate containing 96 columns with 50 μL of either Ni-NTA beads (Qiagen) for 
HIS6-tagged proteins or G-sepharose 4B beads (GE Healthcare) for GST-fusion proteins. 
The columns were washed with 4 x 0.5 mL of wash buffer, using a QIAvac vacuum 
manifolder (Qiagen) before a further samples for analysis of the flow through was 
collected. Bound proteins were eluted by adding 60 uL of elution buffer and collected 
by a short centrifugation step. 15 uL of the eluted fraction was used for another 
analysis step via SDS-PAGE gel. 
 
2.3.5 Cell lysis and sample preparation 
Protein purification was usually carried out at 4°C. Cell pellets were thawed and re-
suspended in 6 ml per gram cell pellet of lysis buffer (HIS6-constructs; 50 mM Tris-HCl 
pH 8, 10 mM Imidazole, 300 mM NaCl and 0.5 mM TCEP. All other constructs; 50 mM 
Tris-HCl pH 8, 300 mM NaCl, 2 mM EDTA, 1 mM DTT). 
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GST HIS 
Re-suspension 
Buffer 20 mM Tris-HCl pH 7.7  20 mM Tris-HCl pH 7.7  
Lysis Buffer 1 
20 mM Tris-HCl pH 7.7  
40% succrose (w/v) 
2 mg/mL lysozyme 
2 mM EDTA 
20 mM Tris-HCl pH 7.7  
40% succrose (w/v) 
2 mg/mL lysozyme 
2 mM EDTA 
Lysis Buffer 2 
150 mM Tris-HCl pH 7.7  
900 mM NaCl 
0.45% OTG (w/v) 
30% glycerol 
30 mM MgSO4 
12 U/mL Dnase 1 
3 mM TCEP 
0.3 mM PMSF 
60 mM Tris-HCl pH 7.7  
120 mM Imidazole pH 8.0 
900 mM NaCl 
0.45% OTG (w/v) 
30% glycerol 
30 mM MgSO4 
12 U/mL Dnase 1 
3 mM TCEP 
0.3 mM PMSF 
Wash Buffer 
100 mM Tris-HCl pH 7.7 
300 mM NaCl 
1 mM TCEP 
100 mM Tris-HCl pH 7.7 
40 mM Imidazole pH 8.0 
300 mM NaCl 
1 mM TCEP 
Elution Buffer 
100 mM Tris-HCl pH 7.7 
300 mM NaCl 
10 mM reduced Glutathione 
1 mM TCEP 
100 mM Tris-HCl pH 7.7 
500 mM Imidazole pH 8.0 
300 mM NaCl 
1 mM TCEP 
  
Table 2-9 Lysis and purification buffers for small-scale expression and solubility screen. 
 
 
Re-suspension was supplemented with 1 protease inhibitor cocktail tablet EDTA-free 
(Roche) per 50 mL lysate to prevent protein degradation. 10 U/ml of Benzonase® 
Nuclease (Novagen) and 0.25 mg/mL (end concentration) of hen’s egg lysozyme (Sigma 
Aldrich) were added to reduce viscosity and support lysis. The samples were incubated 
at 4 °C for 30 min. To complete the lysis process, the lysate were sonicated on ice at 
40 % power at 50 % duty cycle, 3-5 times for 30 sec with 1 min rest between cycles 
(Branson Sonifier 450). To clarify the lysate, samples were centrifuged at 20,000 rpm at 
4 °C for 40 min in a Beckman JA-25.50. Samples of the lysate as well as the supernatant 
were analysed by SDS-PAGE to monitor the purification steps. 
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2.3.6 His-affinity chromatography 
Ni2+-affinity chromatography was carried out as an initial purification step of 
His6-tagged proteins. 1-2 mL Ni-NTA beads (Qiagen) per 40 mL clarified supernatant 
was added and samples incubated for 1 h at 4 °C before loading on a PolyPrep 
disposable column (BioRad). Beads were washed with 20 CV wash buffer (50 mM Tris-
HCl pH 8, 20 mM Imidazole, 800 mM NaCl, 0.5 mM TCEP).  The proteins were eluted by 
adding 5 CV elution buffer (50 mM Tris/HCl pH 8, 500 mM Imidazole, 300 mM NaCl). 
The eluted protein was concentrated for the next purification step using VivaSpin 
concentrators (Sartorius) with a molecular weight cut-off of 5 kDa. Samples for SDS-
PAGE analysis were collected from the flow through, beads and elution. Ni2+-affinity 
chromatography was also used for on-column refolding of His-tagged proteins. Details 
are described in section 2.3.11.2. 
 
2.3.7 GST-affinity chromatography 
GST-fusion proteins were purified via GST-affinity chromatography by adding 1-2 mL 
G-sepharose 4B beads (GE Healthcare) per 40 mL clarified supernatant and incubated 
for 1 h at 4 °C before loading on PolyPrep disposable columns. Beads were washed 
with 20 CV lysis buffer buffer.  
 
2.3.7.1 Elution without tag removal 
The protein was eluted from the column by applying 10 mM reduced Glutathione 
(Merck). The eluted protein was concentrated for the next purification step and 
samples for SDS-PAGE analysis were collected from the flow through, beads and 
elution. 
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2.3.7.2 Elution including tag removal 
After washing the beads (containing the bound protein) with lysis buffer, the beads 
were further washed with 5CV 3C-cleavage buffer (50 mM Tris-HCl pH 8, 800 mM NaCl, 
1 mM DTT) for equilibration. The beads were then removed from the column and 
transferred into a 15 mL falcon tube with additional 3C buffer. Approximately 0.5 mg 
GST-tagged rhinovirus 3C protease (made in house) per 1 L culture was used to remove 
the GST-tag by incubating over night at 4 °C. Beads were transferred back to the 
column and the protein eluted with 3C buffer. The eluted protein was concentrated for 
the next purification step and samples for SDS-PAGE analysis were collected from the 
flow through, wash, beads – before 3C cleavage, beads – after 3C cleavage and elution. 
 
2.3.7.3 GST-affinity purification of the modified tandem CARD construct of NOD2 
A specially designed construct of the tandem NOD2-CARDs (amino acid (aa) 28-218, 
pGEX-6P1) containing a thrombin cleavage site between the two CARDs was used to 
express and purify the CARDs individually [131]. The protein was loaded on the column 
and washed as described above in 2.3.7. The beads containing the bound protein were 
equilibrated with a buffer suitable for thrombin cleavage (50 mM Tris-HCl, 150 mM 
NaCl, 2 mM CaCl2, 2 mM DTT). 25U thrombin (Thermo Scientific) was added to cleave 
NOD2-CARDb over night at 4 °C. NOD2-CARDb was eluted using 3C-cleavage buffer 
because of the high salt content as well as to prepare for the following 3C-protease 
cleavage, which was carried out as described above. 
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2.3.8 Amylose-affinity chromatography 
MBP-fusion proteins were purified via amylose-affinity chromatography by adding 1-2 
mL amylose beads (NEB) per 40 mL clarified supernatant and incubated for 1 h at 4 °C 
before loading on PolyPrep disposable columns. Beads were washed with 20 CV lysis 
buffer buffer. The protein was eluted from the column by applying 10 mM Mannose 
(Sigma Aldrich). The eluted protein was concentrated for the next purification step and 
samples for SDS-PAGE analysis were collected from the flow through, beads and 
elution. 
 
2.3.9 Ion exchange chromatography 
The tandem CARDs of NOD2 form a tight intramolecular interaction, which makes 
another purification step necessary for the NOD2-CARDa sample eluted after 3C 
cleavage to remove contaminating NOD2-CARDb.  Remaining CARDb was removed on 
an anion exchange column at pH 7.5. This method is based on the fact that at this pH, 
CARDa with a pI of 4.80 has a higher net negative charge than CARDb, which has a pI of 
6.71, and binds more strongly to the positively charged matrix. The NOD2-CARDa 
sample in 3C cleavage buffer was diluted to 75 mM NaCl and applied on an 
equilibrated HiTrap Q FF 5 ml column (GE Healthcare) using a flow rate of 5 mL/min 
and washed with 3 CV buffer. NOD2-CARDa was eluted by applying a step-wise salt 
gradient: 150 mM, 300 mM, 450 mM, 600 mM and 1M NaCl, using 1CV each with 
another final 3 CV of 1M NaCl. Fractions were analysed via SDS-PAGE. 
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2.3.10 Size exclusion chromatography 
A final purification step was performed using size exclusion chromatography (SEC) to 
remove high-molecular contaminants, change buffer and to ensure mono-dispersity of 
the sample. The samples were concentrated to 4 mL and ejected onto either a pre-
equilibrated Superdex-75 16/60 or Superdex-200 column (GE Healthcare), depending 
on the size of the protein. Columns were connected to an Äkta Prime (GE Healthcare) 
and typically run in 50 mM Tris-HCl pH 7.5 (or 50 mM HEPES pH 7.5), 150 mM NaCl, 
2 mM DTT. Collected fractions were analysed on SDS-PAGE gels, pooled and 
concentrated.   
 
2.3.11 Protein refolding  
2.3.11.1 Batch semi-refolding with 3 M urea 
The cell pellet was re-suspended in 50 mL lysis buffer (100 mM NaH2PO4, 
10 mM Tris-HCl, 3 M urea) at pH 8. One protease inhibitor cocktail tablet EDTA-free 
was added to the re-suspension. For lysis, the samples were sonicated at 40 % power 
and finally centrifuged at 20’000 rpm, 4 °C for 40 min. The supernatant was collected 
and 1 mL of Ni-NTA added before the sample was incubated for 30 min at 4°C. After 
loading the solution on a PolyPrep disposable column, a washing step with 12 CV wash 
buffer (3 M urea, 100 mM NaH2PO4, 10 mM Tris-HCl) at pH 6.3 was carried out. The 
protein was eluted by decreasing the pH to 4.5. Before dialysis in 4 litres refolding 
buffer (1 M urea, 300 mM NaCl, 100 mM NaH2PO4, 2 mM reduced glutathione), the 
eluted protein was diluted to <50 μg/mL. Dialysis was performed over night at 4 °C and 
the buffer was exchanged to 0 M urea on the next day. After 10 h, the pH was 
increased to 7 for the following concentration step. 
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2.3.11.2 On-column refolding with 6 M guanidinium hydrochloride (GdmCL) 
Cell lysis was performed as described in 2.3.5. In this case, the supernatant was 
discarded and the pellet re-suspended with Pellet Wash Buffer 1 by extended 
vortexing. The centrifugation was repeated for 20 min, before the cell pellet was 
washed again with Pellet Wash Buffer 2, for a high salt washing step. During the 
washing steps, the pellet changed its colour to white. Finally, a third cycle of 
re-suspending and centrifugation was applied, using the Binding Buffer. At this step, he 
supernatant was collected and incubated with 1 mL Ni-NTA beads for 30 min at 4 °C. 
The solution is transferred to a disposable PolyPrep column and unbound protein was 
washed off using 10 CV Wash Buffer. Refolding was carried out by adding 10 CV wash 
buffer, containing just 1 M GdmCl and the second time 0 M. Protein was eluted with 
increasing imidazole to 500 mM. 
 
Pellet Wash 
Buffer 1 
Pellet Wash 
Buffer 2 Binding Buffer Wash Buffer 
50 mM Tris-HCl pH 8  
100 mM NaCl 
2 mM EDTA 
1 % TritonX 100 
1 mM TCEP 
50 mM Tris-HCl pH 8  
1 M NaCl 
1 mM TCEP 
50 mM Tris-HCl pH 8  
300 mM NaCl 
6 M GdmCl 
5 mM Imidazole 
1 mM TCEP 
50 mM Tris-HCl pH 8 
800 mM NaCl 
6 M GdmCl 
20 mM Imidazole 
1 mM TCEP 
 
Table 2-10 Buffers for on-column refolding. 
 
 
2.3.12 NMR sample preparation 
Protein expression and purification did not differ from the protocol described in this 
section 2.2 except that cultures were grown in either M9 minimal medium using 
15N-ammonium sulfate (Cambridge Isotope Laboratories) as only nitrogen source or 
the commercially available Spectra9 medium (Cambridge Isotope Laboratories). 
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Purified protein samples were dialyzed over-night into NMR buffer (NOD2 constructs: 
100 mM NaCl, 20 mM Na-Phosphate pH 7.1, 2 mM TCEP, all other proteins: 50 mM (or 
100 mM) NaCl, 20 mM HEPES pH 7, 2 mM TCEP) and concentrated to 280 - 450 μL 
before 5 - 10% (v/v) 99.9 %-deuterium oxide (Cambridge Isotope Laboratories) was 
added. 5 mm Norell® or Shigemi NMR tubes (both Sigma Aldrich) were used. 
Experiments have been kindly set up by Geoff Kelly, Biomolecular NMR Centre, The 
Francis Crick Institute. 1D 1H- and 2D 15N-HSQC spectra were recorded at 25 °C.  
 
2.3.13 SDS-PAGE electrophoresis 
Expression and purification steps were monitored by taking samples at each step for 
SDS-PAGE. In most cases, 20 μL samples were mixed at a 1:1 ratio with 2x SDS loading 
buffer (Thermo Scientific), followed by heating up to 95°C for 5min. Pellet samples 
were first re-suspended in 8 M Urea. 5-20 μL of the samples were loaded onto a pre-
cast NuPage 4-12% BIS-TRIS Novex gel (Thermo Scientific) and run in 1x MES buffer 
(Thermo Scientific) at 200V. Typically Precision Plus Protein™ All Blue Standards 
Marker (BioRad) or SeeBlue®Plus2 (Thermo Scientific) was used as a molecular weight 
marker. Gels were stained with InstantBlue protein stain (Expedeon). 
 
2.3.14   Determination of protein concentration 
A NanoDrop ND-1000 spectrophotometer was used to determine protein 
concentration by ultraviolet (UV) absorption spectroscopy, in which the absorbance A 
between 220-350 nm was scanned. According to Beer-Lambert’s law, the absorbance 
A is a linear function of the proteins concentration c (M): 
Equation 2.1                                    A = ε * c * l 
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The primary amino acid sequence of the protein, including any fusion tags, was used to 
calculate the theoretical 280 nm molar extinction coefficients ε (M-1cm-1) with the 
Protparam calculator (see section 2.2.2). ε of a protein can be calculated making use of 
the average ε values for the three chromophores in proteins, which absorb light at 
280nm: tryptophans, tyrosines and cysteines forming disulphide bonds, assuming that 
the extinction coefficients of the amino acids are the same, both in the protein and 
free in solution. Concentration c of the protein was then determined using molar 
absorption at 280 nm with a path length l of 1 mm. Amino acids with aromatic rings 
are the primary reason for the absorbance peak at between 276 and 282 nm, 
therefore the absorbance spectrum for a protein sample scanned between 250-350 
nm (near-UV) mainly reflects tryptophan (Trp) and tyrosine (Tyr) contents as the main 
contributors and to a smaller extent phenylalanine (Phe) (Figure 2-2) [135].  
 
 
 
 
 
 
 
 
 
Figure 2-2 UV absorption spectra of Trp, Tyr and Phe. The three spectra illustrate aromatic 
model compounds (solid lines) versus “average” aromatic amino acid residues as determined 
using a set of globular, water-soluble proteins (dotted lines). Figure adapted from Current 
Protocols in Protein Science, unit 7.2 [135]. 
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In addition to the protein concentration, a near-UV scan was also used to monitor 
aggregation and DNA contamination in protein samples. Aggregations cause light 
scattering that can be detected at wavelengths >300 as light is scattered away from 
the detector, resulting in a distorted spectrum. DNA contamination, on the other hand, 
is typically characterized by a “flattening out” of the spectrum at <280 nm as nucleic 
acids absorb light around 250-270 nm.  
 
2.3.15 Concentration, verification and storage of protein samples 
VivaSpin centrifugal concentrators with a molecular weight cut-off of 5 kDa were used 
for sample concentration according to manufacturer’s instructions. The purity of the 
protein sample was analysed by SDS-PAGE and molecular weight was verified by 
electrospray ionisation mass spectrometry (performed by Dr Steve Howell, The Francis 
Crick Institute). Final purified protein samples were aliquoted (20-50 μL), flash-frozen 
in liquid nitrogen and stored at -80°C.    
 
 
2.4 Biochemical and biophysical analysis 
2.4.1 Co-expression and GST-pull downs 
Two CARD constructs of interest were co-transformed and -expressed in E.coli, 
followed by GST-pull down experiments to study direct CARD-CARD interactions. This 
experiments is based on the fact that the constructs are cloned into two expression 
plasmids encoding for different tags and antibiotic markers as further described below. 
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2.4.1.1 Small scale co-expression and purification screen of selected CARDs 
CARD constructs have been cloned into the expression plasmids pET49b (N-terminal 
GST-tag and His6-tag, kanamycin-resistance) and pET52-47 (N-terminal His6-tag, 
ampicillin-resistance) to perform pull down experiments. Selected constructs have 
been co-transformed into BL21 (DE3) gold cells and co-expressed in 1 mL ZYM 505 
media. Expression and following pull-down experiments have been performed as 
described in chapter 2.2.4. 
 
2.4.1.2 NOD2-CARDab and RIP2-CARD 
The expression plasmid pGEX-6P1 (N-terminal GST-tag, ampicillin-resistance) was used 
for NOD2-CARDab constructs and pHMBP (N-terminal His6-tag and MBP-tag, 
kanamycin-resistance) for RIP2-CARD. The plasmids were simultaneously transformed 
into Rosetta2 (DE3) cells and grown in 150 mL LB media at 37 °C followed by induction 
at 18 °C over night. Cells were lysed in 25mL lysis buffer (300 mM NaCl, 50 mM Tris-HCl 
pH 8, 2 mM EDTA, 2mM DTT). After lysate clarification, 150 mL G-sepharose beads 
were added to the supernatant and incubated for 2h at 4°C. The sample was then 
loaded on a 5 mL gravitation column (Sigma Aldrich) and washed with 3x 1 mL lysis 
buffer. Proteins were eluted with 10 mM glutathione. Control experiment was 
performed by co-expression of the MBP-tag alone with NOD2-CARDab.  
 
2.4.2 Quantitative analysis of protein-protein interactions 
There are several ways to determine binding constants. Commonly used techniques 
are isothermal titration calorimetry (ITC), analytical ultracentrifugation, nuclear 
magnetic resonance (NMR), surface plasmon resonance or fluorescence spectroscopy. 
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The measured signal is related to the changes in concentration of free versus bound 
ligand, therefore, a protein-ligand interaction can be represented as:  
 
Equation 2.2                                    P + L  PL 
 
The strength of the interaction can be described by either the association constant KA 
or the dissociation constant KD and are related as follow: 
 
 
Equation 2.3                              KD =                       =                
 
According to the mass balance relationship, the total protein concentration (PT) as well 
as the total ligand concentration (LT) can be defined as: 
 
Equation 2.4                    PT = [PL] + [P]   and   LT = [PL] + [L] 
 
Substituting Equation 2.4 into Equation 2.3 gives: 
 
 
Equation 2.5                     KD = 
 
 
 
Solving Equation 2.5 for PL (concentration of formed complex): 
[P][L] 
[PL] 
1 
KA 
([PT] – [PL]) ([LT] – [PL]) 
[PL] 
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                                KD [PL] = PTLT – [PL]∙([PT]+[LT]) + [PL]2  
thus 
                                  [PL]2 – [PL]∙(PT + LT + KD) + PTLT = 0 
 
Solving the quadratic equation gives [PL]: 
 
 
Equation 2.6              [PL] = 
 
This represents the general expression used to relate the measured signal obtained 
from the various quantitative techniques to the concentration of formed complex.  
Differentiation of Equation 2.6 with respect to LT gives: 
 
Equation 2.7                                       =          +  
 
where r = KD/PT and Lr = LT/PT 
 
2.4.3 Nuclear magnetic resonance (NMR) spectroscopy 
NMR spectroscopy was used to characterize the folded state of certain purified 
proteins. NMR spectra were obtained from several Bruker spectrometers with 
magnets ranging from 600MHz to 800 MHz and recorded at 25°C. Samples were 
dialysed into 50 mM HEPES pH 7.1, 100 mM NaCl, 2 mM TCEP and 10% D2O was added 
to each sample. Final volumes were 500 μL for 5 mm Norell®  or 300 μL for Shigemi 
(PT + LT + KD) – √((PT + LT + KD)2 – 4PTLT) 
2 
d[PL] 
d[LT] 
1 
2 
1 – (1 – r) / 2 – Lr / 2 
√(Lr2 – 2Lr – 2Lr (1 – r) + (1 – r)2)  
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NMR tubes with protein concentrations varying depending on the constructs. NMR 
spectra and data analysis were kindly provided by Dr Geoff Kelly and Dr Kovilen 
Sawmynaden (The Francis Crick Institute). 
 
2.4.4 Isothermal titration calorimetry (ITC) 
ITC is a quantitative technique that can be used to study interactions (protein-protein, 
protein-ligand, protein-nucleic acid) and their thermodynamic properties (reviewed in 
[136-138]). ITC is a thermodynamic technique which monitors the heat change upon 
complex formation between molecules in solution. This is equal to the enthalpy 
change (ΔH) given that the pressure stays constant. Stoichiometry, association 
constant and enthalpy can be determined in a single experiment. The Gibb’s free 
energy (ΔG°) and the entropy (ΔS°) of binding can then be determined from ΔH and KA, 
according to the following relationships: 
 
Equation 2.8                               ΔG° = - RT ∙ lnKA 
 
Equation 2.9                              ΔG° = ΔH° - TΔS° 
 
where ΔG° = Gibb’s free energy (kcal mol-1), R = universal gas constant (1.987 cal K-1 
mol-1), T = absolute temperature in Kelvin (0°C = 273.15 K), KA = association constant 
(M-1). 
 
By performing ITC titrations at different temperatures, the change in heat capacity 
(ΔCp°) for the reaction can be calculated from: 
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Equation 2.10                              ΔCp° =                
 
The change of binding heat capacity ΔCp° is defined as the temperature dependence of 
the binding enthalpy change and reflects the change in solvation of the free molecules 
compared to the complex [139]. 
 
2.4.4.1 Determination of binding partners 
The fraction of injected ligand (v∙ΔLI) which binds to the cell protein is proportional to 
the heat absorbed or developed during each calorimetric titration/injection (QI) as well 
as to the binding enthalpy of the reaction: 
 
Equation 2.11                            QI = v ∙ ΔLI ∙ ΔH 
 
where v = reaction volume of the cell. 
Whereas probably most of the titrant will interact with the cell protein for the first few 
injections, the protein in the cell becomes more saturated as the titration carries on, 
therefore less heat is developed or absorbed and the size of the peaks decreases. After 
saturation, any heat observed represents the heat of dilution of the titrant. For the 
analysis, this heat of dilution can be corrected by averaging the enthalpies of the 
injections measured after reaching saturation and subtracting this average from the 
raw data. Alternatively, the heat of dilution can be obtained by performing a separate 
titration experiment in which the heat of dilution is measured by injecting the titrant 
into buffer only. The obtained binding data are then integrated and analysed using the 
dΔH° 
dT 
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ORIGIN software, which is provided by the manufacturer (MicroCal). The heats of 
binding are normalised as a function of ligand concentration (kcal/mole of injectant). 
Further, the binding isotherm can be obtained by plotting the normalised heat per 
injection versus the molar ratio of ligand over protein in the sample cell ([LT]/[PT]). This 
can be fitted using a non-linear least-square fitting. The sigmoidal curve obtained 
allows then the determination of the binding parameters ΔH, KA and n as shown in  
Figure 2-3.  
 
2.4.4.2 Considerations and parameters in ITC 
A number of parameters should be considered regarding sample preparation and 
experimental setup. Firstly, since ITC measures the total heat change in the sample cell 
during titration, both cell sample and titrant need to be dialyzed into the same buffer 
in order to minimize any artefacts from mismatched buffer components. A pH with low 
heat of ionization should be chosen so that the measured enthalpy does not reflect 
both complex formation and buffer ionization. Secondly, ΔH is temperature dependent 
and if no binding heat signal is detected, this could be due to a binding heat change 
near zero at a given temperature. In this case, experimental temperature should be 
changed by at least 5 to 10 °C in either direction. Additionally, an accurate 
determination of the protein concentration is crucial to determine the binding 
parameters, since the binding isotherm is obtained by plotting the normalised heat per 
injection versus the molar ratio of ligand over protein in the sample cell. To determine 
an optimal cell sample concentration ([P]), the unitless parameter c is used which 
characterises the shape of the binding isotherm (Equation 2.12) [140]. 
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Figure 2-3 Example of an ITC titration. The upper plot shows the signal directly recorded of 
the power (μcal/sec) versus time. The lower plot shows the integrated heat plot; the amount 
of heat measured at each injection which is normalized to the number of moles of injectant 
(kcal/mol) versus the molar ratio of the injectant added to the cell sample. Figure adapted 
from Current Protocols in Protein Science, unit 20.4 . 
 
 
The recommended c value lies between 10 and 100 in order to obtain a sigmoidal 
curve that enables accurate determination of KA, ΔH and n (Figure 2-4). 
 
Equation 2.12     c = KA∙[P]∙n 
 
where KA = association constant, P = cell sample concentration and n = stoichiometry. 
ΔH 
N 
KA 
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Figure 2-4 Simulated binding isotherms at various c values. The binding isotherm is 
characterized by the unitless value c, which reflects the shape of the curve: at low c values 
(<1), the binding isotherm is too shallow to allow reliable determination of KA, n and ΔH while 
at high c values (>500), the binding isotherm is too steep and too few data points are collected 
at the transition point to determine KA. A c value between 10 and 100 is recommended. Figure 
adapted from the MicroCal ITC200 user-manual, 2009. 
 
 
2.4.4.3 Materials and methods 
An ITC200 MicroCalorimeter (MicroCal) was used for all ITC experiments. Samples 
were dialysed into ITC buffer (50 mM HEPES-HCl pH 7.5, 150 mM NaCl, 2 mM TCEP). 
Typically, the protein concentration in the sample cell was 30-50 μM and 8 to 10-fold 
higher in the syringe. Titrations were carried out with 19 consecutive 2 μL injections at 
a stirring speed of 1000 rpm and with a duration of 4 seconds, spacing of 180 seconds 
and filter period 5 seconds. The first injection was always smaller (0.2 μL volume in 0.4 
seconds) to compensate for dilutions and/or losses from the tip of the syringe during 
experimental set-up. Data from the first injection was not included in the analysis. 
Heats of dilution were determined from the last few injections of the titration if full 
saturation was reached and subtracted from the raw data. ITC data were analysed 
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using the ORIGIN7 software (MicroCal) supplied by the manufacturer and fitted by 
least-square procedures assuming a one-site binding model. 
 
2.4.5 Far-UV circular dichroism 
CD is an absorption spectroscopy technique used to gain secondary structure 
information of proteins in solution (reviewed by Martin and Schilstra [141]).  This 
technique is based on the absorption of circularly polarized light by molecules in an 
asymmetric environment, where the difference in absorption of left and right circularly 
polarized light is measured. These follow the Beer-Lambert law (Equation 2.1) and the 
observed parameter ΔA can be defined as: 
 
Equation 2.15                 ΔA = ΔAL – ΔAR = (εL – εR)c∙l = Δε∙c∙l 
 
where Δε = differential molar extinction coefficient, c = sample concentration, l = 
cuvette path-length, AL and AR = absorption of left and right circularly polarized light. 
 Apart from the protein secondary structure content, this technique can also be 
used to gain information about the stability of proteins by monitoring CD signals on a 
fixed wavelength (e.g. 222 nm) at variable temperatures.    
 
2.4.5.1 General considerations 
A critically important thing is that the instrument must always be purged with 
high-purity, oxygen-free, nitrogen (generally run at ~ 3-5 L/min) for at least 20 minutes 
before starting the light source and throughout the measurements. If oxygen is 
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present it may be converted to ozone by the far-UV light from the high intensity arc, 
and ozone will damage the expensive optical surfaces.  
As with all spectroscopic techniques the samples should be of the highest 
possible purity. Misleading results can be obtained even with relatively low levels of 
impurities if these have strong CD signals. Sample concentrations should be accurately 
known; this is particularly essential for the analysis of far-UV CD spectra for secondary 
structure content. 
 
 
 
 
 
 
 
 
 
 
Figure 2-5 CD reference spectra. Far-UV CD spectra illustrating the characteristic curves for 
α-helix (black), β-sheet (blue) and random coil (red) conformations. These were obtained from 
the analysis of poly-lysine under various conditions. Figure adapted from unpublished data 
with kind permission from Dr Steve Martin, The Francis Crick Institute. 
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 One major problem in CD measurements is that the signals become seriously 
distorted if too little light reaches the photomultiplier. In far-UV measurements, the 
absorbance of the sample itself is generally rather small and the major problems are 
caused by buffer components. The majority of simple buffer components will generally 
permit CD measurements to measure below 200 nm. However, high concentrations (> 
1mM) of reducing agents (dithiothreitol and 2-mercaptoethanol) should be avoided 
whenever possible.  
  
2.4.5.2 Materials and methods 
CD analysis has been carried out with a protein concentration of 0.15 mg/mL in a 1 mm 
path length quartz cuvette in CD buffer (150 mM NaCl and 25 mM Tris-HCl pH 8). CD 
spectra were obtained on a JASCO-J815 spectropolarimeter. All spectra were corrected 
for buffer signals. Far-UV CD was used to study secondary structure content and 
spectra were collected from 260 nm to 195 nm at 20 °C, with typically 15 averaged 
scans. Thermal unfolding was carried out at 222 nm at increasing temperatures from 
10 °C to 95 °C. CD data analysis was performed with help from Dr Steve Martin and 
Dr Laura Masino (The Francis Crick Institute). The CD signal was measured in 
millidegrees and converted to Δεmrw using equation 2.17: 
 
Equation 2.17                     Δεmrw =  
 
where Δεmrw = mean residue CD extinction coefficient (M-1cm-1), S = CD signal in 
millidegrees, mrw = mean residue weight of the protein (molecular weight of protein 
divided by its number of residues), c = protein concentration (mg/mL) and l = cell path 
length (cm). 
S∙mrw 
32980∙c∙l 
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2.4.6 Thermofluor 
This fluorescence based experiment was used in this work solely to search for optimal 
buffer conditions or additives under which the protein sample showed maximum 
thermal stability. The thermofluor assay is based on the concept that a hydrophobic 
fluoroprobe is added to the sample prior temperature increase: The probe is quenched 
in aqueous solution, however, when the protein undergoes thermal unfolding, the 
hydrophobic regions of the protein become exposed and the probe will be able to bind 
those regions. The resulting increase in fluorescence emission can be plotted as a 
function of temperature [142]. 
 
2.4.6.1 Materials and methods 
5 μL protein solution at 1 mg/mL was mixed with the prior diluted (1:300) fluorophore 
SyPro Orange (Thermo Scientific) and added to 96-well plates containing 12.5 μL of 
various buffers obtained from commercially available screens: Solubility & Stability and 
Slice pH both from Hampton Research. Plates were sealed and heated from 20 to 90 °C 
in increments of 1 °C/min in a Real time PCR machine (QPCR, Applied Biosystems).  
The data were analysed using Prism software, where the sigmoidal curve was fitted 
using the Boltzmann equation in order to determine Tm. 
 
2.4.7 SEC MALLS 
Size-exclusion chromatography coupled to multi-angle laser light scattering 
(SEC-MALLS) provides a technique which allows the determination of the molecular 
weight of your protein sample.  MALLS represents a type of static light scattering and is 
based on the principle that the intensity of scattered light is proportional to the molar 
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mass of a particle and that this intensity also depends on the scattering angle. For this 
reason MALLS data is collected at several angles to the incident laser beam [143]. 
 
2.4.7.1 Materials and methods 
For SEC-MALLS analysis, samples were concentrated to values between 1.5 to 3 mg/mL 
and applied to a Superdex-200 10/300 GL column (GE Healthcare) mounted on a Jasco 
HPLC pre-equilibrated in MALLS buffer (CARD9: 100 mM BIS-TRIS propane pH 7.5, 250 
mM LiCl, 2 mM TCEP, 3 mM Sodium azide. Others: 150 mM NaCl, 50 mM HEPES pH 
8.0, 2 mM TCEP, 3 mM Sodium azide). The system was run at a flow rate of 1 mL/min. 
Scattered light intensity of the column eluate was recorded at 16 angles using a 
DAWN-HELEOS laser photometer (Wyatt Technology). Average molecular masses and 
poly-dispersity terms were determined using the ASTRA software version 5.1 (Wyatt 
Technology). Data analysis was performed with help from Dr Ian Taylor and Dr Neil Ball 
(The Francis Crick Institute). 
 
2.4.8 Fluorescence polarisation assays (FPA) 
Polarisation measurements can provide information on the size and shape of proteins. 
These measurements are based on the principle of photoselective excitation of 
fluorophores by polarized light. In most cases, the fluorophores are oriented randomly 
in the solution. Excitation with polarized light will result in a selective excitation of 
those fluorophore molecules whose absorption transition dipole is parallel to the 
electric vector of the excitation. This selective excitation results in a partially oriented 
population which can have polarized fluorescence emission. The extent to which the 
emitted light will be polarized depends on how fast the fluorophore tumbles in 
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solution. If the fluorophore tumbles fast (small molecule) during the fluorescence 
lifetime, then the emitted light will be depolarized. If it tumbles slowly, as when 
attached to a large protein, then the emitted light will be polarized. Fluorescence 
polarization (P) is the ratio of orthogonal fluorescence intensities defined by equation 
2.18: 
   
Equation 2.18   P =   
 
where IVV and IVH are the vertical and horizontal emission components, respectively, 
with the exciting beam polarized in the vertical direction. The instrument factor G 
corrects for polarization introduced by the optical components of the detection system 
[144]. 
 
2.4.8.1 Instrumentation 
A simple representation of a general spectrofluorimeter is shown in Figure 2-6. It 
consists of a light source which typically is capable of exciting light ranging from 200 to 
900 nm (e.g. xenon lamp). This is followed by an excitation monochromator, an optical 
device which transmits a narrow band of light wavelengths onto the sample. 
Fluorescence emitted from the sample cell enters the emission monochromator, which 
is positioned at a 90° angle to the excitation light path to eliminate background signal 
and reduce noise due to stray light. Both monochromators normally contain adjustable 
slits at the entrance and exit to further control the range of transmitted light. The 
emitted light enters the photomultiplier tube, which amplifies the signal and provides 
a voltage output proportional to the emitted light intensity [144].  
IVV - G ∙ IVH 
IVV + G ∙ IVH 
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Figure 2.6 Schematic diagram of a general spectrofluorimeter.  
 
 
2.4.8.1 Materials and methods  
Labelling 
Alexa-488-C5-maleimide (Thermo Scientific) was dissolved in dimethyl sulfoxide to 
obtain a stock solution of around 3 mM. Labelling of the proteins was carried out in 
500 mM NaCl (or 150 mM), 20 mM Tris-HCl at pH 7.5 and 0.5 mM TCEP. Purified 
His6-MBP-BCL10 C29A/C57A and His6-MBP-RIP2-CARD C455A were mixed with 3-fold 
molar excess of Alexa-488-C5-maleimide and incubated at room temperature for 2 
hours. Gel filtration chromatography (Superdex-200 16/60) was used to remove the 
excess dyes and change buffer to 150 mM, 20 mM Tris-HCl at pH 7.5 and 0.5 mM TCEP. 
 
Fluorescence polarization assay 
Fluorescence polarization was measured using excitation/emission wavelengths of 
490 nm/522 nm on a Jasco FP-8500. 80 μL of sample was loaded into a cuvette with 3 
mm pathlengths. Instrument settings were as follows: slit excitation/emission; 5/5 nm, 
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sensitivity; low, response; 1 second, data interval; 10 seconds, duration; 7200 seconds. 
Fluorescence polarization assays were performed at 25 °C with a protein concentration 
of 10 μM. 3 μM CARMA1, CARD9 or NOD2-CARDab was added in selected 
experiments. 5 μg 3C protease was added to the samples for removal of the MBP-tag 
after about 100 seconds.  
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3.1 Overview 
To fully understand the mechanisms underlying recruitment of downstream effector 
molecules and signal transduction in immune signalling pathways, it is essential to 
investigate the protein-protein interactions involved on the molecular level. CARDs 
belong to the death domain superfamily and mediate many protein-protein 
interactions in the innate as well as the adaptive immune system. However, at the 
start of this project, only the structure of a 1:1 complex between Procaspase9-CARD 
and APAF1-CARD provided an insight into homotypic CARD-CARD interactions [116]. 
On the other hand, death domains have been shown to form multi-protein signalling 
platforms and are able to accommodate six binding partners simultaneously. Based on 
the apoptosome model, it has been suggested that CARDs are forming a ring-like 
structure. However, in this case, an additional oligomerisation domain (as provided by 
the NOD) is necessary to bring the CARDs into proximity. The question remains now, 
what are the general requirements for CARDs to form a complex and are these only 
with a 1:1 stoichiometry or are oligomeric signalling platforms also formed by CARDs? 
 A main reason for the lack of structural information so far is due to the 
tendency of CARDs to aggregate when attempted to purify them as individual 
domains. The aim of this chapter was therefore to screen all human CARDs in 
co-expression and co-purification (pull-down) experiments with the goal to find soluble 
CARD-pairs, which can be taken further for biochemical and biophysical investigations. 
The reason for using co-expression and pull-down experiments is firstly that the 
solubility of CARDs may be enhanced by forming complexes and therefore burying 
hydrophobic patches. Secondly, with the structure of the apoptosome in mind, beads 
would potentially mimic an additional oligomerisation domain by bringing CARDs into 
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proximity to form the platform possibly needed to pull down a binding partner. This 
way, we would screen for soluble, interacting CARD pairs addressing all possibilities 
mentioned above how CARDs may interact. 
 Excluded from this screen are the CARDs of cIAP1 and cIAP2; we are interested 
in interacting CARD pairs, but protein interaction studies by Dr Pascal Meier (ICR, UK) 
using the yeast two-hybrid system had not revealed any other CARD interacting with 
cIAP1 or cIAP2.  
 
3.2 Expression and solubility screens of all human CARDs 
As a first step, all human CARDs were cloned into two different expression vectors, 
which were meeting the requirements for co-expressions: The CARDs were cloned to 
be expressed as His6-tagged as well as GST-fusion proteins. To control first, if these 
constructs are suitable for the co-expression experiments, the CARDs were tested for 
their expression and solubility individually.  
 
3.2.1 Construct design and cloning 
CARD constructs were designed using bioinformatics tools for secondary structure and 
domain boundary predictions (e.g. Jpred [145]), as the primary sequence similarity of 
the members of the DD superfamily is very low (4.7 - 25.3 %) [117]. A multiple 
sequence alignment of all 33 human CARDs generated using ClustalOmega is shown in 
Figure 3-1 [146]. The constructs were designed assuming that all CARDs contain a six 
helical bundle as shown in the structures of APAF1 and Procaspase-9 [116].  
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Figure 3-1 Multiple sequence alignment of all human CARDs.  This alignment depicts 
sequence conservation of all 33 human CARDs, which is highlighted in blue. This Figure was 
generated using only the CARD sequences of all CARD-containing proteins. JalView was used 
including the alignment tool Muscle (http://www.ebi.ac.uk/ Tools/msa/muscle/). Secondary 
structure elements were added based on the crystal structures of APAF1- and CARMA1-CARD 
(PDB: 1CY5 and 4LWD respectively). 
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However, as domain boundaries were not obvious in all cases, the N- and C-termini 
were set generously and prolines were chosen in most cases as the indicators for 
flexible regions and unlikely to be involved in forming an alpha helix.  
Based on published studies on NOD1 and RAIDD, two constructs have been 
tested each, one construct containing just the CARD, and another which was 
C-terminally extended; extended constructs of NOD1 and RAIDD have been shown to 
increase solubility and stability of the molecules. Additionally, for tandem CARDs, 
constructs containing both domains as well as the single domains have been designed. 
 Generating such a large number of recombinant proteins requires an efficient 
method for cloning. One suitable method is ligation-independent cloning (LIC), which 
does not require the use of restriction endonucleases, DNA ligase or alkaline 
phosphatases. Therefore, all constructs were made by LIC based PCR cloning into E.coli 
expression vectors using human cDNAs of CARD containing proteins as templates for 
the PCR (received from Pascal Meier [ICR, UK], Margot Thome [UNIL, CH] and 
SourceBioScience).  
 The vectors used were pET49b (N-terminal His6-GST-tag, kanamycin resistance), 
and pET52-47 (N-terminal His6-tag, ampicillin resistance) with the intention for the 
co-expression experiments to use the His6-GST-fusion constructs to pull down the 
His6-CARDs via GST-binding affinity chromatography using G-sepharose beads (GE 
Healthcare). The full description of the constructs can be found in the section in 
Table 3-1 and 3-2. 
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3.2.2 Small scale expression and solubility screen 
In total 36 His6-CARD (pET52-47) and 36 His6-GST-CARD (pET49b) constructs have been 
successfully cloned.  The constructs were transformed into BL21 (DE3) Gold cells and 
expressed in a small scale, using 48- and 96-deep well plates. To select the best 
temperature for protein expression, initial screens were performed with the majority 
of the constructs to compare the expression, yield and solubility of the proteins when 
incubated at 30 °C for 4 hours or 25 °C and 18 °C overnight. Similarly, IPTG 
concentrations of 0.1 mM and 1 mM were compared. In both cases, no significant 
differences were observed (data not shown), therefore, an induction temperature of 
18 °C and an IPTG concentration of 1 mM was used for all following experiments.  
 The purification protocol used was provided by Vangelis Christodoulou (The 
Francis Crick Institute) and is shown schematically in Figure 3-2. The cells were lysed 
with lysozyme and the supernatant clarified before being applied to columns 
containing either G-sepharose or Ni-NTA beads for metal affinity chromatography. The 
flow through was collected for further analysis before the bound proteins were eluted. 
To monitor the purification, samples for SDS-PAGE analysis were collected from 
different purification steps: uninduced and induced cells, supernatant, flow through 
and elution. Samples of the beads could not be analysed in this set-up due to the use 
of 96-deep well plates. The resulting gels of the induced cells sample together with the 
elution are shown in Figure 3-3 for all the His6-proteins and in Figure 3-4 for the 
His6-GST-fusion proteins with Tables 3-1 and 3-2 containing the construct details. Gels 
containing the uninduced cell samples, supernatant and flow through are not shown.  
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Figure 3-2 Small scale expression and purification. Small scale expression and purification 
experiments have been performed using 48- and 96-deep well plates, respectively. Induced 
cells were grown over night before being harvested. Cells were lysed and supernatants 
collected and clarified prior to loading on the columns containing either G-sepharose or 
Ni-NTA beads. The flow through (FT) was collected only for analysis before the bound proteins 
were eluted. SDS-PAGE analysis has been performed by taking samples of the un-induced and 
induced cells, the supernatants, the flow through and the eluted proteins. 
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Figure 3-3 Small scale expression and solubility screen of His6-tagged CARD constructs. SDS-
PAGE analysis of the samples collected from the induced cells (A) and from the eluted proteins 
from the Ni-NTA columns (B). The constructs are numbered as listed in Table 3-1. 
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# CARD Construct MW (kDa) pI expressed soluble 
1 NOD1 9-104 13.3 5.62 √ √ 
2 NOD1 ext 15-138 16.4 6.09 √ √ 
3 NOD2 ab 28-218 23.8 5.97 x x 
4 NOD2 a 28-120 12.7 5.6 x x 
5 NOD2 b 120-218 13.5 6.66 x x 
6 IPAF 1-92 13 6.69 √√√ x 
7 ASC 105-195 12.7 6.7 √√√ √ 
8 APAF1 1-98 13.4 6.17 √√ √√√ 
9 RIP2 435-528 13.1 6.28 √ x 
10 NALP1 1377-1469 12.9 7.99 √√√ √√√ 
11 Caspase1 1-92 12.5 6.28 √√ x 
12 Procaspase9 1-112 15.2 7.06 √ √ 
13 Procaspase2 28-128 13.6 6.44 √√√ x 
14 CARD8 336-431 13.1 5.75 √√√ √ 
15 CARD9 1-104 14.2 6.14 √√√ √√ 
16 RAIDD 1-101 13.7 5.76 √√√ √√√ 
17 RAIDD ext 1-136 17.7 5.88 √√ √√ 
18 Iceberg 1-90 12.3 6.48 √ √√ 
19 RIG-I ab 2-190 24.6 5.47 √√√ √√ 
20 RIG-I a 2-91 12.8 5.38 √ √ 
21 RIG-I b 91-190 14.1 6.3 √ √ 
22 MDA5 ab 1-201 25.3 5.28 √ x 
23 MDA5 a 1-100 13.7 6.64 √ x 
24 MDA5 b 112-201 12.6 5.1 x √ 
25 MAVS 1-95 13.3 6.12 √ x 
26 Caspase4 1-95 13.1 7.11 x x 
27 Caspase5 50-150 14 9.35 x x 
28 Caspase12 1-95 12.4 5.61 x x 
29 BCL10 10-114 15.1 7.14 √√√ x 
30 CARMA1 18-110 13.2 5.86 √√√ √√√ 
31 CARMA2 6-111 14.3 6.58 x x 
32 CARMA3 12-118 14.6 5.73 √ x 
33 CARD6 1-103 14.1 6.35 √√√ √ 
34 COP1 1-99 13.2 5.75 √√ x 
35 ARC 1-95 12.7 5.72 √√√ √ 
36 BINCARD 1-116 15.9 8.28 x x 
 
Table 3-1 His6-CARD constructs from the small scale expression and purification experiment. 
Listed are all His6-CARD constructs and their details together with the results following the 
small scale expression and purification experiment as seen in Figure 3-3. Results are illustrated 
as heavily √√√, moderately √√ and minimally √ expressed/soluble constructs based on the visual 
analysation of the SDS-PAGE gels. Unexpressed/insoluble constructs are marked with x. 
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Figure 3-4 Small scale expression and solubility screen of GST-tagged CARD constructs using 
pET49b. SDS-PAGE analysis of the samples collected from the induced cells (A) and from the 
eluted proteins from the G-sepharose columns (B). The constructs are numbered as listed in 
Table 3-2. 
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# CARD Construct MW (kDa) pI expressed soluble 
1 NOD1 9-104 38.6 5.54 √ √ 
2 NOD1 ext 15-138 41.8 5.87 √ √ 
3 NOD2 ab 28-218 49.2 5.83 x x 
4 NOD2 a 28-120 38.1 5.53 x x 
5 NOD2 b 120-218 38.8 6.28 x x 
6 IPAF 1-92 38.3 6.17 √√√ x 
7 ASC 105-195 38 6.17 √√√ x 
8 APAF1 1-98 38.7 5.91 √√ √ 
9 RIP2 435-528 38.4 5.89 √√√ x 
10 NALP1 1377-1469 38.3 6.61 √√√ √ 
11 Caspase1 1-92 37.8 5.9 √√√ x 
12 Procaspase9 1-112 40.5 6.28 √ x 
13 Procaspase2 28-128 39 6.13 √√√ x 
14 CARD8 336-431 38.4 5.61 √√√ x 
15 CARD9 1-104 39.6 5.84 √√√ √ 
16 RAIDD 1-101 39.1 5.61 √√√ √ 
17 RAIDD ext 1-136 43 5.7 √√ x 
18 Iceberg 1-90 37.7 6.09 √√√ x 
19 RIG-I ab 2-190 49.9 5.45 √ x 
20 RIG-I a 2-91 38.1 5.41 √√ x 
21 RIG-I b 91-190 39.4 5.92 √ x 
22 MDA5 ab 1-201 50.6 5.34 √√ x 
23 MDA5 a 1-100 39.1 6.11 √√ x 
24 MDA5 b 112-201 37.9 5.26 √ √ 
25 MAVS 1-95 38.6 5.82 √√ x 
26 Caspase4 1-95 38.5 6.34 x x 
27 Caspase5 50-150 39.4 8.1 x x 
28 Caspase12 1-95 37.7 5.53 x x 
29 BCL10 10-114 40.4 6.4 √√ x 
30 CARMA1 18-110 38.5 5.68 √√√ √ 
31 CARMA2 6-111 39.7 6.2 √√ x 
32 CARMA3 12-118 39.9 5.61 √√ x 
33 CARD6 1-103 39.4 6.04 √√ x 
34 COP1 1-99 38.6 5.61 √√√ x 
35 ARC 1-95 38.1 5.72 √√ √ 
36 BINCARD 1-116 41.3 8.28 √ x 
 
Table 3-2 GST-CARD constructs from the small scale expression and purification experiment. 
Listed are all GST-CARD constructs and their details together with the results following the 
small scale expression and purification experiment as seen in Figure 3-4. Results are illustrated 
as heavily √√√, moderately √√ and minimally √ expressed/soluble constructs based on the 
visual analysation of the SDS-PAGE gels. Unexpressed/insoluble constructs are marked with x. 
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The screens clearly show that His6-constructs are yielding more overexpressed protein 
overall as well as more soluble constructs in this small scale experiment. This is 
surprising as the GST-tag has been reported to improve protein solubility [147]. The 
GST-constructs seem to be expressed in most cases, although the SDS-PAGE analysis of 
the elution samples after GST-binding affinity purification results in rather weak bands. 
A further reason for using a GST-tag was that the purification using G-sepharose 
reduces non-specific binding when compared with Ni-NTA and hence would result in 
purer proteins when used for pull-down experiments. However, considering that the 
GST-tag did not show the expected increase in solubility, it was assumed that pulling 
down potential complexes on Ni-NTA bead would probably be more successful. As the 
pET-49b expressed GST-constructs contain an additional N-terminal His6-tag, all 
GST-CARD constructs had to be re-cloned into a different vector (modified pET-49b) 
resulting in GST-only tagged proteins. This new vector was especially designed 
in-house by Vangelis Christodoulou and is simply called pGST. Once all constructs were 
successfully cloned into the pGST vector, the same small scale expression and 
purification screen was repeated. SDS-PAGE analysis of the induced cell samples and 
the elution can be seen in Figure 3-5. In this case, the expression level is extremely 
poor and basically not observable on the gels. Similar to the screen before, the gel of 
the elution sample shows still weak bands. The reason for the lack of expression is not 
known and possibly an error in the backbone of the new vector. If co-expressions 
needed to be performed the CARD proteins clearly would need to be re-cloned into a 
different vector to gain back the expression level as achieved with the pET49b vector.  
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Figure 3-5 Small scale expression and solubility screen of GST-tagged CARD constructs using 
the new vector pGST. SDS-PAGE analysis of the samples collected from the induced cells (A) 
and from the eluted proteins from the G-sepharose columns (B). The constructs are numbered 
as listed in Table 3-2.         
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Taking a look at which His6-CARDs turned out to be soluble, it was not surprising that 
most of them were CARDs whose structure has already been solved such as APAF1, 
ICEBERG, RAIDD and Rig-I. However, the screen also showed that other CARDs 
including CARD6, CARD9 and especially CARMA1 could be suitable proteins for further 
structural and biophysical studies. These are proteins for which no biophysical 
information was published yet. Unfortunately however, interaction partners of the 
CARDs (as stated in the literature), which show the highest solubility are in most cases 
insoluble or only a small fraction is soluble as listed in Table 3.3.    
CARDs CARD interaction partners and their solubility 
NOD1 √ RIP2 x, Caspase9 √ 
ASC √ Caspase1 x, NALP1 √√√ 
APAF1 √√√ Caspase9 √ 
NALP1 √√√ Caspase9√/APAF1 √√√,  Caspase1 x 
Caspase 9 √ APAF1 √√√ 
CARD8√ Caspase1 x, Iceberg√ √, COP1 x 
CARD9 √√ BCL10 x 
RAIDD √√√ Caspase2 x 
Iceberg √√ Caspase1 x, CARD8 √ 
RIG-I ab √√ MAVS x 
MDA5 b √ MAVS x 
CARMA1 √√√ BCL10 x 
CARD6 √ - 
ARC √ Caspase2 x 
 
Table 3-3 Interaction partners of CARDs. Listed are the His6-CARD constructs which were 
either soluble or only partially soluble together with their potential interaction partner(s).  
Results are illustrated as heavily √√√, moderately √√ and minimally √ soluble constructs based on 
the visual analysation of the SDS-PAGE gels. Unexpressed/insoluble constructs are marked 
with x. 
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3.2.3 Co-expression and co-purification 
The small scale expression and solubility screens showed that CARMA1- and 
CARD9-CARD could be suitable proteins for further investigation. However, both of 
these CARDs interact with BCL10-CARD, which could not be successfully purified in 
either screen. Therefore, co-expression was performed using BCL10 together with a 
selection of other CARDs in the hope that solubility could be increased by expressing 
BCL10 with its interaction partners CARMA1, CARMA2, CARMA3 and CARD9. 
Additionally, a number of other CARDs were selected (both soluble [APAF1] and 
insoluble constructs [e.g. Caspase-4]) for co-expression with BCL10 as negative 
controls. The CARD co-expression pairs were purified twice, once via GST-affinity 
chromatography and once via metal affinity chromatography. The SDS-PAGE analysis 
of the elution samples is shown in Figure 3-6 with the corresponding list shown in 
Table 3-4. Neither of the co-expressed CARDs increased the solubility of BCL10 
significantly, nor could any BCL10 be pulled down with GST-CARMA1.  
 
 
 
Figure 3-6 Small scale co-expression and co-purification. SDS-PAGE analysis of the elution 
samples collected from purifying the co-expressed proteins via G-sepharose beads (left) and 
Ni-NTA (right). The constructs are numbered as listed in Table 3-4. 
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 Expressed CARD used for purification 
# GST His Elution G-sepharose Elution Ni-NTA 
1 BCL10 CARMA1 - CARMA1 
2 CARMA1 BCL10 CARMA1 CARMA1 
3 BCL10 CARMA2 - - 
4 CARD8 BCL10 (CARD8) CARD8 / (BCL10) 
5 BCL10 CARMA3 - - 
6 CARMA3 BCL10 - - 
7 BCL10 RIP2 - - 
8 CARD9 BCL10 CARD9 CARD9 / (BCL10) 
9 BCL10 CARD6 - CARD6 
10 MAVS BCL10 MAVS MAVS / (BCL10) 
11 BCL10 APAF1 - APAF1 
12 APAF1 BCL10 - APAF1 / (BCL10) 
13 BCL10 CASP4 - - 
14 CASP4 BCL10 - - 
15 BCL10 CASP5 - - 
16 CASP5 BCL10 - CASP5 / (BCL10) 
 
Table 3-4 Small scale co-expression and purification. BCL10 was co-expressed and purified 
with a number of selected CARDs in an attempt to increase solubility. Listed are the chosen 
pairs of CARDs as well as the constructs in the elution sample after the purification using either 
G-sepharose or Ni-NTA.  
 
 
3.2.4 Large scale test expression and purification of selected CARDs 
After the expression and solubility screens of the individual CARDs, several constructs 
were identified to be soluble. In order to obtain sufficient quantities of protein for 
further studies it was necessary to express and purify these constructs in a larger scale. 
The small scale purification protocol differs from standard protocols (e.g use of 
detergents or lysis method, further details can be as seen in section 2.3.6 and 2.3.7). 
To determine how well the small scale expression translates to larger scales, two GST-
tagged CARDs were picked which are expected to behave differently: CARMA1, our 
best expressed CARD of the small scale screens and Iceberg, which showed 
Results | 3 
 
127 
 
significantly lower levels of expression. GST-tagged CARMA1 and Iceberg were 
expressed on a 750 mL scale using BL21 (DE3) Gold cells with an induction temperature 
of 18 °C for 16 hours. After GST-affinity chromatography, the GST tag was removed by 
cleavage with 3C protease in batch overnight and the cleaved protein collected the 
next day. Individual steps of the purification are shown in Figure 3-7. CARMA1 could be 
eluted from the beads and was soluble at room temperature. In contrast, Iceberg was 
largely insoluble, similar to its behaviour in the small scale screen. It is important to 
point out that the sample of the beads with the bound GST-fusion protein can be 
misleading about the amount of soluble untagged protein , as fusion to GST, a 27.3 kDa 
protein, can increase solubility, whereas its removal may render the protein insoluble 
and lead to its precipitation on the beads. Large scale purification of His6-tagged 
CARMA1, CARD9 and BCL10 has also been performed and is further described in 
Chapter 5.  
 
 
Figure 3-7 Purification of GST-CARMA1/-Iceberg. The purification steps were monitored by 
SDS-PAGE. P; pellet, SN; supernatant, FT; flow through, W; wash, B; beads, -E; batch sample 
before adding 3C-protease, +E; batch sample after adding 3C-protease, FTE; eluate 1, WE; 
eluate 2. The fractions collected containing the eluted proteins are marked with a red box. 
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In parallel with the GST-constructs, several His6-CARDs were selected for large scale 
expression and purification by affinity chromatography. Proteins were eluted from 
Ni-NTA beads using concentrations of imidazole increasing up to 500 mM. SDS-PAGE 
analysis of the purification of CARD6, IPAF and ASC CARDs are shown in Figure 3-8. In 
all cases, the protein elutes during the wash step at a maximum concentration of 75 
mM imidazole indicating the proteins may form soluble aggregates where His6-tags are 
not fully exposed. The large scale purification of His6-tagged CARMA1, CARD9 and 
BCL10 is further explained in Chapter 5.  
 
 
 
 
 
 
 
 
Figure 3-8 Purification of His6 IPAF, -CARD6 and -ASC. The purification steps were monitored 
by SDS-PAGE. P; pellet, SN; supernatant, FT; flow through, W; wash, B; beads. The protein was 
eluted by an imidazole gradient from of 75 mM to 500 mM. 
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 Regarding the disappointing expression level of the GST-tagged CARD 
constructs using the newly designed vector pGST, a complete re-cloning of all human 
CARDs into a new GST-vector for co-expression and pull-down screens was not taken 
any further because Qiao et al. (2013) [103] demonstrated the filament formation of 
BCL10-CARD at this point. This completely changed the aspect of how to approach the 
investigation of CARDs if the idea of filamentous CARD assembly wanted to be 
addressed as well. For this reason, the attempt to perform a wide range of co-
expressions and pull-down experiments was dismissed and the focus was set on a 
selection of CARDs: Firstly, various experiments with CARMA1, CARD9 and BCL10 has 
already been performed (see Chapter 5) and provided a good system to look further 
into the polymerisation of CARDs. Secondly, another focus was set on the tandem 
CARDs of NOD2 as preliminary work has already been performed in our group and 
especially because the structure of the N-terminal NOD-CARDa had recently been 
solved by a former group member. This provided the opportunity to compare intra- 
and intermolecular CARD-CARD interactions (see Chapter 4). 
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3.3 Summary 
CARDs are essential domains for mediating the formation of multi-protein complexes 
during intracellular signal transduction in innate and acquired immune signalling 
cascades. Therefore, it is of significant interest to understand the specificity and 
molecular features underlying these interactions. This project is focused on the 
biochemical and biophysical investigation of homotypic CARD-CARD interactions.  
 To gain insight into general properties of CARD-mediated protein interactions, 
all 33 human CARDs were cloned as His6- and His6-GST fusion proteins to perform 
co-expression and pull-down experiments via GST-affinity chromatography in order to 
identify soluble and interacting CARD pairs. Small scale expression and solubility 
screens of the individual domains, however, demonstrated a poor outcome in 
identifying soluble GST-constructs. To enable pull-down experiments via metal-affinity 
chromatography instead, all CARDs were re-cloned into a newly designed 
GST(-only)-vector. However, expression levels using this new vector were extremely 
poor.  
 On the other hand, solubility screens of the individual CARDs identified 14 
His6-constructs and 6 His6-GST-constructs as potential candidates for expression in 
large-scale. Surprisingly, more His6-constructs than GST-constructs turned out to be 
soluble or partially soluble. Our attention especially fell on the highly soluble 
CARMA1-CARD. More regarding this construct is described in Chapter 5. 
 Co-expression and pull-down experiments have not been taken any further at 
this point, as the EM analysis of BCL10-CARD filament lead us to the decision to focus 
on specific CARDs (NOD2, RIP2, CARMA1, CARD9, BCL10) to address this new aspect of 
complex formation via filamentous assemblies. 
  
 
 
 
 
 
 
 
 
Chapter 4 
 
 
Intra- and intermolecular CARD-CARD interactions of NOD2 
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4.1 Overview 
NOD2, an intracellular pattern recognition receptor and member of the 
NOD-like-receptor family (NLR), is stimulated by peptidoglycans of the bacterial cell 
wall and believed to undergo ligand-induced oligomerisation through its NACHT 
domain, followed by the recruitment of RIP2 through CARD-CARD interactions, which 
ultimately leads to NF-kappaB activation [69]. Following up on previous work carried 
out in our group [131], which discovered an intramolecular interaction between the 
tandem CARDs of NOD2, the aim of my project was to biophysically and structurally 
investigate the interaction between these two domains.  
 Members of the death domain superfamily have been shown to engage in 
three distinct types of interactions to mediate formation of higher order complexes 
called type 1, 2 and 3 [117]. My goal was to investigate whether the intramolecular 
interaction between CARDa and CARDb of NOD2 is a type 1, 2 or 3 interaction or may 
be formed via a new binding interface. In addition to canonical 1:1 interactions as 
observed in the APAF1-Caspase-9 complex, members of the death domain superfamily 
have also been shown to be responsible for the formation of higher-order complexes 
such as the Apoptosome, MyDDosome, or even filaments [17, 54, 103].  Therefore, 
further questions were addressed: Are both NOD2-CARDs required to recruit the 
downstream effector RIP2-CARD? Does the CARD of RIP2 form higher order complexes 
and if so, does NOD2 enhance polymerisation?   
 The structure of NOD2-CARDa has recently been determined in our group. 
Based on this new structure, mutants have been generated in order to investigate the 
above raised questions using a range of biophysical techniques including ITC, NMR, CD 
as well as fluorescence spectroscopy.  
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4.2 The intramolecular interaction of the tandem CARDs of NOD2 
As introduced in section 1.6.5.1, NMR data suggested that two NOD2-CARDa 
tryptophans (most likely W59, W63 or W68) may play a crucial role in binding of 
CARDb. To validate this observation, experiments needed to be designed to test if the 
intramolecular interaction between CARDa and CARDb may use binding surfaces either 
equivalent to type 1, 2, and 3 or equivalent to tandem DEDs. 
 
4.2.1 NOD2 constructs 
4.2.1.1 CARDa 
All five possible tryptophan mutants were generated by replacing the residue with an 
alanine. Furthermore, in order to select CARDa residues that may be involved in type 1, 
2, or 3 binding interfaces, structures of those death domain family members forming 
higher-order complexes were chosen and superimposed onto the NOD2-CARDa 
structure. The filamentous complex of MAVS-CARD was the first higher order CARD 
structure solved via x-ray crystallography. [133] Residues in each binding site of 
MAVS-CARD were highlighted before an overlay with CARDa was performed using the 
Dali pairwise alignment [148], with results evaluated in PyMOL [149]  (Figure 4-1). 
Additionally, the same overlap was performed with other death domain superfamily 
complex structures such as Procaspase-9-APAF1 (type 1, APAF1 (PDB: 4RHW, chain A), 
Procaspase-9 (PDB: 4RHW, chain E)) or the MyDDosome (type 1,2 and 3, MyD88 (PDB: 
3MOP, chain A), IRAK4 (PDB: 3MOP, chain G)) to select CARDa residues for mutational 
studies. Those residues potentially in the right place of a type 1, 2 or 3 interaction can 
be found in Table 4-1 with the sequence alignment of the template molecules shown 
in Figure 4-2. Interestingly, residues determined using the death domains of MyD88 
Results | 4 
 
134 
 
and IRAK4 led to similar results as the overlap of CARDa with MAVS-CARD, even 
though these molecules belong to different subfamilies. The mutants E69K, E72K and 
R86A, which were also identified have already been generated and previously analysed 
in the group [131]. 
 
 
Figure 4-1 Residues of MAVS-CARD essential for type 1, 2 and 3 interactions. Left: To 
demonstrate the most important residues involved in type 1, 2 or 3 interaction of CARDa, we 
selected MAVS-CARD (PDB: 3J6J) and highlighted the residues of each binding site. Right: 
NOD2-CARDa in grey is superimposed with MAVS-CARD. The tryptophans W59 and W63 are 
highlighted in black. Figures were created using PyMOL. 
 
Table 4-1 Selected CARDa residues. Residues of CARDa which are potentially involved in a type 
1,2 or 3 interaction, determined by superimposing CARDa with the death domains of IRAK4, 
MyD88 and the CARD of MAVS via Dali pairwise alignment and inspection in PyMOL. E69K, 
E72K and R86A have been already cloned and analysed by Fridh and Rittinger (2012). 
 
 IRAK MyD88 MAVS  
Type1a R38 R38 R86 
Type1b E64/ E69 / E72  E54 / D58 / Y71 / H75 Y71 / E72 / H75 
Type2a D90 / W93 / N94 N94 / K95  E69 / N94 / K95 
Type2b S49  / E51 / D113 S49 / D113 S47 / S49 / E51 
Type3a E69 / E72/ Q79 Q79 E69 / E51 / Q79 
Type3b S49 / Q79 - S49 / Y71 / Q79 
Results | 4 
 
135 
 
 
Figure 4-2 Design of NOD2-CARDa mutants. The design of CARDa mutants was based on an 
overlap with available structures of complexes formed by the death domain superfamily; 
MyD88 (PDB: 3MOP, chain A), IRAK4 (PDB: 3MOP, chain G) and MAVS (3J6J). Residues chosen 
for site-directed mutagenesis are in red, whereas the green residues have already been tested 
by Dr Veronica Fridh [131]. The tryptophans of CARDa are shown in cyan. All overlays have 
been performed using the Dali pairwise alignment. Figure was completed using JalView [150], 
with primary sequence alignment via Muscle [151]. The secondary structure was added 
manually to this figure and corresponds to the structure of NOD2-CARDa.  
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After performing site-directed mutagenesis; a small scale expression and solubility 
screen was performed to determine which mutants are suitable for further 
experiments (SDS-PAGE analysis shown in Appendix A 4-1). A list of all mutants tested 
and their solubility can be found in Table 4-2. Mutants selected for further 
investigations were: W59A, W63A, W98A, S49A, H75A, Q79A and N94A. 
 
 
Mutation Solubility Potential interaction site 
S49A √ Type2b/3b 
N94A √√ Type2a 
Q79A √ Type3a/3b 
Q79K x Type3a/3b 
H75A √√ Type 1b 
H75Q √√ Type 1b 
K95A x Type 2a 
E51A x Type 2b/3a 
E51K x Type 2b/3a 
W59A √√ Tryptophan 
W63A √ Tryptophan 
W68A x Tryptophan 
W93A x Tryptophan 
W98A √√√ Tryptophan 
 
Table 4-2 NOD2-CARDab mutants with mutations in CARDa. Mutations listed are all located in 
CARDa and have been analysed by SDS-PAGE for solubility. Results are illustrated as heavily 
√√√, moderately √√ and minimally √ soluble constructs based on the visual analysation of SDS-
PAGE gels. Insoluble constructs are marked with x . 
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4.2.1.2 CARDb 
From previous work, it was known that CARDb alone is an unstable protein, which 
easily precipitates. Therefore, any mutations inserted in CARDb of the tandem CARD 
constructs were likely to have a severe effect on its solubility and stability. However, 
given the lack of information regarding the binding surface on CARDb, it was worth 
trying to generate mutants, which may be sufficiently soluble and stable for further 
experiments. In the absence of a structure of NOD2 CARDb, a homology model was 
generated in SwissModel in order to select surface residues for mutagenesis [152]. The 
solution structure of BinCARD (PDB: 4DWN) was found to have the highest z-score with 
NOD2-CARDa as a result of a Dali structural alignment [148] and was therefore used as 
template.  
 To predict the binding site of CARDb and to be able to design appropriate 
CARDb mutant constructs, CARDa was aligned with available structures of tandem 
domains. In these alignments, the focus was set on the its tryptophans W59 and W63: 
When NOD2-CARDa was aligned with RIG-I tandem CARDs (PDB: 4A2Q), the 
tryptophans were not located near the binding site of RIG-I-CARDa and b. Interestingly, 
further alignments have revealed that when NOD2-CARDa is aligned with the tandem 
DEDs of MC159 (PDB: 2BBZ), residue W59 and W63 are in the position of the 
DED-interface as shown in Figure 4-3. DED1 is highly divergent from a typical DED fold; 
therefore, the interaction differs from the known modes of interaction within the DD 
superfamily. Both CARDa and the model CARDb were then superimposed with the 
MC159 tandem DEDs to select residues of CARDb, which are potentially at the 
interface (Figure 4-4). D133, H137, R138 and R182 have been chosen for site-directed 
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mutagenesis, whereas E158 and Q201 were added as negative controls, located at the 
opposite end of the molecule. 
 
 
 
 
 
 
Figure 4-3 MC159 tandem DED. Left: The tandem DED of MC159 (grey, PDB: 2BBZ) with the 
interface highlighted in red and blue. Right: NOD2-CARDa in gold superimposed with tandem 
DEDs of MC159. Tryptophans W59 and W63 of NOD2-CARDa are highlighted in black. Figures 
were generated using PyMOL. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-4 Model of the tandem CARDs of NOD2. The recently determined solution structure 
of NOD2-CARDa (green) in combination with a model of NOD2-CARDb (blue, created with 
SwissModel). The orientation between the two domains is based on the tandem DEDs of 
MC159. Highlighted are the positions of tryptophan W59 and W63 in light green, which are 
NOD2-CARDa 
 
NOD2-CARDb 
 
N 
 
N 
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believed to play a crucial role in CARDb binding. Residues in CARDb chosen for side directed 
mutagenesis are shown in light blue. Figure was generated using PyMOL. 
 
After performing site-directed mutagenesis to insert mutations in CARDb of the NOD2 
tandem CARD constructs, a small scale expression and solubility screen was performed 
to determine which mutants to focus on (SDS-PAGE analysis data shown in Appendix 
A 4-2). A list of the mutants produced and their solubility can be found in Table 4-3. 
Mutants selected for further investigations were: D133A, H137A, E158A and Q201A. 
 
 
 
 
 
 
Table 4-3 NOD2-CARDab mutants with mutations in CARDb. Mutations listed are located in 
CARDb and have been screened regarding their expression and solubility. Solubility is based on 
the visual analysation of SDS-PAGE gels. 
 
4.2.2 NMR titration experiments with the tryptophan CARDa mutants 
NMR is a very powerful technique to map residues of the interaction site of a protein 
upon complex formation with its binding partner. The experiments recorded in this 
case are 15N-HSQCs. The chemical shifts of the N-H cross correlations are sensitive to 
their chemical environment and hence titrating the binding partner to the 15N-labelled 
sample will change the environment of the residues involved in complex formation. 
This can be monitored as chemical shift changes in both dimensions when the spectra 
before and after the addition of the ligand are superimposed [153]. The NMR titration 
Mutation Solubility 
D133A √ 
H137A √ 
H137Q √ 
R138A x 
R182A x 
E158A √ 
E158K x 
Q201A √√ 
Q201K √√√ 
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experiments with the individual NOD2 CARDs were first performed by Kovilen 
Sawmynaden, a former group member. Spectra of a 15N-NOD2-CARDa sample were 
recorded before and after unlabelled NOD2-CARDb was added. Protein samples were 
in 100 mM NaCl, 20 mM Na-Phosphate pH 7.1 and 2 mM TCEP and experiments were 
recorded at 25 °C. Full spectra of these experiments can be seen in Appendix A 1-1. 
When CARDb was titrated into CARDa, the majority of the peaks are changing their 
chemical shifts and therefore it is not possible to use the assigned CARDa spectrum to 
identify single peaks of the complex spectrum. However, the saturation transfer 
difference experiment shown in Figure 1-18, indicated that the tryptophans are playing 
a key role in CARDb binding. The chemical shift changes of two tryptophans are clearly 
visible when the spectra of ‘CARDa’ and ‘CARDa + CARDb’ are superimposed 
(Figure 1-19). Based on these observations, my goal was to repeat the titration 
experiments using different tryptophan mutants. Examination of mutants lacking a 
specific tryptophan should give insight into which of the two tryptophans is at the 
CARDa-CARDb interface. However, recombinant expression of the tandem CARDs (to 
obtain the single CARDs) was significantly reduced in minimal (M9) media. A 
commercial ‘rich’ isotopically-labelled medium was sourced to see if this could 
alleviate the problem. However, this did not appear to solve the observed problem 
with protein expression and hence, the amount of bacterial culture required to obtain 
sufficient protein for NMR experiments became prohibitively expensive. Using a 
maximum of 6 litres per tryptophan mutant, it became clear that the mutants’ 
expression was still too low and the protein yield (e.g end concentration of the sample 
NOD2-CARDa W63A: 18 μM in 250 μL) not sufficient to complete the titration 
experiments as the signal to noise ratio was too poor.  
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4.2.3 Isothermal titration calorimetry with CARDa mutants 
Due to the problems associated with the expression of 15N-labelled NOD2 CARDs, it 
was decided to further investigate the NOD2 mutants by isothermal titration 
calorimetry (ITC) using unlabelled proteins. ITC is a technique, which can be used to 
measure the binding affinity and thermodynamic parameters of a protein-protein 
interaction. Titration of NOD2-CARDa WT (>200 μM) into NOD2-CARDb WT at 25 °C 
has previously been shown to be exothermic with a KD of 1 μM and a binding 
stoichiometry of 1:1 (n = 0.8-1.0) [131]. All of the following experiments have been 
performed using the same experimental conditions  (50 mM Tris pH 7.5, 100 mM NaCl, 
2 mM DTT) and were done in triplicate.  
 Fridh et al. (2012) already performed ITC experiments with NOD2-CARDa E69K, 
E72K and R86A. These residues were selected to interrupt a type 1 interaction. 
However, titration with wild type CARDb showed that these residues in CARDa are not 
important in the binding of CARDb. My goal was to test further mutants which were 
predicted to be involved in a type 2 and 3 interaction as well as the tryptophans 
mutants described above. Mutants tested were W59A, W63A, W98A, S49A, H75A, 
Q79A and N94A. The individual titrations are presented in Figures 4-5 and 4-6, 
including the calculated stoichiometry and thermodynamic parameters. Titrations 
performed with the wild type, H75A, Q79A, N94A and W98A resulted in exothermic 
reactions of complex formation. Binding constants and thermodynamic parameters 
derived from titrations were calculated after fitted to a single-site binding model, with 
KD= 1/KA and ΔG= -RTlnKA. Standard deviations were calculated between triplicate 
measurements. Dissociation constants varied between 0.6 and 2.3 μM.  
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W63A S49A 
W59A Wild type 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 N KA ΔH ΔS KD  ΔG 
  [M
-1] [cal mol-1] [cal mol-1 K-1] [μM] [kcal mol-1] 
WT 0.81 ± 0.004 9.60E+05 ± 2.8E+04 -3031 ± 10 17.2 ± 0.1 1.05 ± 0.03 -8.16 ± 0.02 
W59A - - - - - - 
W63A - - - - - - 
W49A - - - - - - 
Figure 4-5 ITC analysis of NOD2-CARDa mutants.  The upper plot shows the raw data for the 
titration of NOD2 CARDa into CARDb at 25 °C. The lower plot shows the binding isotherm for 
the interaction. Just one experiment per mutant is shown above, however, listed are the 
binding constants and thermodynamic parameters derived from three titrations by calculating 
the average. Data were fitted to a single-site binding model. Standard deviations were 
calculated between triplicate measurements 
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W98A H75A 
Q79A N94A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 N KA ΔH ΔS KD  ΔG 
  [M
-1] [cal mol-1] [cal mol-1 K-1] [μM] [kcal mol-1] 
W98A 0.86 ± 0.007 6.25E+05  ± 4.7E+04 -3181 ± 35 15.8 ± 0.2 1.61 ± 0.12 -7.90 ± 0.05 
H75A 0.66 ± 0.004 1.57E+06  ± 4.5E+04 -6000 ± 62 8.2 ± 0.2 0.65 ± 0.02 -8.45 ± 0.02 
Q79A 0.67 ± 0.006 4.54E+05  ± 3.5E+04 -3365 ± 38 14.6 ± 0.2 2.27 ± 0.17 -7.71 ± 0.05 
N94A 0.75 ± 0.004 7.21E+05  ± 2.1E+04 -3045 ± 32 16.6 ± 0.1 1.46 ± 0.04 -7.99 ± 0.02 
Figure 4-6 ITC analysis of additional NOD2-CARDa mutants.  The upper plot shows the raw 
data for the titration of NOD2 CARDa into CARDb at 25 °C. The lower plot shows the binding 
isotherm for the interaction. Just one experiment per mutant is shown above, however, listed 
are the binding constants and thermodynamic parameters derived from three titrations by 
calculating the average. Data were fitted to a single-site binding model. Standard deviations 
were calculated between triplicate measurements 
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Due to the difficulties with the stability of CARDb the stoichiometry of complex 
formation n was < 0.7 in most experiments. A better value of n = ~0.9 could be 
achieved with the assumption that the cell sample concentration of CARDb was lower 
than the original value (with a proportion of CARDb partially misfolded). The heat 
generated with NOD2-CARDa mutants W59A, W63A and S49A was not sufficient to 
allow fitting of the data. No improvement in signal could be achieved when the 
experiments were repeated at different temperatures (12 °C and 18 °C). This indicates 
that the mutations W59A, W63A and S49A interrupt complex formation. These 
mutants have been structurally analysed via circular dichroism (far-UV spectra) and 
NMR (1D proton spectra) to confirm that these proteins are all folded (data not 
shown). 
 
4.2.4 Circular Dichroism to identify interacting CARDb residues 
Circular dichroism (CD) was previously used to analyse the fold and stability of the 
individual NOD2 CARDs as well as the tandem construct [131]. Protein stability was 
assessed by thermal unfolding of the proteins between 5 and 95 °C with 
measurements at 222 nm (Figure 1-16). Protein concentration was 0.15 mg/ml in CD 
buffer (150 mM NaCl, 25 mM Tris-HCl pH 8). NOD2-CARDa unfolded with a midpoint 
(Tm) at 66.2 °C whereas CARDb unfolded with a midpoint at 38.0 °C. However, the 
tandem construct showed two transitions occurring at higher temperatures 
(Tm1 = 55.6 °C and Tm2 = 80.8 °C) than for the individual domains.  
 To determine the orientation of the tandem CARDs of NOD2 with respect to 
one another, it was important to gain information not only about CARDa residues 
involved in the interface, but also of CARDb. Up to this point, only wild type CARDb had 
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been purified. From previous work we knew that CARDb alone is an unstable protein, 
which shows precipitation after recording experiments at 25 °C. Therefore, it could be 
expected that a mutation interrupting the intramolecular interaction may lead to a 
misfolded CARDb, which in turn would precipitate upon cleavage from the stabilising 
CARDa. However, small scale solubility screen showed that the majority of the tandem 
CARD constructs with mutations in CARDb are soluble and we were able to purify the 
tandem CARD constructs with single mutations (located in CARDb) D133A, H137A, 
E158A and Q201A. Based on the ITC results with CARDa mutants, the tandem 
constructs containing wild type and W98A were chosen as a positive controls and 
W59A and S49A as negative controls. To our surprise, the obtained melting curve of 
the various tandem NOD2 constructs all showed a single transition point with 
midpoints all between 59 °C and 62 °C (Figure 4-7). 
 
 
 
 
 
 
 
 
 
 
Figure 4-7 CD thermal unfolding of NOD2 tandem CARD mutants. Thermal unfolding 
experiments of various NOD2 tandem CARD mutants measured between 10 °C and 90 °C at 
222nm showed single transition points within 59 °C and 62 °C.  
61.8 °C 
60.9 °C 
60.7 °C 
60.4 °C 
60.6 °C 
59.0 °C 
56.3 °C 
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The melting profile obtained differed from what we expected (Figure 1-16) and 
therefore, CD thermal unfolding experiments were repeated with the single domains 
of the wild type CARDa, CARDb and both CARDs mixed in at equimolar concentration 
prior the experiment. The resulting curves are presented in Figure 4-8. NOD2-CARDa 
unfolded with a midpoint (Tm) at 74.3 °C whereas CARDb unfolded with a midpoint at 
43.5 °C. The tandem CARD construct showed one transition occurring at 61.6 °C. If 
both domains were purified separately and then mixed, the thermal stability was 
higher than CARDb alone although the melting point is 51.8 °C, which is a similar to the 
result obtained by Fridh et al. 
 
 
 
 
 
 
 
  
 
 
Figure 4-8 Thermal unfolding of wild type constructs. Thermal unfolding of the samples was 
performed at a single wavelength (222 nm) between 10 and 90 °C.  
 
 
 
 
61.8 °C 
74.3 °C  
43.5 °C 
51.8 °C 
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 We can only speculate about the reasons for the discrepancy between the data 
obtained in this work and the data by Fridh et al., as equivalent conditions and 
instrumentations were used. One possibility is that the protein sample used by Fridh et 
al. was contaminated. A contamination could have interfered with the thermal 
unfolding of the NOD2 tandem CARDs by stabilising CARDa, which then would increase 
the melting temperature resulting in two transition points.  
 Unfortunately, the difference of the various midpoints obtained here between 
the different mutants are not significant enough to draw any conclusions. A single 
mutation does not seem to interrupt the complex nor destabilise the protein 
significantly. This even applies to the W59A and S49A mutants, which were shown via 
ITC to be essential for the CARDb interaction.  
 The main difference between the CD experiments performed and the ITC 
experiments, is that the CARDs were still connected with the linker in the CD 
experiments whereas they were separate domains in the ITC titrations. For this reason, 
the CD experiments were repeated for several mutants, although this time including 
the thrombin site between CARDa and CARDb. This would allow purification of the 
domains together, before separating them by cleaving the linker with thrombin in 
hope that the interaction will be weakened and a difference between the mutants can 
be observed. However, the melting curves obtained for the tandem CARD mutants 
after thrombin cleavage result in midpoints that still only vary between ~3 °C, although 
overall they are lower and between 52 °C and 55 °C (Figure 4-9). The midpoints 
obtained in this experiment were similar to the values measured when CARDa and 
CARDb were individually purified and mixed prior the thermal unfolding experiment.  
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Based on these results it was concluded that CD is not providing significant differences 
between the mutants to draw any conclusions and suggesting that one mutation is not 
sufficient to disrupt the interaction enough to monitor stability differences via thermal 
unfolding. 
 
 
 
 
 
 
 
 
 
 
Figure 4-9 CD thermal unfolding of NOD2 tandem CARD mutants after thrombin cleavage. 
The tandem NOD2-CARDab mutants contain a thrombin cleavage site between the two 
domains. Prior to CD thermal unfolding experiments, the sample was cleaved with thrombin. 
The thermal unfolding profile of the individually purified CARDa and CARDb mixed together is 
included to demonstrate the similarity of the curves and midpoints. 
 
 
4.2.5 Isothermal titration calorimetry with CARDb mutants 
Given that CD has not provided a clear answer if any NOD2-CARDb mutations are 
having an effect on CARDa binding, it was decided to test if the mutated CARDb 
domains can be cleaved from CARDa and further purified individually to perform ITC 
experiments as described with the CARDa mutants in section 4.3.3. Fortunately, it was 
54.9 °C 
51.8 °C 
53.2 °C 
52.6 °C 
53.9 °C 
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possible to complete ITC experiments using wildtype CARDa by titrating it into the 
sample cell containing the CARDb mutants D133A, H137A, E158A or Q201A. The 
individual titrations and the thermodynamic parameters are presented in Figure 4-10. 
Titrations performed with all four CARDb mutants resulted in an exothermic reaction 
of complex formation. The binding curves could be fitted to a single-site binding model 
with a dissociation constant of 0.9 - 3 μM. As expected, some CARDb mutants did not 
seem very stable at room temperature. The noise level of the baseline was significantly 
higher than in previous experiments with CARDa mutants. The instability of D133A is 
represented in the stoichiometry of n = 0.53 ± 0.004. Similar to the experiments with 
CARDa mutants, the assumption of a lower actual concentration of CARDb resulted in a 
better value of up to n~0.85, implying that a part of the D133A cell sample was not 
properly folded and functional.  
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D133A H137A 
Q201A E158A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N KA ΔH ΔS KD ΔG 
 
  [M-1] [cal mol-1] [cal mol-1 K-1] [μM] [kcal mol-1] 
D133A 0.53 ± 0.004 4.05E+05 ± 7.9E+04 -2444 ± 38 17.3 ± 0.4 2.92 ± 0.5 -7.65 ± 0.12 
H137A 0.79 ± 0.008 1.15E+06 ± 5.5E+04 -2100 ± 38 20.6 ± 0.2 0.95 ± 0.04 -8.27 ± 0.03 
E158A 0.77 ± 0.011 7.51E+05 ± 1.4E+05 -2800 ± 95 17.3 ± 0.5 1.68 ± 0.25 -8.02 ± 0.11 
Q201A 0.97 ± 0.010 1.60E+06 ± 5.4E+05 -2881 ± 71 18.3 ± 0.7 1.04 ± 0.24 -8.47 ± 0.21 
 
Figure 4-10 ITC analysis of NOD2-CARDb mutants.  The upper plot shows the raw data for the 
titration of NOD2 CARDa into CARDb at 25 °C. The lower plot shows the binding isotherm for 
the interactionJust one experiment per mutant is shown above, however, listed are the 
binding constants and thermodynamic parameters derived from three titrations by calculating 
the average. Data were fitted to a single-site binding model. Standard deviations were 
calculated between triplicate measurements 
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4.3 Intermolecular CARD-CARD interactions of NOD2 and RIP2 
Having demonstrated that CARDa residues W59A, W63A and S49A are probably 
involved in the intramolecular CARD-CARD interaction of NOD2 CARDa and CARDb, the 
next goal was to map residues involved in the binding site of the NOD2-RIP2 
CARD-CARD intermolecular interaction. This would allow the generation of a model to 
gain insight into the architecture of the NOD2-RIP2 interaction. With recent literature 
suggesting that CARDs form higher order complexes [54], we were interested to test if 
both CARDs of NOD2 are essential for RIP2 recruitment. Additionally, highly insoluble 
CARDs such as BCL10 have recently been shown to form filaments by Qiao et al. (2013) 
[103], with filament formation significantly enhanced in the presence of the upstream 
scaffold protein CARMA1. With RIP2 having proved to be a problematic construct to 
work with and being a downstream effector molecule in the NOD2 signalling pathway, 
the question arose if RIP2-CARD also forms filaments and if they are nucleated by 
NOD2.  
 
4.3.1 Pull-down experiments with NOD2 tandem CARD mutants 
4.3.1.1 Constructs used 
Previous work carried out in our group on the interaction between NOD2 and RIP2 
involved co-expression and pull-down studies [131]. Based on results with the mutants 
tested so far, it was suggested that the tandem CARDs of NOD2 use the basic residues 
R38 and R86, located on the CARDa domain, for the interaction with RIP2 CARD. The 
majority of the new NOD2 tandem CARD mutants (amino acid (aa) 28-218, pGEX-6P1, 
GST-fusion) already created for section 4.3 has shown that the residues tested are not 
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involved in the NOD2 intramolecular interaction, therefore, these constructs were 
further analysed in this study for RIP2 binding. 
 Former group members have shown that RIP2-CARD cannot be expressed and 
purified without a solubility enhancement tag such as GB1 (Immunoglobulin binding 
domain of Streptococcal protein G) or MBP. In light of these observations RIP2-CARD 
aa 432-529 was cloned into pET-XM1 (kind gift of Sebastian Charbonnier, CNRS, 
Illkirch), an expression vector generating proteins with an N-terminal MBP-tag. MBP, 
which has a molecular weight of 40 kDa, is a highly soluble protein and is often used as 
a solubility enhancer of their fusion partner.  
 
4.3.1.2 Small scale co-expression and pull-down experiments 
The two vectors containing either GST-NOD2-CARDab or MBP-RIP2-CARD were co-
transformed into BL21 (DE3) Gold cells and plasmid stability was maintained by 
addition of kanamycin and carbenicillin to the growth media of 150 mL LB. After 
induction and incubation at 18 °C overnight, the cells were harvested and lysed by 
sonication in 150 mM NaCl, 50 mM TRIS-HCl pH 8, 2mM DTT. The supernatant was 
loaded onto 150 μL GST-sepharose beads solution. Pull-down experiments were 
carried out using 5 mL polystyrene columns (Sigma Aldrich). Beads were washed with 
three times 1 mL lysis buffer. Elution was carried out by adding 10 mM reduced 
glutathione to the buffer. Samples for SDS-PAGE analysis were taken at every step and 
the pull-down experiment with wild-type GST-NOD2-CARDab/MBP-RIP2-CARD is 
shown in Figure 4-11 A. Expression analysis showed that both proteins were expressed 
although RIP2-CARD was overexpressed to a greater degree. The gel shows that 
MBP-RIP2-CARD clearly bound to the NOD2 protein. Control experiments were 
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performed to exclude any non-specific binding of the MBP fusion tag by using wild-
type NOD2-CARDab co-expressed and purified with only MBP (Figure 4-11 B). The 
same pull-down experiments were repeated with all NOD2-CARDab mutants available 
and are shown in Figure 4-12. Mutant R38A, originally shown in Fridh et al. (2012) to 
lose the ability to bind RIP2, was used in this study as a negative control experiment. 
All new mutants were able to bind RIP2-CARD. 
 
 
 
 
 
 
 
 
 
 
Figure 4-11 Control gels of GST-pull-down experiments.   (A) Co-expression and pull-down 
analysis using glutathione sepharose beads. MBP-RIP2-CARD (52 kDa, red) interacts with 
GST-NOD2 CARDab (48.5 kDa, orange) on the beads and both proteins can be eluted. (B) The 
MBP-tag (40 kDa, blue) does not bind GST-NOD2-CARDab. Both proteins are present in the 
supernatant following co-expression but only GST-NOD2 CARDab is present in the beads and 
elution sample. C: cell, SN: supernatant, FT: flow through, W1-3: washing steps, B: beads, EL: 
elution. 
 
 
 
 
A B 
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Figure 4-12 GST-pulldowns: Effect of NOD2 CARDab mutants on RIP2 binding. Co-expression 
of MBP-RIP2-CARD with NOD2-CARDab containing point mutations (CARDa: R38A, S29A, 
W59A, W63A, H75A, Q79A, N94, W98A. CARDb: D133A, H137A, E158A, Q201A) MBP-RIP2-
CARD interacts with GST-NOD2 CARDab on the beads and both proteins can be eluted. Bands 
corresponding to GST-NOD2 CARDab (48.5 kDa) are marked orange and bands corresponding 
to MBP-RIP2-CARD (52 kDa) are marked red. C: cell, SN: supernatant, FT: flow through, W3: 
third washing step, B: beads, EL: elution. 
Results | 4 
 
155 
 
4.4 NOD2-CARDab and RIP2-CARD polymerisation study  
It has been recently shown by electron microscopy and x-ray crystallography that 
CARDs can form a helical filamentous assembly. Polymerisation was quantitatively 
assessed in that study via fluorescence polarisation assays. Additionally, these assays 
were used to show that an upstream regulator can enhance polymerisation by 
nucleating these filaments. In these experiments mentioned, polymerisation was 
initiated by cleaving the CARD from its MBP-fusion protein [103].  
 The goal of this part of the project was to set up a fluorescence polarisation 
assay to test if RIP2-CARDs may undergo filament assembly when cleaved off its MBP-
tag. Additionally, we wanted to test if the tandem CARDs of NOD2 can initiate and/or 
enhance RIP2 polymerization. 
 
4.4.1 Constructs, expression and purification 
Our MBP-RIP2 aa432-529 construct, which has been shown to be soluble and able to 
bind NOD2-CARDab, had to be re-cloned using the LIC-vector pHMBP, which was 
designed in-house. This plasmid generates the desired protein construct including an 
N-terminal His6-MBP-tag with a 3C cleavage site for tag-removal. Furthermore, the 
protein needed to be labelled with a fluorophore-maleimide at a location where the 
probe would not sterically interfere with any CARD-CARD interface. Hence, labelling on 
the CARD itself needed to be avoided. For this reason, C455, which is located at the 
CARD, was changed to an alanine via site-directed mutagenesis. However, to include a 
cysteine in our construct, two different approaches were taken: firstly, one construct 
was extended on the N-terminus to aa 413-529 to include the natural occurring 
cysteine C414 of the RIP2 sequence; secondly, another construct was designed by 
Results | 4 
 
156 
 
MBP-RIP2-CARD 
GST-NOD2-CARDab 
extending the fragment to the RIP2 C-terminus at aa 540 instead and inserting the 
mutation S539C. The newly designed constructs needed to be tested if they were still 
soluble and if NOD2-CARDab binding can still be achieved. The same pull-down 
experiment as described above in section 4.4.1.2 were performed with the MBP-RIP2-
CARD C455A (aa 413-529) and MBP-RIP2-CARD C455A/S539C (aa 432-540). SDS-PAGE 
analysis is shown in Figure 4-13. Although both RIP2 constructs are on the beads, only 
MBP-RIP2-CARD C455A (aa 413-529) is eluted together with NOD2-CARDab. For this 
reason, this construct was chosen for the following fluorescence polarisation assays. 
Larger scale purification was performed via Amylose resin and size exclusion 
chromatography following the standard protocol described in section 2.2.8 and 2.2.10. 
 
 
 
 
 
 
 
 
 
Figure 4-13 GST-pulldowns with modified MBP-RIP2-CARD constructs. (A) MBP-RIP2-CARD 
C455A/S539C (aa432-540) with GST-NOD2 CARDab. (B) Co-expression of MBP-RIP2-CARD 
C455A (aa413-529) with GST-NOD2-CARDab and although both RIP2 constructs are on the 
beads only MBP-RIP2-CARD C455A (aa 413-529) is eluted together with NOD2-CARDab. C: cell, 
SN: supernatant, FT: flow through, W3: third washing step, B: beads, EL: elution. 
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4.4.2 Fluorophore labelling 
The fluorophore used in this study was Alexa Fluor® 488 C5 maleimide (Thermo 
Scientific), a green fluorescent dye designed for conjugation to a thiol group. The 
protein sample was concentrated to 50 μM prior to mixing with a 3-fold molar excess 
of Alexa Fluor® 488 C5 maleimide. After 2 h incubation at room temperature with the 
MBP-RIP2 construct, the sample was loaded onto a disposable PD-10 desalting column 
before another gel filtration chromatography step was performed using 150 mM NaCl, 
20 mM Tris-HCl pH 7.5 and 0.5 mM TCEP to remove free dyes (Figure 4-14). The 
following monomeric peak containing the labelled RIP2 was collected and 
concentrated to ~10 μM for further studies. 
 
 
 
 
 
 
 
 
 
 Figure 4-14 His6-MBP-(3C)-RIP2-CARD C455A (aa 413-529) gel filtration purification after 
labelling.  Elution profiles of the Alexa Fluor® 488 C5 labelled His6-MBP-(3C)-RIP2-CARD C455A 
(aa 413-529) using a Superdex 200 16/60 gel filtration column. The peak of monomeric 
MBP-RIP2 was collected and pooled. The buffer used was 150 mM NaCl, 20 mM Tris-HCl pH 
7.5, 0.5 mM TCEP. 
Volume mL 
mAU 
Void 
MBP-RIP2 
Dye 
Results | 4 
 
158 
 
4.4.3 Biophysical analysis 
4.4.3.1 UV spectrum 
To determine the protein concentration as well as the degree of labelling, a UV 
spectrum was recorded to measure the absorbance of the conjugate solution at 
280 nm and 495 nm. The concentration for the labelled protein was calculated using 
equation provided by Alexa Fluor® 488 supplier (Thermo Scientific): 
 
Equation 5.1:           Protein concentration  = [A280 – 0.11(A494)] / [ε280(Protein)] 
In this equation, 0.11 is a correction factor for the fluorophore’s contribution to 
the A280. 
 
An absorption of 0.62 at 495 nm and 0.73 at 280 nm was measured. With an extinction 
coefficient of 72,000 cm-1M-1 and 74,830 cm-1M-1 for Alexa Fluor® 488 C5 and MBP-
RIP2 respectively, a protein concentration of 8.9 μM was calculated and a dye 
concentration of 8.6 μM.  Thus it can be concluded that >93 % of the cysteines have 
been labelled.  
 
4.4.3.2 CD spectroscopy 
Before the fluorophore labelling process, it was shown in section 4.4.1 that the 
MBP-RIP2 (aa413-529) is functional and able to pull-down NOD2-CARDab. To ensure 
this construct remained folded even after the labelling process, the sample of the 
labelled MBP-RIP2 was used for CD spectroscopy to determine the secondary structure 
content. The MBP-RIP2 construct is still clearly alpha-helical (Figure 4-15). The intensity 
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of this spectrum, however, is probably affected by possible errors in the estimate of 
protein concentration due to the fluorophore (see 4.4.3.1).  
 
 
 
 
 
 
 
Figure 4-15 Far-UV CD spectra of labelled His6-MBP-(3C)-RIP2 C455A (aa 413-529). Far-UV CD 
(220-250 nm) was carried out to analyse the secondary structure content of the labelled 
His6-MBP-(3C)-RIP2. Protein concentration was ~0.15 mg/mL and spectra recorded at 20 °C.  
 
 
4.4.3 Fluorescence polarisation assay with RIP2 and NOD2 
Fluorescence polarisation assays as described by Qiao et al. [103] was used to 
investigate potential polymerisation of RIP2 in the presence or absence of NOD2. In 
preparation for the fluorescence polarisation assay, the excitation and emission 
spectra of the Alexa Fluor® 488 labelled MBP-RIP2 were recorded (Figure 4-16). Both 
excitation and emission maxima are close together and we decided on using an 
excitation of 492 nm and emission of 522 nm for the assay. Fluorescence polarization 
assays were performed at 25 °C in a buffer containing 150 mM NaCl, 20 mM Tris-HCl 
pH 7.5 and 0.5 mM TCEP. The sample volume was 80 μL with a MBP-RIP2 
concentration of 9 μM. About 100 seconds after starting the experiment with a 
recording time of 2h (7200 seconds) 5 μg of His6-3C protease (purified in-house) was 
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added to the cuvette for removal of the MBP-fusion to allow RIP2 polymerization 
(Figure 4-17). The 3C cleavage was clearly monitored with a decrease in fluorescence 
polarisation as the molecular weight of the labelled protein drops from 55.5 to 13.5 
kDa resulting in faster tumbling molecules, hence orientational distribution becomes 
randomized prior to emission, resulting in lower fluorescence polarization [154]. The 
FPA experiment was repeated, but with the addition of 2 μM (end concentration) 
NOD2-CARDab in an NOD2-induced RIP2 polymerization experiment (Figure 4-18 blue). 
However, a polymerisation of RIP2-CARD following 3C cleavage could not be recorded 
either in presence or absence of NOD2-CARDab molecules (Figure 4-17 and 
Figure 4-18 blue). As it has been suggested in the literature that CARD9 may also 
interact with the RIP2-NOD2 complex [78, 80], an additional FPA experiments was 
performed, similar to the previous ones but by adding 2 μM of CARD9 aa 1-277 (Figure 
4-18 red). However, the result was similar and no polymerisation of RIP2 could be 
monitored. After the experiments the samples were analysed via SDS-PAGE. As seen 
on the gel, all MBP-RIP2 has been cleaved during the experiments (Figure 4-19). 
 
 
 
 
 
 
 
 
Figure 4-16 Fluorescence spectra. Excitation and emission spectra of Alexa® Fluor 488 labelled 
His6-MBP-(3C)-RIP2-CARD C455A (aa 413-529). 
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Figure 4-17 Fluorescence polarization assay 1. The fluorescence polarisation of Alexa 488-
labeled His6-MBP-(3C)-RIP2-CARD C455A (aa413-529) was monitored before and after removal 
of the MBP-tag by 3C protease cleavage. The temporary drop in polarization at the beginning 
of the experiment represents the addition of 3C protease. 
 
 
 
 
 
 
 
 
 
Figure 4-18 Fluorescence polarization assay 2. Blue: Alexa 488-labeled His6-MBP-(3C)-RIP2-
CARD C455A (aa413-529) in the presence of substoichiometric amounts (1/5) of NOD2-CARDab 
upon MBP removal by 3C protease cleavage. Red: Same experimental setup as (Blue) but in the 
presence of substoichiometric amounts (1/5) of CARD9 aa 1-277 in addition to NOD2. 
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Figure 4-19 SDS-PAGE analysis pre- and post-FPA. 1: uncleaved labelled MBP-RIP2-CARD (56 
kDa), 2: NOD2-CARDab (22 kDa), 3: CARD9 aa 1-277 (34 kDa), 4: 3C protease (21.7kDa), 5: post 
FPA sample - only MBP-RIP2, 6: post FPA sample with added NOD2-CARDab, 7: post-FPA 
sample with NOD2 and CARD9. 
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4.5 Summary 
In this chapter, preliminary work from former group members has been used as a basis 
to further define the binding interface of both, the intramolecular interaction of NOD2 
tandem CARDs and the intermolecular interaction of NOD2-CARDab with RIP2-CARD.  
Expression problems with the NOD2 tandem CARDs, especially mutant proteins, in 
medium other than LB, forced us to abandon NMR titration experiments. Mutational 
analysis was therefore continued using ITC. I was able to show that NOD2-CARDa 
mutants W59A, W63A and S49A  were unable to bind CARDb. Comparing the binding 
surface of NOD2-CARDa involving these three residues, the interaction with CARDb 
resembles the intramolecular interaction between DED1 and DED2 of MC159 or 
Caspase-8. However, no residues could be identified in NOD2-CARDb that interfered 
with the intramolecular interaction. 
 Previous pull-down experiments revealed that R38 and R86 in NOD2-CARDa are 
essential for RIP2 binding. All new NOD2-CARDab mutants generated for the ITC 
analysis were then used for pull-down experiments with MBP-RIP2-CARD in order to 
further define the binding interface between NOD2 with RIP2. However, all new 
mutants showed no significant effect and were able to pull-down RIP2-CARD. This data 
is consistent with previous studies by former group members that suggested that it is 
mainly NOD2-CARDa that recognises RIP2-CARD. 
 Due to the discovery that CARDs can form filamentous assemblies that play a 
signalling role, fluorescence polarisation assays were carried out with RIP2-CARD to 
investigate its ability to polymerise upon MBP-tag removal. However, no 
polymerisation could be detected in the absence or the presence of NOD2-CARDab. 
 
  
 
 
 
 
 
 
 
Chapter 5 
 
 
Study of CARMA1, CARD9 and BCL10 
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5.1 Overview 
CARMA1 and CARD9 are both adaptor proteins containing an N-terminal CARD 
followed by a coiled-coil domain. They are key in initiating the formation of the CBM 
signalosome for NF-κB activation and MAPK in lymphoid cells (CARMA1) and myeloid 
cells (CARD9). CBM-complex assembly involves the recruitment of BCL10 via a CARD-
CARD interaction to further complete the signalosome by binding to MALT1.  
 At the time when we discovered that the construct of CARMA1-CARD is highly 
soluble (as seen in Chapter 3), no structures of CARMA1, CARD9 or BCL10 were 
available. Therefore, the original aim of the work described in this chapter was to 
structurally characterise these individual CARD domains and to biophysically 
investigate the CARD-CARD binding modes involved in forming a complex between 
CARMA1 and BCL10 as well as CARD9 and BCL10. Those two systems, strikingly similar 
from a structural point of view, yet so different in a cellular context, make the 
comparison between the characteristics of CARMA1 and CARD9 even more intriguing. 
Additionally, a characterisation of CARMA1 and CARD9 and how they interact with 
BCL10 could pave the way towards the final goal of finding a general mode of 
interaction between CARD domains. 
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5.2 CARMA1 
This section explores the two approaches used to characterise CARMA1. Firstly the 
attention was focused on the production, purification and characterisation of the 
CARMA1-CARD domain in isolation, with the goal to determine its biophysical 
properties and ultimately its structure. In the second stage of the study, the focus was 
turned to constructs comprising the N-terminal CARD followed by different segments 
of the coiled-coil domain. This approach is based on the rationale, that CARD-
containing proteins may require an additional domain, which undergoes 
oligomerisation to enable the interaction with its binding partners. Therefore, the 
coiled-coil segments may provide a platform for BCL10 recruitment. 
 
5.2.1 CARD of CARMA1 
5.2.1.1 Expression and purification 
The results from the small scale solubility screen (see section 3.2.2) originally drew our 
attention to CARMA1-CARD. These experiments showed that the CARD of CARMA1 
containing aa 18-110 is well expressed either as GST-fusion or as a His6-tagged protein. 
It was also possible to purify CARMA1-CARD aa 18-110 from a larger expression using 
750 mL LB media, performing either a Ni-NTA purification for the His-tagged protein or 
GST-affinity chromatography for the GST-fusion construct. In both cases, soluble 
CARMA1-CARD was obtained after elution using 500 mM Imidazole (for the His-tagged 
protein) or 3C cleavage (for the GST-tagged protein) (see Figure 3-7 and Figure 5-1 
respectively).  For this reason, CARMA1-CARD was chosen for further biophysical 
investigation as it was one of the most soluble constructs of the expression screens 
and – in contrast to other CARDs like APAF1, RAIDD or NOD1, which also showed high 
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solubility – there was nothing known about the structure of CARMA1 at that time. 
Both CARMA1-CARD samples (after either GST-affinity chromatography or Ni-NTA 
purification) were further purified via gel filtration chromatography to remove any 
remaining contaminants. The pure protein samples could be concentrated up to 20 
mg/ml without showing any signs of precipitation.  
 
 
 
 
 
 
 
 
Figure 5-1 His6-CARMA1-CARD purification. SDS-PAGE analysis following purification of His6-
tagged CARMA1-CARD aa18-110 (13.2 kDa). M; protein marker, P; pellet, SN; supernatant, FT; 
flow through, W; washing step. The protein was eluted by an imidazole gradient. 
 
 
5.2.1.2 Crystallisation experiments 
Although interested in the structural details of homotypic CARD-CARD interactions, 
obtaining the crystal structure of CARMA1-CARD would open up opportunities to 
investigate the molecular details of possible binding sites. Therefore, several initial 
crystallisation screens were kindly set up by Lesley Haire and Roksana Ogrodowicz; 
CARMA1-CARD (aa 18-110) obtained after 3C cleavage of the GST-tag was used to set 
up an initial screens at 17 mg/ml, using the sitting drop method and an incubation 
temperature of 18 °C (using the following screens: Imperial College screen (designed 
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by Lesley Haire), Classics lite and pH clear 1 (both Qiagen)). In addition, further screens 
(pH clear 1 and 2, Classics lite, Wizard 1 and 2 (Rigaku reagents)) were set up using 
His6-CARMA1 at 10 mg/mL and 20 mg/mL. I observed that the ratio between 
precipitation and clear drops was balanced. Unfortunately, no crystals formed after an 
incubation time longer than 13 days.  
 
5.2.1.3 NMR spectroscopy 
In parallel to the crystallisation trials, 1D-1HNMR spectroscopy was used to analyse the 
structural integrity of CARMA1-CARD, while 2D and 3D NMR experiments were carried 
out to assess if structural studies of CARMA1-CARD would be possible by NMR. In 
these experiments, only the 3C cleaved CARMA1-CARD (aa18-110) construct originally 
expressed as GST-fusion was used. The protein sample was dialysed against 20 mM 
HEPES pH 7, 50 mM NaCl, 2 mM TCEP and concentrated to 200 μM. A 1D-1H NMR 
spectrum was recorded at 25 °C on a 600 MHz spectrometer (Figure 5-2).  
 
 
 
 
 
 
 
 
Figure 5-2 1D-1H NMR spectrum of CARMA1-CARD. NMR analysis shows that CARMA1-CARD 
contains tertiary structure as peaks at a chemical shifts >9 ppm and ≤0.5 ppm can be observed. 
The spectrum was recorded at 25 °C on a 600 MHz spectrometer. 
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Peaks at a chemical shift >9 ppm and ≤0.5 ppm indicate that CARMA1 contains a 
hydrophobic core and is properly folded. To further analyse if structure determination 
by NMR would be possible, a 13C-15N labelled CARMA1-CARD sample was produced to 
carry out heteronuclear multidimensional NMR experiments.  The 13C-15N labelled 
protein sample was prepared by growing bacteria in 4 litres minimal medium using 
15N-ammonium sulphate as well as 13C-glucose. Purification was carried out as for the 
unlabelled sample and the purified protein was dialysed against 50 mM NaCl, 20 mM 
HEPES pH 7.0 and 2 mM TCEP before concentrating it to 500 μM. A 1H-15N HSQC was 
recorded at 25 °C which is shown in Figure 5-3.  
 
 
 
 
 
 
 
 
 
 
 
Figure 5-3 1H-15N HSQC spectrum of CARMA1-CARD. The 2D spectrum of CARMA1-CARD 
shows sharp linewidth of the peaks and confirms the previous result of the 1D proton 
spectrum, that CARMA1 is properly folded. A protein concentration of 500 μM was used in 
50 mM NaCl, 20 mM HEPES pH 7, 2 mM DTT and the spectrum was recorded at 25 °C on a 
600 MHz spectrometer. 
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13C ppm 
1H-(N) ppm 
The spectrum is of very good quality because the peaks are well dispersed; this 
confirms the previous result obtained from the 1D proton spectrum that CARMA1 is 
properly folded. With a peak number of 102 (plus 7 prolines in the sequence, which 
can’t be observed in this spectra) nearly all 106 residues are observable. The sharp 
linewidth of the peaks is consistent with a single species in solution, most likely a 
monomer. For structure determination, the quality of triple-resonance spectra is 
essential and for this reason, a short HNCO was recorded (Figure 5-4); The HNCO 
experiment is the most sensitive multi-dimensional experiment and considerably quick 
to record, and for this reason is normally chosen as the first spectrum to test a protein 
sample before running other 3D experiments [155].  
 
 
 
 
 
 
 
 
 
 
 
Figure 5-4 1H-13C-15N HNCO experiment of CARMA1-CARD. The H-C(O) plane of the HNCO 
shows sharp peak linewidth and a peak count of 90. A protein concentration of 500 μM was 
used in 50 mM NaCl, 20 mM HEPES pH 7, 2 mM DTT and the spectrum was recorded at 25 °C 
on a 600 MHz spectrometer. 
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Similarly to the HSQC spectrum, the HNCO spectrum also shows sharp peak linewidths 
and a good peak distribution. An estimated peak count of 90 coincides with the 96 
residues of the protein. From those preliminary experiments it can be concluded that 
an assignment and a structural determination would be possible with a complete set of 
3D experiments. Unfortunately, before more crystallisation screens were set up and 
additional NMR experiments recorded, Li et al. (2012) [156] published the crystal 
structure of CARMA1-CARD and the focus was shifted towards longer CARMA1 
constructs and CARD9. 
 
5.2.2 CARD-coiled-coil constructs of CARMA1 
5.2.2.1 Construct design 
As previously explained, the reasons for producing extended constructs of CARMA1 is 
based on the rationale that CARD-containing proteins may require an additional 
domain, which undergoes oligomerisation, to enable the interaction with partner 
CARDs [54]. As seen in Figure 5-6 A, CARMA1-CARD is predicted to be followed by a 
coiled-coil domain, which is connected with the CARD by a linker of unknown 
structure. Importantly, the coiled-coil is an oligomerisation domain, which could be an 
important feature to enable CARD-CARD interactions. The MultiCoil software [157] 
was used to predict potential coiled-coil regions in CARMA1 (Figure 5-5). There are 
four predicted coiled-coil segments starting and ending around residues 130-175, 200-
300, 300-350, and 350-430, respectively (Figure 5-6 A). Based on the prediction, 15 
constructs have been designed starting at amino acid 18 and ending at various lengths 
along the coiled-coil domain (Table 5-1). 
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Figure 5-5 Prediction of coiled coil structures by MultiCoil. Approximatly four potential coiled 
coil regions in CARMA1 are shown, around 130-175, 200-300, 300-350, and 350-430 [157]. 
 
      A                  
 
 
Figure 5-6 CARMA1-CARD-CC constructs. A; Secondary structure prediction (JPred [145]) of 
the CARMA1 CARD and coiled-coil (CC) domain is illustrated with the designed constructs 
C1-C15. B; SDS-PAGE gel results of the small scale expression and purification screens of the 15 
CARMA1 constructs, with the induced cell lysate on the left, followed by the proteins eluted 
from the Ni-NTA-column on the right. The constructs have been numbered and listed in 
Table 5-1. 
Residues 
Residues 
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Table 5-1 CARMA1-CARD-CC constructs. 15 constructs of CARMA1, including the CARD domain 
and additional amino acids on the C-terminal domain, have been screened by small scale 
expression and purification experiments. Results are illustrated as heavily √√√, moderately √√ 
and minimally √ expressed/soluble constructs based on the visual analysation of SDS-PAGE 
gels. Unexpressed/insoluble constructs are marked with x. 
 
 
All constructs have been cloned into pET52-47 to obtain N-terminally His6-tagged 
proteins. To screen the newly generated CARMA1 constructs efficiently, a small scale 
expression and solubility screen with Ni-NTA was carried out as described in section 
2.2.4. Most of the constructs containing fractions of the first two predicted coiled-coil 
segments (up to residue 299) were soluble. 
 To be able to determine the function of the additional coiled-coil segments, 
purification of the constructs aa 18-395 and aa 18-449, both containing the full coiled-
coil, was attempted by modifying the lysis buffer (300 mM NaCl, 50 mM 
L-Arginine/Glutamic acid, 50 mM Tris-HCl pH 8, 10 mM Imidazole, 0.3 mM TCEP, 10 % 
glycerol) to possibly enhance protein stability/solubility. However, SDS-PAGE gel 
#  construct MW [kDa] pI  expressed soluble 
1 18-129 15.3 5.90 √√√ √√√ 
2 18-190 22.9 6.21 √√√ √ 
3 18-200 24.1 5.95 √√√ √√ 
4 18-238 28.7 6.28 √ √√ 
5 18-242 29.2 5.92 x x 
6 18-251 30.3 6.03 √√√ √√√ 
7 18-260 31.4 6.16 √√√ √√√ 
8 18-291 35.0 6.17 √√√ √√√ 
9 18-299 35.9 6.17 √√√ √√√ 
10 18-339 40.8 5.76 √√√ x 
11 18-357 42.8 5.56 √√√ x 
12 18-395 47.5 5.49 √√√ √ 
13 18-425 51.4 5.53 √√√ √ 
14 18-440 53.1 5.71 √√√ √ 
15 18-449 54.1 5.59 √√√ √ 
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analysis of the different purification steps showed that most of the protein still 
remained insoluble or irreversibly bound to the Ni-NTA beads (Figure 5-7). The small 
amount of protein finally eluted with 500 mM Imidazole was not suitable for further 
purification steps due to protein precipitation.  
 
 
 
 
 
 
 
 
 
Figure 5-7 His6-CARMA1 purification. SDS-PAGE analysis following expression of His6-tagged 
CARMA1 aa18-395 (47.5 kDa) and aa 18-449 (54.1kDa). M; protein marker, P; pellet, SN; 
supernatant, FT; flow through, W; washing step, B; Beads and EL; elution. 
 
 
In addition, considering the possibility that a different tag could enhance solubility, 
constructs CARMA1 aa 18-440 and aa 18-449 were cloned into pET52 to express 
STREP-tagged proteins. Purification with the above mentioned modified lysis buffer 
(excluding Imidazole) was attempted using StrepTactin sepharose beads (GE 
Healthcare) and 2.5 mM desthiobiotin for elution. As this approach did not lead to any 
soluble proteins either, a 24-well small scale solubility screen using different lysis 
buffers with a variation of salts, pH and additives such as glycerol, trehalose or triton 
X-100, was performed and the lysate analysed via SDS-PAGE. However, even in this 
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49 
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case no improved condition was found (data not shown). For this reason, the focus 
was then set on the truncated constructs containing only up to 2 of the 4 coiled-coil 
segments to further analyse them via SEC-MALLS.  
 
5.2.2.2 SEC multi-angle laser light scattering 
According to the MultiCoil prediction in Figure 5-5, the CARMA1-coiled-coil most likely 
forms a dimer. To investigate the influence of the different coiled-coil fractions on 
protein oligomerisation, we used multi angle laser light scattering coupled to size 
exclusion chromatography (SEC-MALLS) to investigate the molecular masses of 
selected constructs in solution. The constructs chosen for these experiments were 
CARMA1 aa 18-129, 18-200 and 18-299. They have been successfully purified following 
a standard Ni-NTA purification protocol (2.2.6) including 10% glycerol. The purified 
proteins were concentrated to 3 mg/mL before loading onto a S200 10/300 GL column 
equilibrated in 150 mM NaCl, 50 mM HEPES pH8, 1mM EDTA, 1 mM TCEP and 3 mM 
Azide at 4 °C. For the construct CARMA1 aa 18-129, SEC-MALLS analysis resulted in a 
main peak with a recorded molecular weight of 14.7 kDa consistent with a monomer 
(calculated MW = 15.3 kDa). A small amount (< 7%) of the protein forms a dimer, 
showing up as a second peak with a molecular weight of 30.1 kDa (Figure 5-8). For 
CARMA1 aa 18-200, only one peak was monitored resulting in a molecular weight of 
46.5 kDa (calculated MW for the monomer = 24.1 kDa) which is clearly forming a dimer. 
The third sample, CARMA1 aa 18-299, unfortunately eluted mainly in the void and 
could not be further analysed. In this case, purifying and analysing the next shorter 
CARMA1 construct (aa 18-291)  could provide more insights. 
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Figure 5-8 SEC-MALLS analysis of CARMA1. The chromatogram shows the UV absorbance and 
the molecular weight calculation of the samples. The samples were loaded at 3 mg/mL.  Black; 
SEC-MALLS analysis of CARMA1 aa 18-129, resulted in a main peak with a recorded molecular 
weight of 14.7 kDa consistent with a monomer (calculated MW = 15.3 kDa). Second peak 
corresponds to a dimer with a molecular weight of 30.1 kDa. Red; For CARMA1 aa 18-200, only 
one peak was monitored resulting in a molecular weight of 46.5 kDa (calculated MW for the 
monomer = 24.1 kDa). 
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5.3 CARD9 
5.3.1 CARD of CARD9 
5.3.1.1 Constructs, expression and purification  
CARD9 also comprises an N-terminal CARD followed by a coiled-coil similar to 
CARMA1. More interestingly, it has been shown that CARD9 also recruits BCL10 via 
CARD-CARD interaction in myeloid cells. Therefore, the His6-tagged CARD9 aa 1-104, 
which appears to be at least partly soluble in the small scale expression and solubility 
screen (see section 3.2.2) was expressed in 750 mL LB medium and purified using 
Ni-NTA beads to investigate if we could obtain a reasonable quantity of CARD9 for 
further experiments (Figure 5-9). Unfortunately, it became soon clear that most of 
CARD9 is insoluble.  Protein from the supernatant, which was loaded on the Ni-beads 
and eluted was collected but quickly precipitated during the attempt to concentrate it 
for a further purification step.  
      
 
 
Figure 5-9 His6-CARD9-CARD purification. SDS-PAGE analysis following expression of 
His6-tagged CARD9-CARD aa1-104 (12 kDa). M; protein marker, P; pellet, SN; supernatant, FT; 
flow through, W; washing step. The protein was eluted with an imidazole concentration of 75 
mM and increasing to 500 mM. 
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Having found that CARD9 aa 1-104 is not a suitable construct to work with, further 
cloning was carried out. Taking into account the fact that the boundaries for the 
previous construct (aa 1-104) were set generously to safely include the full CARD, 
there was still room to both shorten or lengthen the new constructs at the C-terminus. 
Therefore, three more (aa 1-98, aa 1-122 and aa 1-129) constructs were designed and 
cloned into pET52-47 to express His-tagged proteins. Upon successful cloning, the 
proteins were immediately expressed in a larger scale of 750 mL LB medium. The 
purification was performed as described in 2.2.6. Figure 5-10 shows that all constructs 
are soluble. For CARD9 aa 1-98 a further purification step was carried out via size 
exclusion chromatography. The fractions collected were pooled and concentrated. 
Unfortunately the protein precipitated during the process.  
 
 
 
 
 
 
 
 
 
Figure 5-10  His6-CARD9-CARD purification. SDS-PAGE analysis following expression of His-
tagged CARD9-CARD aa 1-98 (13.6 kDa), aa 1-122 (16.1 kDa) and aa 1-129 (17 kDa). P; pellet, 
SN; supernatant, FT; flow through, W; washing step, B; beads, EL; elution. The protein was 
eluted with an imidazole concentration of 500 mM. 
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5.3.1.2 CARD9-CARD aa 1-98: Thermofluor 
At this point, it had to be taken into account that we are not only looking for soluble 
constructs, but also for proteins, which were suitable for crystallisation trials. This 
means, smaller constructs are more likely to lack flexible and unstructured N- and 
C-termini, which could affect the propensity to crystallize [158]. For this reason, the 
focus was directed towards CARD9 aa 1-98, the shortest construct available so far. To 
identify buffer conditions that would allow CARD9 aa 1-98 to be highly concentrated 
(at least > 5mg/mL) for crystallisation experiments, the purified protein sample was 
used for Thermofluor analysis. This fluorescence-based experiment is a screen to 
search for buffer conditions or additives under which the protein shows maximum 
thermal stability. Stability was measured by thermal unfolding of the protein and 
determination of the different melting points (Tm), which can vary considerably 
depending on the specific conditions. The protein was mixed with the fluorophore 
SyPro Orange (Thermo Scientific) and added to two 96-well screens. The screens 
tested were the commercially available Solubility & Stability and Slice pH both from 
Hampton Research. The data were analysed with the Prism software where the 
sigmoidal curve was fitted using the Boltzmann equation in order to determine Tm. 
Selected results following data analysis are shown in Figure 5-11 and 5-12 as well as 
Table 5-2 ad 5-3. Whereas the top 10 conditions from the Slice pH screen vary in most 
cases between pH 6.4 and pH 8.5, it becomes clear that CARD9 seems to be most 
stable in BIS-TRIS propane. Additionally, additives such as sodium bromide, glycerol 
and lithium chloride also increase stability of CARD9.   
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Figure 5-11 Slice pH thermofluor assay with CARD9 aa 1-98. The 10 best conditions are shown 
for the Slice pH screen. Values of Tm were determined by fitting the sigmoidal curve using the 
Boltzmann equation and they are listed in Table 5-2 together with the corresponding 
conditions. 
 
 
 
 
 
 
 
 
 
 
Table 5-2 Evaluation of Slice pH thermofluor assays with CARD9 aa 1-98. The 10 best 
conditions are shown for the Slice pH screen with their melting Temperature obtained by 
fitting the sigmoidal curve using the Boltzmann equation. This screen shows that the pH can 
vary between 6.3 and pH 8.5 buffer depending, but it becomes clear that CARD9 aa 1-98 seems 
to be most stable in BIS-TRIS propane at pH 7.3. 
Well Buffer Tm 
E4 1M BIS-TRIS propane pH 7.3 71.0 
E3 1M BIS-TRIS propane pH 7.0 70.5 
E2 1M BIS-TRIS propane pH 6.7 70.1 
E1 1M BIS-TRIS propane pH 6.4 69.2 
F10 1M Tris pH 7.3 67.1 
H1 1M BIS-TRIS propane pH 8.5 67.0 
F6 1M TRIS hydrochloride pH 7.2 66.8 
F8 1M TRIS hydrochloride pH 7.8 66.6 
C12 1M BIS-TRIS pH 6.3 66.6 
F7 1M TRIS hydrochloride pH 7.5 66.5 
Temperature °C 
%
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Figure 5-12 Solubility and Stability thermofluor assay with CARD9 aa 1-98. The 10 best 
conditions are shown for the Solubility and Stability screen. Values of Tm are listed in Table 5-3 
together with the corresponding conditions. 
 
 
 
Well Additive Tm 
E10 Ethylammonium nitrate 69.56 
G6 Glycerole, Lithium chloride 67.21 
G5 Sodium bromide 63.56 
E6 Tetraethylammonium bromide 65.22 
C5 Adipic acid 64.91 
D8 Non Detergent Sulfobetaine 211 64.38 
D2 L-Glutathione reduced/oxidized 64.1 
G4 Lithium chloride 63.9 
F6 Lithium nitrate 63.37 
D5 MgCl2, CaCl2  63.22 
 
Table 5-3 Evaluation of the Solubility and Stability thermofluor assays with CARD9 aa 1-98. 
The 10 best additives are shown for the Solubility and Stability screen together with the 
obtained melting temperature. Additives such as sodium bromide, glycerol and lithium 
chloride increase thermal stability of CARD9 aa 1-98. 
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5.3.1.3 Crystallisation experiments 
Based on the results from the thermofluor assays, a new purification protocol was 
established with a lysis buffer made of 150 mM BIS-TRIS propane pH 7.5, 400 mM LiCl, 
50 mM L-Arginine/Glutamic acid, 10 mM Imidazole, 10 % glycerol and 0.2 mM TCEP. 
The size exclusion buffer was altered to 100 mM BIS-TRIS propane pH 7.5, 250 mM 
LiCl, 2 mM TCEP and 5 % glycerol. Similar to the purification performed beforehand, 
CARD9 aa 1-98 was soluble under these condition, and the final concentration could be 
increased up to 10 mg/ml. Therefore, crystallisation screens were kindly set up by 
Lesley Haire and Roksana Ogrodowicz for CARD9 (aa 1-98) at 10 mg/mL using the 
sitting drop method (Index screen (Hampton Research), IC screen (Imperial College 
screen, designed by Lesley Haire) and Wizard 1 and 2). All plates were incubated at 
18 °C but unfortunately no crystals were obtained.  
 Only initial experiments were set up at that point, because the specific lysis 
buffer determined via Thermofluor opened up possibilities to focus on longer CARD-9 
constructs as described in the next section. 
 
5.3.2 CARD-coiled-coil constructs of CARD9 
5.3.2.1 Constructs design 
In a similar fashion to what was done for CARMA1, there was the interest to 
investigate the role of the coiled-coil of CARD9 oligomerisation. In preparation for this, 
15 CARD9 constructs were designed ending at various positions along the coiled-coil 
domain (Table 5-4).  In case of CARD9, two coiled-coil prediction software programmes 
were used to design the constructs: COILS and MultiCoil [157, 159]. There are four 
predicted coiled-coil segments ending at around residues 180, 230, 380, and 420, 
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respectively (Figure 5-13). All constructs were cloned into pET52-47 to obtain 
N-terminally His6-tagged proteins. To screen the newly generated CARD9 constructs 
efficiently, a small scale expression and solubility screen with Ni-NTA was carried out 
as described in 2.2.4. (Figure 5-14) The screen shows that constructs up to residue 277 
are soluble including the first two segments of the coiled-coil. Interestingly, this is a 
result that closely resembles what was found for CARMA1 (Figure 5-6).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-13 Prediction of coiled coil structures by COILS and MultiCoil. Approximate four 
potential coiled coil regions in CARD9 are predicted using COILS (top) and as a comparison 
MultiCoil (bottom). Segments are located around 110-180, 180-230, 230-380, and 380-420 
[157, 159]. 
Residues 
Residues 
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          A              
 
 
Figure 5-14 CARD9-CARD-CC constructs. A: Secondary structure prediction (JPred [145]) of the 
Card9 CARD and coiled-coil (CC) domain is illustrated with the designed constructs C1-C15. 
B: SDS-PAGE gel results of the small scale expression and purification screens of the 15 CARD9 
constructs, with the induced cell lysate on the left, followed by the proteins eluted from the 
Ni-NTA-column on the right. The constructs have been numbered and listed in Table 5-2.           
Residues 
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#  construct MW [kDa] pI  expressed soluble 
1 1-115 15.3 5.75 x x 
2 1-142 18.43 5.77 √√√ √√√ 
3 1-174 22.3 6.25 √√ √√√ 
4 1-184 23.5 6.25 √√ √√√ 
5 1-200 25.3 6.32 √√√ √√√ 
6 1-223 28.0 6.08 √√√ √√√ 
7 1-231 29.0 6.43 √√√ √√√ 
8 1-243 30.5 6.87 √√√ √√√ 
9 1-277 34.3 6.33 √√√ √√ 
10 1-297 36.9  6.04 √√√ √ 
11 1-336 41.6 6.26 √√√ x 
12 1-387 47.6 6.25 √√ √ 
13 1-403 49.5 5.99 √√√ x 
14 1-420 51.4 6.08 √√√ x 
15 1-431 52.6 5.85 √√ x  
Table 5-4 CARD9-CARD-CC constructs. 15 constructs of CARD9, including the CARD domain 
and additional amino acids on the C-terminal domain, have been screened by small scale 
expression and purification experiments. Results are illustrated as heavily √√√, moderately √√ 
and minimally √ soluble constructs. Unexpressed/insoluble constructs are marked with x. 
 
 
5.3.2.2 SEC multi-angle-laser-light scattering 
To investigate the influence of the different coiled-coil fractions on protein 
oligomerisation, we used SEC-MALLS to investigate the molecular masses in solution of 
selected constructs, equivalent to the experiments on CARMA1 in section 5.2.2.2. The 
constructs chosen for these experiments were CARD9 aa 1-98, 1-142, 1-200 and 1-277. 
They have been successfully purified following the optimised protocol for CARD9 as 
described above in 5.3.1.3. The purified proteins were concentrated to 1.5 mg/mL and 
3 mg/mL (precipitation was observed at higher concentrations) before loading onto a 
S200 10/300 GL column. For the shortest construct CARD9 aa 1-98, which only 
contains the CARD motif, SEC-MALLS analysis resulted in a main peak with a recorded 
molecular weight of 13 kDa consistent with a monomer (calculated MW = 13.4 kDa). A 
small amount of the protein (<6 %) forms a dimer, showing up as a second peak with a 
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molecular weight of 26.2 kDa (Figure 5-15). For CARD9 aa 1-142, 1-200 and 1-277 
however, analysis resulting in molecular weights corresponding to dimers with 
34.7 kDa, 47.9 kDa and 68.4 kDa respectively. A small amount (<6%) of tetramers are 
formed, which seem independent of the protein concentration. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-15 SEC-MALLS analysis of CARD9. The chromatogram shows the UV absorbance and 
the molecular weight calculation of the samples. The samples were loaded at 1.5 and 3 mg/mL.  
1; SEC-MALLS analysis of CARD9 aa 1-98 resulted in a main peak with a recorded molecular 
weight of 13 kDa consistent with a monomer (calculated MW = 13.4 kDa). 2: A molecular 
weight of 26.2 was recorded for CARD9 aa 1-142, corresponding to a dimer. 3 and 4: CARD9 aa 
1-200 and 1-277 both are forming dimers with a molecular weight of 47.9 kDa and 68.4 kDa 
respectively, whereas <6% of the protein samples form a tetramer at both concentrations. 
 
1 2 3 4 
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5.4 BCL10 
5.4.1 Constructs, expression and purification 
As it has been shown that Bcl10 forms a homotypic CARD interaction with either 
CARMA1 or with CARD9 in a cellular dependent context, successful purification of 
BCL10 would allow us to investigating these CARD-CARD interactions.  However, 
expression tests of the CARD of BCL10 (BCL10-CARD aa 10-104) on a 750 mL scale 
showed that although this protein is expressed very well, it is mostly expressed as 
inclusion bodies (Figure 5-16). Therefore, a refolding protocol was developed for 
BCL10-CARD (aa 10-104), based on a protocol by Jang and Park (2011) [160]. Whereas 
standard refolding protocols include highly denaturing conditions such as 8M urea, this 
specific protocol contains just 3M urea in the lysis buffer, to partially unfold the 
proteins, assuming they form soluble aggregates. After centrifugation of the cell lysate, 
the supernatant was applied to a Ni-NTA column and the protein eluted by decreasing 
the pH. Refolding of BCL10 occurred by dialysis to remove the urea slowly. In parallel, a 
standard refolding protocol was performed as well. It differed from previous protocols 
by using 6 M guanidinium hydrochloride (GdmCl), several pellet washing steps, and 
included a fast protein-refolding on column. The refolding was performed by reducing 
the GdmCl concentration to 1 M and 0 M, before the protein was eluted with 
imidazole. Unfortunately, in both cases, the protein did not refold properly and 
aggregated.  
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Figure 5-16 His6-BCL10-CARD purification. SDS-PAGE analysis following expression of 
His-tagged BCL10-CARD aa10-104 (13.2 kDa). M; protein marker, P; pellet, SN; supernatant, FT; 
flow through, W; washing step. The protein should have been eluted by starting with an 
imidazole concentration of 75 mM and increasing to 500 mM. 
 
 
Given these results, a different approach had to be taken. The structure of 
MAVS-CARD has been solved by Potter et al. in 2008 by x-ray crystallography as a 
MBP-fusion protein. Additionally, discussion with Dr Kovilen Sawmynaden in the group 
revealed, that he managed to purify a RIP2-MBP fusion protein successfully, whereas 
His6-RIP2 and GST-RIP2 were insoluble. Therefore, fusion to MBP seemed a promising 
method for generating soluble BCL10 molecules. The pET-XM1 was used to generate 
several MBP-fusion proteins: MBP-BCL10 aa 10-107, aa 10-163 and aa 10-210. Upon 
further analysis, it became quickly clear that these constructs are soluble, but the 
proteins were prone to degradation making impossible to perform a full purification 
protocol. Looking again at the secondary structure prediction, the N-terminus was 
slightly extended and the construct MBP-BCL10 aa 6-123 was designed. The new 
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construct was expressed and purified following the standard protocol for 
MBP-constructs as described in section 2.3.8. Unlike previous BCL10 constructs, the 
MBP-fusion is not only soluble, but also less prone to degradation and can be purified 
obtaining a reasonable yield for further experiments. The purification steps were 
analysed via SDS-PAGE which is shown in Figure 5-17. 
 
 
 
 
 
 
 
 
Figure 5-17  MBP-BCL10 aa 6-123 purification. SDS-PAGE analysis following expression of 
MBP-fusion BCL10 aa10-104 (54 kDa) using amylose resins. The protein was eluted with 10 
mM Maltose. M; protein marker, C; induced cells, SN; supernatant, FT; flow through, W; 
washing step, EL; elution.  
 
 
5.4.2 Biophysical analysis of MBP-BCL10 
MBP, which has a molecular weight of 40 kDa, is a highly soluble protein and is 
nowadays often used as a solubility enhancement tag for fusion proteins. Although we 
obtained soluble MBP-BCL10 aa 6-123, it had to be considered that the actual BCL10 
CARD-construct with only 16 kDa is much smaller than its fusion partner and the 
question remained if the CARD is in a folded state. For this reason, CD was used to 
analyse the secondary structure content of MBP-BCL10 aa 6-123 in comparison to MBP 
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alone. Spectra were recorded at 20 °C using a concentration of 0.15 mg/ml in 300 mM 
NaCl, 50 mM HEPES pH8, 1 mM EDTA, 1 mM TCEP and 10 mM Maltose. Figure 5-18, 
where data has been nomralised to mean residue ellipticity, shows a high helical 
content for both MBP (52.5%) and MBP-BCL10 (47.9%). When these values are then 
applied to the total number of residues of each protein with MBP: 371 and 
MBP-BCL10: 489, we calculated a difference of 40 residues more alpha helical for MBP-
BCL10, which correlates well with the 6 a-helices of the CARD domain fold. These 
results suggest that MBP-BCL10 is folded. 
 
 
 
 
 
 
 
Figure 5-18 Far-UV CD spectra of MBP and MBP-BCL10 aa 6-123. Far-UV CD (200-250 nm) was 
carried out to analyse the secondary structure content of MBP (black) and MBP-BCL10 aa 6-
123 (red). The difference of the two profiles is shown in light grey. Protein concentration was 
0.15 mg/mL and spectra recorded at 20 °C. 
 
 
In addition to the CD analysis, we wanted to investigate the oligomeric state and the 
homogeneity of the MBP-BCL10 aa 6-123 sample. The homogeneity of a protein 
sample can be just as important as purity regarding the likelihood to form a crystal 
lattice when setting up in crystallisation trays. The SEC-MALLS (S200 10/300 GL) was 
performed in 200 mM NaCl, 50 mM HEPES pH8, 1 mM EDTA, 1 mM TCEP and 3 mM 
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Azide at 4 °C with a loaded sample concentration of 2.5 mg/ml. As a comparison, a 
sample of the MBP-tag only was loaded. SEC-MALLS analysis of MBP-BCL10 resulted in 
one peak with an observed molecular weight of 53.3 kDa (Figure 5-19) in agreement 
with the calculated molecular weight of 54 kDa for a monomer. Analysis of the MBP 
sample provided a molecular weight of 38.9 kDa. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-19 SEC-MALS analysis of MBP-BCL10 aa 6-123. The chromatogram shows the UV 
absorbance profile and the molecular weight calculation of the sample. Red: SEC-MALS 
analysis (S200 10/300 GL) of MBP-BCL10 aa 6-123 shows a single peak with a determined 
molecular weight of 53 kDa. The sample was injected at 2.5 mg/mL (47 μM). Blue: The same 
experiment was carried out with MBP only, which resulted in an observed molecular weight of 
38.8 kDa. 
 
 
Having obtained several CARMA1 and CARD9 constructs as well as MBP-BCL10, binding 
studies and setting up crystallisation screens would have been the next step. However, 
at this point, Qiao et al. (2013) [103] published the filament assembly of BCL10 by 
Results | 5 
 
192 
 
fluorescence polarisation assays, which is significantly enhanced in the presence of 
CARMA1. This study also involved the EM analysis of the BCL10-filament. These 
experiments were based on similar constructs as prepared already in this study: 
CARMA1-CARD with the addition of different coiled-coil segments and BCL10 as an 
MBP fusion protein. Taking into account our laboratory set-up and possibilities, this 
study changed our approach significantly: The focus was on looking further into the 
questions of CARD-filaments via fluorescence polarisation assays.  
 
5.5 Fluorescence polarisation assays with BCL10 and CARMA1 
It was recently shown that the signalosome formed by CARMA1, BCL10 and MALT1 is a 
helical filamentous assembly with CARMA1 nucleating BCL10 filament formation (Qiao 
et al. 2013). This study assessed the polymerisation quantitatively via fluorescence 
polarisation assays. Additionally, these assays showed that CARMA1 can enhance 
polymerisation of BCL10. In these experiments, polymerisation was initiated by 
cleaving BCL10 from its MBP-fusion protein.  
 Having also previously observed that MBP-BCL10 constructs are indeed soluble 
and folded, our goal was to set up a fluorescence polarisation assay to observe 
filament assembly between CARD9 and BCL10 using the published CARMA1-induced 
BCL10 polymerisation enhancement as a positive control. Having several CARMA1 and 
CARD9 constructs cloned and purified comprising different coiled-coil fragments, both 
CARMA1 and CARD9 could be compared regarding their ability to enhance BCL10 
polarisation and the role of their coiled-coils. 
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5.5.1 Constructs, expression and purification 
The MBP-BCL10 construct was re-cloned using the LIC-vector pHMBP, which has been 
described before with RIP2 (see section 4.5.1). This plasmid generates the desired 
protein construct including an N-terminal His6-MBP-tag with a 3C cleavage site for 
tag-removal. Additionally, we chose to work with full length BCL10 for two reasons: 
firstly, to maintain consistency with the published data. Secondly, the BCL10 needs to 
be labelled with a fluorophore-maleimide at a location where the probe does not 
sterically interfere with any potential CARD-CARD interface. Hence, attaching the 
probe on the CARD itself must be avoided. Therefore, the two cysteines C29 and C57, 
which are located in the CARD were mutated to alanine using site-directed 
mutagenesis. Three further cysteines C-terminal of the CARD (C119, C121 and C215) 
still remain in the BCL10 full length protein. The newly generated full length His6-MBP-
(3C)-BCL10 C29/57A was expressed in 8L of LB media and purified via Ni-NTA using a 
lysis buffer of 500 mM NaCl, 50 mM Tris-HCl pH 7.5, 20 mM Imidazole, 0.5 mM TCEP 
and 10% glycerol. The different purification steps were analysed via SDS-PAGE and are 
shown in Figure 5-20. As an additional purification step as well as buffer exchange in 
preparation for the fluorophore labelling, the eluted protein was further purified on a 
S200 16/60 gel filtration column equilibrated in 500 mM NaCl, 50 mM Tris-HCl pH 7.5, 
0.5 mM TCEP. The elution profile together with SDS-PAGE gel of the peak fractions can 
be seen in Figure 5-21.  
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Figure 5-20 His6-MBP-(3C)-BCL10 C29/57A purification. SDS-PAGE analysis following 
expression of His-MBP-tagged BCL10 full length double mutant (69 kDa). C; induced cells, SN; 
supernatant, FT; flow through, W; washing step, EL; elution. The protein was eluted with an 
imidazole concentration 500 mM. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-21 His6-MBP-(3C)-BCL10 C29/57A gel filtration purification. Elution profiles of the 
His6-MBP-(3C)-BCL10 C29/57A from a Superdex 200 16/60 gel filtration column together with 
the SDS-PAGE gel of the peak fractions. Fractions 34-37 were collected. The buffer used was 
500 mM NaCl, 50 mM Tris-HCl pH 7.5, 0.5 mM TCEP. 
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5.5.2 Fluorophore labelling 
The fluorophore used in this study was Alexa Fluor® 488 C5 maleimide. The protein 
sample was concentrated to 50 μM prior mixing with a 3-fold molar excess of Alexa 
Fluor® 488 C5 maleimide. After 2h incubation at room temperature, another gel 
filtration chromatography was performed using 150 mM NaCl, 20 mM Tris-HCl pH 7.5 
and 0.5 mM TCEP to remove free dyes. At this step, around 80% of the protein was in 
the void, which can be seen in the gel filtration profile of Figure 5-22. The following 
monomeric peak containing the labelled BCL10 was collected and concentrated to 
10 μM for further studies. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-22 His6-MBP-(3C)-BCL10 C29/57A gel filtration purification after labelling. Elution 
profiles of the Alexa Fluor® 488 C5 labelled His6-MBP-(3C)-BCL10 C29/57A from a Superdex 200 
16/60 GL gel filtration column together. The peak of monomeric BCL10 was collected and 
pooled. The buffer used was 150 mM NaCl, 20 mM Tris-HCl pH 7.5, 0.5 mM TCEP. 
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5.5.3 Biophysical analysis 
5.5.3.1 UV spectrum 
To estimate the protein concentration as well as to determine the degree of labelling, 
a UV spectrum was recorded to measure the absorbance of the conjugate at 280 nm 
and 495 nm. The concentration for the labelled protein was calculated as described in 
chapter 4.5.3.1.  The UV spectrum is shown in Figure 5-23. An absorption of 0.419 at 
495 nm and 0.284 at 280 nm was measured. With an extinction coefficient of 72,000 
cm-1M-1 and 71,000 cm-1M-1 for Alexa Fluor® 488 C5 and MBP-BCL10 respectively, a 
protein concentration of 10 μM and a dye concentration of 19 μM were calculated. 
There are two possibilities to explain this discrepancy: considering the BCL10 construct 
contains three cysteines, one could conclude that 63% of the cysteines are labelled. On 
the other side, considering the size of the fluorophore, steric effects could mean that 
only one label can possibly be attached to either C119 or C121. This would mean 95% 
of the protein sample is labelled, a similar result as achieved with RIP2 in Chapter 4. 
 
 
 
 
 
 
 
 
Figure 5-23 UV spectra of the labelled His6-MBP-(3C)-BCL10 C29/57A. Protein concentration 
was calculated by recording a UV spectrum and measuring the absorption at 280 nm (protein 
+dye) and 495 nm (dye). 
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5.5.3.2 CD spectroscopy 
To ensure this construct remained folded during the labelling process, the sample of 
the labelled MBP-BCL10 was used for CD spectroscopy to determine the secondary 
structure content. The MBP-BCL10 construct is clearly alpha-helical (Figure 5.24). The 
intensity of this spectrum, however, is probably affected by possible errors in the 
estimate of protein concentration due to the fluorophore (see 4.4.3.1) 
 
 
 
 
 
 
 
 
Figure 5-24 Far-UV CD spectra of labelled His6-MBP-(3C)-BCL10 C29/57A. Far-UV CD (220-250 
nm) was carried out to analyse the secondary structure content of the labelled His6-MBP-(3C)-
BCL10 C29/57A. Protein concentration was 0.15 mg/mL and spectra recorded at 20 °C. 
 
 
5.5.4 Fluorescence polarisation assay 
In preparation for the fluorescence polarisation assay, the excitation and emission 
spectra of the Alexa Fluor® 488 labelled MBP-BCL10 were recorded (Figure 5-25). Both 
excitation and emission maxima are close together an excitation of 492 nm and 
emission of 522 nm was used for the assay. Fluorescence polarization assay was 
performed at 25 °C in a buffer containing 150 mM NaCl, 20 mM Tris-HCl pH 7.5 and 0.5 
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mM TCEP. The sample volume was 80 μL with a MBP-BCL10 concentration of 10 μM. 
About 100 seconds after starting the experiment with a recording time of 2h (7200 
seconds) 5 μg of GST-3C protease (purified in-house) was added to the cuvette for 
removal of the MBP-fusion to allow BCL10 polymerization. To investigate the 
stimulation of BCL10 polymerisation by CARMA1 the experiment was repeated in the 
presence of 2 μM (end concentration) CARMA1 aa 18-200 in the CARMA1-induced 
BCL10 polymerization experiment.  
 
 
 
 
 
 
 
 
Figure 5-25 Fluorescence spectra. Excitation (blue) and emission (red) spectra of Alexa® Fluor 
488 labelled MBP-BCL10 C29A/C57A.  
 
As in the FPA experiments in Chapter 4, the 3C cleavage here resulted in a decrease in 
fluorescence polarisation as the molecular weight of the labelled protein drops from 
69 to 26 kDa. However, the decrease is much smaller (130 mP to 120 mP) compared to 
the decrease seen upon MBP-RIP2 cleavage (220 mP to 90 mP). This is mainly due to a 
much lower initial value of the polarization. Since the molecular weight of MBP-BCL10 
is even higher than that of MBP-RIP2 (69 vs 55 kDa) the difference is likely due to the 
fact that the Alexa fluorophore is much more flexible when attached to BCL10 
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compared to RIP2 and therefore, its tumbling is not strongly restricted by the size of 
the protein. This is in line with the fact that the Alexa-488 fluorophores are coupled to 
the cysteine residues on the unstructured C-terminus of BCL10 whereas RIP2 has the 
Alexa-488 fluorophore attached only on a 16-residues extension preceding the CARD. 
There is no further significant change in polarisation after the initial drop over the time 
scale of the experiment either in the presence or absence of CARMA1 molecules 
(Figure 5-26), so BCL10 does not polymerize under our experimental conditions. 
 
 
 
 
 
Figure 5-26 Fluorescence polarization assay. Alexa 488-labeled MBP-BCL10 C29/57A in the 
presence (purple) and absence (grey) of substoichiometric amounts (1/5) of CARMA1 
aa 18-200 upon MBP removal by 3C protease cleavage. The temporary fluorescence drops at 
the beginning of the experiment represent the addition of CARMA1 and/or 3C protease. 
 
 
As no polymerisation could be detected with this sensitive assay in the contrast to 
published data [103], it was considered that the added glycerol (7μL of 50% glycerol) 
from the 3C protease stock may play a role in supressing oligomerisation. For this 
reason, another fluorescence polarisation assay was recorded where glycerol from the 
3C stock solution was removed by dialysis prior the experiment. Figure 5-27 shows that 
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the glycerol was not inhibiting any polymerisation as no change in fluorescence 
polarisation was detected.  
 
 
 
 
 
 
Figure 5-27 Fluorescence polarization assay without glycerol. Alexa 488-labeled MBP-BCL10 
C29/57A in the presence (red) and absence (blue) of substoichiometric amounts (1/5) of 
CARMA1 aa18–200 upon MBP removal by 3C protease cleavage. Any glycerol from the 3C 
stock solution has been removed via dialysis prior to the experiment. 
 
 
In both assays recorded, we could clearly monitor that the GST-3C protease requires 
about 2000s (~30min) to fully cleave all MBP-BCL10. To rule out every factor and 
possibility in order to know the reason why the fluorescence polarisation assay doesn’t 
show any BCL10 molecule polymerisation, a third attempt was carried out using a 
different 3C protease: an in-house purified His6-3C protease. The new assay carried 
out, which can be seen in Figure 5-28, shows the cleavage time was decreased to 
about 750s (12 min). However, no difference in BCL10-polymerisation compared to the 
previous assays could be monitored. After the experiments, the samples were 
analysed via SDS-PAGE. According to the gel, all MBP-BCL10 has been cleaved during 
the experiment (Figure 5-29). 
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Figure 5-28 Fluorescence polarization assay with His6-3C. Alexa 488-labeled MBP-BCL10 
C29/57A in the presence (orange) and absence (green) of substoichiometric amounts (1/5) of 
CARMA1 aa18–200 upon MBP removal by 3C protease cleavage. In this particular case, we 
used the in-house purified His6-3C protease. 
 
 
 
 
 
 
 
 
 
 
Figure 5-29 SDS-PAGE analysis post FPA. 1: 3C protease (21.7kDa), 2: CARMA1 aa 18-200 (24 
kDa), 3: uncleaved MBP-BCL10, 4: post FPA sample without CARMA1, 5: post FPA sample with 
CARMA1. 
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5.6 Summary 
In this chapter, the focus was set on CARMA1 and CARD9, both of which are adaptor 
proteins that interact with BCL10 via a CARD-CARD interaction, an essential step to 
initiate the formation of a signalosome involving mucosa-associated lymphoid tissue 
MALT1 to mediate NF-κB activation. CARMA1-CARD is a well expressed protein 
construct. No crystals were obtained, although analysis revealed its potential to 
investigate the structure via NMR spectroscopy. At this point, the crystal structure of 
CARMA1-CARD was published.  
 CARD9-CARD on the other hand needed further investigations via thermofluor 
before a suitable condition for purification was finally found. Initial crystallisation 
experiments were set up before the focus was then extended to CARMA1 and CARD9 
constructs involving segments of the following coiled-coil domain. SEC-MALLS analysis 
with constructs containing up to 2 of the 4 coiled-coil segments showed that the 
CARDs alone exist as monomers, while the coiled-coil drives the molecule into dimers. 
However, neither CARMA1 nor CARD9 constructs containing the full 4 segments of the 
coiled-coil domain could be purified successfully.  
 BCL10 on the other hand, is a protein, which is poorly soluble and after failed 
several purification protocols, including refolding experiments, we managed to purify 
BCL10-CARD as an MBP fusion protein. Recent studies showing BCL10 forming 
filaments was addressed by getting into contact with the laboratory of Professor Hao 
Wu and setting up similar fluorescence polarisation assays. However, no 
polymerisation of BCL10 CARDs could be monitored upon MBP-tag removal, neither in 
absence or presence of CARMA1. 
 
  
 
 
 
 
 
 
 
Chapter 6 
 
 
Discussion and outlook 
 
 
 
 
 
 
 
 
 
 
 
203 
Discussion and outlook | 6 
 
204 
 
6.1 Overview 
This thesis was aimed at providing molecular insight into the mechanism by which 
CARDs mediate the formation of multi-protein assemblies. Experiments were initially 
designed assuming that CARDs may either form 1:1 complexes or may require an 
additional oligomerisation domain for complex formation, as observed in the 
apoptosome structure.  
 Another model assumed, that CARDs may be able to form individual signalling 
platforms as observed for members of the death domain subfamily. The focus was set 
on finding a general mode of CARD-CARD interactions by investigating these 
possibilities. However, during the course of this study, the CARD-containing proteins 
have been suggested to form filaments, which established a complete new principle 
regarding the binding characteristics of CARDs.  
 In this Chapter, I will discuss our findings regarding the intramolecular 
interaction of NOD2 tandem CARDs from mutational analysis involving mainly ITC, as 
well as the intermolecular interaction with RIP2 gained from pull-down experiments. 
This is followed by a short look into the purification and characterisation of different 
CARMA1 and CARD9 constructs. To address the latest behavioural insight gained 
during the time course of this study regarding CARDs as filament forming motifs, 
fluorescence polarisation assays will be discussed in the last part of this section. 
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6.2 CARDs - expression and solubility screens 
A main reason for the lack of structural information on CARDs is likely their tendency 
to aggregate when they are purified as individual domains. The first aim was therefore 
to screen all human CARDs in co-expression and pull-down experiments with the goal 
of finding soluble CARD-pairs, which can be taken further for biochemical, biophysical 
and structural investigations. These experiments were designed hoping that 
co-expression would increase the solubility of individual CARDs, but more importantly, 
we hypothesised that CARDs bound to the beads during pull-down experiments may 
potentially mimic an additional oligomerisation domain should this be required for a 
CARD-CARD interaction. In this case, the beads would bring CARDs into close proximity 
to form the platform needed to pull down a binding partner.  
 LIC cloning turned out to be a straightforward method to create all CARD 
constructs for a genome wide screen. The newly generated CARD constructs were first 
tested for their expression and solubility individually. Some variables were set after 
initial experiments (e.g induction temperature was set to 18 °C) whereas others were 
based on previous experience in the group (e.g. E.coli strain: BL21 (DE3) Gold). 
Comparing both His6- and GST-constructs, the number of soluble constructs as 
His6-proteins was significantly higher. This was unexpected because the 26 kDa 
GST-tag can enhance solubility by stabilising the fusion protein [147, 161]. However, in 
this case it could be that the dimerisation of the GST did enhance precipitation through 
aggregation. The observed differences in the expression and solubility profiles 
between all CARDs tested remains unclear at this stage. Similarly, we do not 
understand at this point why the newly designed pGST vector showed such low protein 
expression. This is likely to be a problem with the new vector itself and would need to 
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be tested with established proteins for which we know the amount of expression and 
solubility. 
 The high amount of insoluble constructs found in these two screens is not 
entirely surprising, as many CARDs described in the literature seem to have low 
solubility. The tendency to aggregate is more and more being related to their biological 
function with forming homotypic protein-protein interactions to mediate higher-order 
complex formation and filamentous assemblies regulating downstream signalling. 
Additionally, a number of CARD-containing proteins have been reported to remain in 
an auto-inhibited state until activation occurs via phosphorylation. In these cases, the 
CARDs are undergoing intramolecular interactions and are inaccessible when inactive, 
hence, hydrophobic residues are buried and therefore the protein is monomeric. These 
factors could explain why the purification of isolated domains may interfere with their 
natural environment. As seen in Table 1-2, proteins containing CARDs belong to 
different families including receptor, scaffold, effector or adaptor proteins.  The 
question arises if there is any link between the solubility and the identity of the 
protein. The 14 His6-CARDs which turned out to be partially or completely soluble, 
these CARD proteins are listed together with their overall domain structure, followed 
by their functionality  in Table 6-1. However, there seem to be no obvious 
commonality visible between the CARDs from multi-domain receptor proteins as well 
as single domain adaptor proteins, which have turned out soluble. With 16 out of 33 
isolated CARD structure solved at this point, it is not surprising that 11 are here listed 
with the soluble constructs obtained. 
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CARDs Domain structure  Function PDB  
NOD1 √ NBD-CARD Receptor 2NZ7 
ASC √ Bipartite-CARD Adaptor 2KN6 
APAF1 √√√ NBD-CARD Receptor 3YGS 
NALP1 √√√ NBD-CARD Receptor 3KAT 
Caspase 9 √ Bipartite-CARD Initiation / Effector 3YGS 
CARD8√ Bipartite-CARD Inhibitor 4IKM 
CARD9 √√ Coiled-coil Regulator - 
RAIDD √√√ Bipartite-CARD Adaptor 3CRD 
Iceberg √√ Shorthair-CARD Inhibitor 1DGN 
RIG-I ab √√ Multipartite-CARD Receptor 4P4H 
MDA5 b √ Multipartite-CARD Receptor - 
CARMA1 √√√ Coiled-coil Regulator 4LWD 
CARD6 √ Longhair-CARD Regulator - 
ARC √ Shorthair-CARD Inhibitor 4UZO 
 
Table 6-1 Soluble His6-CARD constructs and their protein function. Listed are the His6-CARD 
constructs, which were either soluble or only partially soluble together with their domain 
structure and protein function.  Results are illustrated as heavily √√√, moderately √√ and 
minimally √ soluble constructs. 
 
 
 Regarding the disappointing expression level of the GST-tagged CARD 
constructs using the newly designed vector pGST, a complete re-cloning of all human 
CARDs into a new GST-vector for co-expression and pull-down screens was not taken 
any further because Qiao et al. (2013) [103] published the filament formation of 
BCL10-CARD at this point. This completely changed the aspect of how to further 
approach the investigation of CARDs if the idea of filamentous CARD assembly wanted 
to be addressed in the time course of this work. For this reason, the attempt to 
perform a wide range of co-expressions and pull-down experiments was dismissed and 
the focus was set on a selection of CARDs: Work with CARMA1, CARD9 and BCL10 has 
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already been performed and provided a good system to look further into the 
polymerisation of CARDs. Another focus was set on the tandem CARDs of NOD2 as 
preliminary work had already been performed in our group and especially because the 
structure of the N-terminal NOD2-CARDa was recently solved by a former group 
member. This provided the opportunity to compare intra and intermolecular 
CARD-CARD interactions. 
 
 
6.3 Intramolecular interaction between the tandem CARDs of 
NOD2 
NOD1, NOD2 and other members of the NLR protein family have emerged as key 
cytosolic pattern recognition receptors for the detection of pathogens and 
endogenous danger signals. Stimulation of these receptors activates signalling 
cascades that lead to NF-κB activation and subsequently to transcription of genes 
mediating pro-inflammatory immune responses. One of the main differences between 
NOD1 and NOD2 is that NOD2 contains two CARDs in tandem. The question 
immediately arises, if this second CARD copy is biologically relevant and if so, what 
difference in function is between the two CARDs of NOD2? An intramolecular 
interaction between CARDa and CARDb had been suggested initially by yeast 
two-hybrid assays by Wagner et al. (2007) [130] and has later been confirmed on the 
purified protein level by our group [131]. At that point, only one CARD-CARD complex 
structure was available, which was that of APAF1-CARD interacting with 
Procaspase-9-CARD via a type 1 interaction (3YGS, also Figure 1-12).  In this 1:1 
complex, strong charge-charge interactions play a crucial role. Fridh and Rittinger 
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analysed the intramolecular interaction of NOD2 CARDs by ITC, mainly focusing on a 
potential type 1 interaction between CARDa and CARDb by targeting acidic as well as 
basic residues in each CARD. Mutants E69K, E72K and R86A, all located in CARDa, were 
expressed and soluble, but ITC results showed that neither of the mutations had any 
effect on complex formation. This strongly suggests that CARDa and CARDb are not 
interacting via a type 1 interface. This suggestion is in line with the results of the NMR 
saturation transfer difference spectroscopy, where two tryptophans of CARDa seemed 
to be located in the interface.   
 My initial approach to characterise this intramolecular interaction of NOD2 in 
more detail was to carry out NMR titration experiments, using NOD2-CARDa 
tryptophan mutants to establish, which of the five potential tryptophans are at the 
interface with CARDb. However, recombinant protein expression of the NOD2 tandem 
CARDs was significantly reduced in minimal (M9) media and even using a commercial 
‘rich’ isotopically-labelled medium it was not possible to produce sufficient protein to 
reach a satisfying signal-to-noise ratio when recording 15N-HSQCs. This low protein 
expression suggested that the mutations changed the protein stability and structure 
severely. Nevertheless, NMR spectra of the proteins indicated that all the tryptophan 
mutants were folded and it is not clear at present why protein expression was so 
dramatically decreased in minimal medium.  
 As an alternative method to study the role of tryptophan residues in the 
intramolecular interaction, we have chosen ITC as used by Fridh and Rittinger. The ITC 
data obtained in this work supports the preliminary NMR data, as the intramolecular 
CARD-CARD interaction of NOD2 is lost when W59 and W63 are mutated to alanine.  
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 Structural alignments with available tandem death-fold domains were carried 
out to test if an intramolecular interface containing W59 and W63 may be similar to 
other tandem motifs. A good overlay was achieved between NOD2-CARDa and the 
tandem DEDs of MC159 (Figure 4-7). Another available structure of a tandem motif is 
that of the tandem DED of Caspase-8 and interestingly, in both structures the 
intramolecular interface between DED1 and DED2 is mainly formed by the 
hydrophobic residues from helices α2a and α5a of DED1 and helices α1b and α4b of 
DED2. A sequence analysis is displayed in Appendix A 6-1. The tryptophans W59 and 
W63 of NOD2 are located at the same hydrophobic DED1 patch forming the interface 
with DED2. Based on this idea, other NOD2 mutants were analysed to test the idea of 
NOD2 interacting in a similar manner as tandem DEDs and to exclude a type 2 and type 
3 interaction. Interestingly, another mutant was identified that was unable to bind 
CARDb: S49A. This residue, which lies in the loop between helices α1 and α2, was 
originally selected because it appeared to be located in a type 3 interface. All CARDa 
residues successfully purified and analysed by ITC are mapped onto CARDa, shown in 
Figure 6-1.  
If W59, W63 and S49 were essential for binding, then the interface would span across 
the whole of helix α2 of CARDa.  However, such an interface seems not fully accessible, 
because of the position of the elongated helix α5. Though one could assume that helix 
α5 may be shorter in the presence of CARDb, with the remaining residues forming 
helix α6, which, in its right place, is folded towards the N-terminal domain between 
helices α1 and α5 (Figure 6-1). This would open up the space spanning from 
tryptophans W59 and W63 till residue S49 thereby allowing binding of CARDb.  
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Figure 6-1 Residues analysed via ITC mapped onto NOD2-CARDa. The solution structure of 
CARDa is shown with S49, W59 and W63 highlighted in blue. Other residues tested without 
showing any effect on CARDb binding are shown in black. In presence of CARDb, helix α5 is 
believed to be shorter to form helix α6, which would be folded back (dashed arrow) towards 
α1 and α5, to complete the 6 alpha-helical bundle of a death-fold. 
 
 
 In order to determine residues in NOD2-CARDb essential for CARDa binding, a 
model of CARDb (Swiss Model) was calculated and then overlaid with DED2 of MC159. 
Selected mutants, which could be expressed and purified were D133A and H137A, with 
negative controls E158A and Q201A. All of these showed binding and no CARDb 
residue could be identified as being essential for the CARDa-CARDb interaction. 
 However, it has to be considered that we are using only alanine mutations in 
this study. Comparison with charge reversal mutations could give more insight into the 
interaction. For example, in a study of NOD1 and RIP2 binding via luciferase reporter 
assays, Boyle et al.[162] showed that the NOD1 mutant E56A had no effect on RIP2 
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binding, whereas a charge reversal mutation disrupted the interaction almost 
completely. Nevertheless, such experiments can also be misleading and the loss of 
binding is not a cause of specifically a charge reversal: Manon et al. [163] analysed the 
same interaction and showed that a charge reversal on a different residue, at NOD1 
R69, was able to disrupt the interaction with RIP2. However, subsequent structural 
analysis of NOD1 showed that R69 forms an internal salt bridge with residue D73, 
therefore, the loss of binding is likely due to the destabilisation of the protein. 
 
 
6.4 Intermolecular interaction of NOD2 and RIP2 
To study the interaction between the tandem CARDs of NOD2 and RIP2, pull-down 
experiments were performed following a protocol developed in the group [131]. 
However, the GB1-RIP2-CARD was replaced by MBP-RIP2-CARD for consistency with 
the MBP-BCL10 studies described in Chapter 5.   
 Although RIP2 is the best studied interaction partner of NOD2, still many 
questions remain about the molecular details of their interaction. Furthermore, due to 
expression problems with individual CARDs, it is still unclear whether both CARDs are 
essential for RIP2 binding and subsequent activation of NF-κB signalling. Some reports 
suggested that neither CARDa nor CARDb alone is able to bind RIP2 [64, 130] and point 
mutations in either CARDs have been shown by Tanabe et al. [164] to prevent NF-κB 
signalling. On the other hand, the shortest construct reported so far able to bind RIP2 
is NOD2-S (aa 1-180) designed by Rosenstiel et al. [165]. This constructs contains 
CARDa and the first three helices of CARDb. Interestingly, even though NOD2-S is able 
to bind RIP2, overexpression does not activate NF-κB unlike the overexpression of the 
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complete tandem CARDs. Probably the most contradictory studies attempting to 
characterise the interface between NOD2 and RIP2 involve the results of Wagner et al. 
[130] and Fridh and Rittinger: Wagner reported that the conserved acidic patch 
involving residues E69 and D70 in NOD2-CARDa are essential for RIP2 binding based on 
yeast-two hybrid assays, whereas Fridh and Rittinger concluded that E59K and E72K 
are not essential for RIP2 binding based on pull-down assays in E.coli. Instead they 
showed that basic residues R38 and R86 were important for recognition of conserved 
acidic residues on RIP2-CARD (D461 and D473). Such an interaction would correspond 
to a type 1 interface. 
 As always with mutational studies, one has to take into account that the loss of 
interaction can result from a mutation, which destabilises the fold rather than 
disrupting the binding. With NOD2-CARDa residues R38A and R86A so clearly losing 
their ability to bind RIP2-CARD, I purified the R38A and R86A MBP-fusion constructs 
and recorded 1D proton NMR spectra (data not shown). In support to Fridh and 
Rittinger’s study, peaks were clearly visible > 9 ppm and < 0.5 ppm and the spectra 
similar to the wild type. Therefore, we conclude these constructs are folded.  
 Having already designed a large number of NOD2 mutants for the ITC 
experiments to investigate intramolecular CARD-CARD interactions, the idea was to 
take these mutants further to study RIP2 binding by performing further pull-down 
experiments. R38A was repeated to serve as a negative control. Interestingly, all new 
mutants tested (CARDa: S49A, W59A, W63A, H75A, Q79A, N94, W98A. CARDb: D133A, 
H137A, E158A, Q201A) are able to bind RIP2-CARD. Mapping all residues tested via 
pull-down on the NOD2-CARDa structure (Figure 6-2) clearly shows that the basic 
patch including R38 and R86 is at the opposite end of the residues detected to be 
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involved in CARDb binding (S49, W59, W63). This would make sense as two different 
binding sites are expected for intra- and intermolecular interactions. Although no 
essential residues of CARDb could be detected so far to be important in RIP2 binding 
(Fridh and Rittinger tested CARDb mutants A106V and Q164K, whereas this study 
added D133A, H137A, E158 and Q201A), I personally doubt that NOD2 has an arbitrary 
duplicate CARD and suspect that they both have different functions and stabilise each 
other. 
 
 
Figure 6-2 NOD-CARDa and RIP2 interaction. The mutational analysis of NOD2-CARDab and 
RIP2-CARD binding identified a basic patch formed by R38 and R86 (shown in blue) in NOD2-
CARDa to be essential for RIP2 binding. The two arginines are located at the opposite end of 
the previously defined intramolecular binding site with CARDb. 
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6.5 CARMA1 and CARD9 - the CBM complex 
The small scale expression and purification screen drew our attention towards an 
exceptionally well expressed and soluble CARD: CARMA1. CARMA1 is a scaffold protein 
and a key player in the formation of the so-called CBM-L signalosome. This complex 
comprises CARMA1, BCL10 and MALT1 and acts downstream of the antigen receptor in 
lymphocytes to activate NF-κB. The CBM-L complex is essential for normal cellular 
functions. Malfunction in activity leads to inflammatory disorders, making it a viable 
target for novel therapeutic design. When we identified the CARD of CARMA1 as a 
highly soluble protein, no structural details of neither CARMA1 nor BCL10 were 
available, which made these two proteins especially interesting for me. Furthermore, 
when I decided to focus on the CARMA1-BCL10 interaction, I also included CARD9 in 
my study, as it has a similar domain structure to CARMA1 (CARD followed by a long 
coiled-coil) and also binds BCL10 to form the equivalent CBM complex in myeloid cells.  
  The purification of CARMA1-CARD was very straightforward and NMR analysis 
demonstrated that CARMA1-CARD was properly folded. Therefore, it was taken further 
to record initial 3D NMR experiments to test its suitability for further structural 
studies. In parallel, crystallisation trays were started. However, before structural 
analysis could be completed, Li et al. published the crystal structure of CARMA1-CARD, 
which shows a typical 6-helical fold characteristic of proteins of the death domain 
superfamily. The focus consequently was set on larger constructs that include the 
adjacent coiled-coil domain, as an oligomerisation domain might be required to form a 
platform to bind other CARDs.  
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 Although the CARD9-CARD seemed partially soluble in our initial expression 
screens, large scale expression/purification yielded largely insoluble protein. However, 
modification of domain boundaries, coupled with Thermofluor assays using 
commercial solubility and stability buffer screens, allowed us to identify better lysis 
buffer conditions containing LiCl and BIS-TRIS propane pH 7.5, which excitingly was 
very effective and led to the successful purification of several stable CARD9-CARD-
coiled-coil constructs of different lengths.   
 To characterise the self-association of CARMA1 and CARD9, SEC-MALLS 
experiments were performed. SEC-MALLS analysis of various CARMA1 constructs 
showed that the CARD itself is a monomer in solution, while addition of the first of four 
coiled-coil fragments, induces dimerisation. Unfortunately, adding a further fragment 
to the protein so the construct contains half of the complete coiled coil (aa 18-299), 
shifted the protein to be eluted in the void peak, corresponding to a molecular weight 
> 1300 kDa. Several attempts to purify CARMA1-CARD together with the full coiled-coil 
were similarly unsuccessful. These data on CARMA1 are consistent with the later 
published observations by Qiao et al. (2013) [103], which showed by EM negative stain 
analysis that the construct aa 1-295 (eluted in the void) forms protein clusters.  
 CARD9 behaved overall similar to CARMA1, although SEC-MALLS analysis of the 
construct containing half of the coiled-coil domain was successful and demonstrated a 
dimeric protein. However, several attempts to purify the entire CARD-coiled-coil 
construct were not successful neither, indicating that adding longer coiled-coil 
fragments is pulling CARD9 into aggregation as well. This suggests that not only 
domain structure and cellular function of CARMA1 and CARD9’s are similar, but also 
the behaviour of their individual molecular building blocks.  
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6.6 Study of filamentous assemblies 
BCL10 is a protein prone to aggregation. During the course of this work, other groups 
also reported their difficulties with BCL10 [156]. The use of an MBP-tag finally proved 
to be successful and several BCL10 constructs appeared to be soluble. However, during 
the course of this work it was shown that BCL10 forms a helical filament after its 
MBP-tag is cleaved off and hence, I decided to set up the reported polymerisation 
assay to test if not only CARMA1 is able to increase polymerisation of BCL10, but also 
CARD9 to investigate what difference the additional coiled-coil fragments may have on 
the ability to nucleate the filaments. 
 The fluorescence polarisation assays performed in this study were based on the 
experiments performed by Qiao et al. (2013) [103]. Purification as well as labelling 
conditions were taken over in detail as described in the publication. In addition, I have 
been in contact with the group leader Professor Hao Wu to ensure purification of 
MBP-BCL10 and labelling were performed according to their protocols. However, as 
seen in section 5.5.4, the cleavage of the MBP-tag can be clearly followed, whereas 
polymerisation of BCL10 molecules cannot be observed within 2h nor after leaving the 
solution at room temperature overnight. Even the addition of CARMA1 to the FPA 
sample did not show any difference.  
 There are similarities between CARMA1/BCL10 and NOD2/RIP2 and similar to 
CARMA1, NOD2  oligomerises when activated.  Furthermore, both their downstream 
effector domains are prone to aggregate heavily when being purified individually and 
soluble purification can only be achieved using a solubility enhancement tag. 
Therefore, the question arose if the new observation about BCL10 filament formation 
can be applied to RIP2-CARD, where NOD2 would nucleate and enhance RIP2 filament 
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formation? FPA experiments were designed and executed similar to BCL10/CARMA1 
and are presented in section 4.4.3 of this work. However, very much to our surprise we 
could not observe RIP2-CARD polymerisation, although the MBP-tag had clearly been 
cleaved. Hence, similar as observed for CARMA1, the addition of NOD2 did not 
nucleate RIP2-CARD filament formation.  
 Our inability to reproduce these FPA experiments is supporting the critical 
voices suggesting that the recently reported CARD filaments may be an artefact of 
CARDs simply being overexpressed. In the literature there are contradicting reports of 
the subcellular distribution of overexpressed BCL10. Guiet and Vito (2000) [105] have 
reported that BCL10 is localised in the cytoplasm as filamentous structures. On the 
other hand, Thome et al. (2001) [166] show only a granular staining pattern of BCL10 
in the cytoplasm of transfected HeLa cells, whereas filamentous structures were only 
observed with a significant higher concentrations of the BCL10 expression vector. At 
present, we cannot explain why neither BCL10 nor RIP2 oligomerise in our assays, in 
contrast to published studies, and believe that further studies are required to fully 
understand the significance of fibre formation and its physiological role. 
 
 
 
 
 
 
 
 
Discussion and outlook | 6 
 
219 
 
6.7 Future directions 
In my thesis I wanted to address the question if there is a common mode of interaction 
in the CARD subfamily. We assumed, based on studies with other members of the 
death domain superfamily, that CARDs may either form “canonical” 1:1 complexes or 
may form multi-protein assemblies as observed in the PIDDosome for example. 
However, during the course of this work another mechanism for assembly of death 
domain family member containing complexes was identified – the formation of 
filaments. Filament formation is still a rather controversial  topic and a key question for 
future studies is to investigate how relevant filament formation is in a physiological 
context and identify how many other members of this domain superfamily may behave 
in such a fashion. 
I also aimed to describe the intramolecular interaction between the tandem CARDs of 
NOD2, and its intermolecular interaction with the CARD of RIP2 in molecular detail. 
While I was able to provide further insight into the binding surfaces involved in these 
interactions using mutagenesis combined with biochemical and biophysical assays, 
ultimately an atomic structure is required to fully understand their architecture. 
However, extensive crystallisation trials in our group have not been able to produce 
any crystals. These studies had focused on the human and mouse proteins and it might 
now be necessary to extend these studies to other proteins from organisms whose 
sequences might be more amenable to crystallisation. Alternatively, other methods 
such as using crystallisation chaperones may be required to reveal the structural 
secrets of the NOD2-RIP2 complex. 
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Appendix 
A 1-1 NMR titration experiment of NOD2 tandem CARDs. 1H-15N-TROSY-HSQC of 
15N-CARDa alone (blue) and in complex with NOD2-CARDb (red). Spectra recoded at 
25 °C. Buffer: 100 mM NaCl, 20 mM Na-Phosphate pH 7.1 and 2 mM TCEP. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
15N 
1H 
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A 2-1 Expression vectors used in this study. Figure for pET52-47, pGST and pHMBP 
were kindly provided by Vangelis Christodoulou. Figure showing pET49b was adapted 
from http://www.merckmillipore.com. 
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A 2-2 Protein sequences of all human CARDs. These CARD constructs have been used 
for the small scale expression and solubility screening in Chapter 3. 
 
Protein Residues Primary Sequence 
NOD1 9-104 
MEIIPSESHPHIQLLKSNRELLVTHIRNTQCLVDNLLKNDYFSAEDA
EIVCACPTQPDKVRKILDLVQSKGEEVSEFFLYLLQQLADAYVDLRP
WL 
NOD1 ext 15-138 
ESHPHIQLLKSNRELLVTHIRNTQCLVDNLLKNDYFSAEDAEIVCAC
PTQPDKVRKILDLVQSKGEEVSEFFLYLLQQLADAYVDLRPWLLEIG
FSPSLLTQSKVVVNTDPVSRYTQQLRHHLG 
NOD2 ab 28-218 
MCSQEAFQAQRSQLVELLVSGSLEGFESVLDWLLSWEVLSWEDYEGF
HLLGQPLSHLARRLLDTVWNKGTWACQKLIAAAQEAQADSQSPKLHG
CWDPHSLHPARDLQSHRPAIVRRLHSHVENMLDLAWERGFVSQYECD
EIRLPIFTPSQRARRLLDLATVKANGLAAFLLQHVQELPVPLALPLE
AAT 
NOD2 a 28-120 
MCSQEAFQAQRSQLVELLVSGSLEGFESVLDWLLSWEVLSWEDYEGF
HLLGQPLSHLARRLLDTVWNKGTWACQKLIAAAQEAQADSQSPKLH 
NOD2 b 120-218 
HGCWDPHSLHPARDLQSHRPAIVRRLHSHVENMLDLAWERGFVSQYE
CDEIRLPIFTPSQRARRLLDLATVKANGLAAFLLQHVQELPVPLALP
LEAAT 
RIP2 435-528 
IAQQWIQSKREDIVNQMTEACLNQSLDALLSRDLIMKEDYELVSTKP
TRTSKVRQLLDTTDIQGEEFAKVIVQKLKDNKQMGLQPYPEILVVSR 
IPAF 1-92 
MNFIKDNSRALIQRMGMTVIKQITDDLFVWNVLNREEVNIICCEKVE
QDAARGIIHMILKKGSESCNLFLKSLKEWNYPLFQDLNGQSLFHQ 
NALP1 1377-1469 
QLLHFVDQYREQLIARVTSVEVVLDKLHGQVLSQEQYERVLAENTRP
SQMRKLFSLSQSWDRKCKDGLYQALKETHPHLIMELWEKGSKKG 
Caspase-1 1-92 
MADKVLKEKRKLFIRSMGEGTINGLLDELLQTRVLNKEEMEKVKREN
ATVMDKTRALIDSVIPKGAQACQICITYICEEDSYLAGTLGLSAD 
ASC 105-195 
QSAAKPGLHFIDQHRAALIARVTNVEWLLDALYGKVLTDEQYQAVRA
EPTNPSKMRKLFSFTPAWNWTCKDLLLQALRESQSYLVEDLERS 
Caspase-9 1-112 
MDEADRRLLRRCRLRLVEELQVDQLWDALLSRELFRPHMIEDIQRAG
SGSRRDQARQLIIDLETRGSQALPLFISCLEDTGQDMLASFLRTNRQ
AAKLSKPTLENLTPVVLR 
APAF1 1-98 
MDAKARNCLLQHREALEKDIKTSYIMDHMISDGFLTISEEEKVRNEP
TQQQRAAMLIKMILKKDNDSYVSFYNALLHEGYKDLAALLHDGIPVV
SSSS 
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Caspase-2 28-128 
GVCGMHPHHQETLKKNRVVLAKQLLLSELLEHLLEKDIITLEMRELI
QAKVGSFSQNVELLNLLPKRGPQAFDAFCEALRETKQGHLEDMLLTT
LSGLQHV 
CARD8 336-431 
ASAPPPFSGAAFVKENHRQLQARMGDLKGVLDDLQDNEVLTENEKEL
VEQEKTRQSKNEALLSMVEKKGDLALDVLFRSISERDPYLVSYLRQQ
NL 
CARD9 1-104 
MSDYENDDECWSVLEGFRVTLTSVIDPSRITPYLRQCKVLNPDDEEQ
VLSDPNLVIRKRKVGVLLDILQRTGHKGYVAFLESLELYYPQLYKKV
TGKEPARVFS 
RAIDD 1-101 
MEARDKQVLRSLRLELGAEVLVEGLVLQYLYQEGILTENHIQEINAQ
TTGLRKTMLLLDILPSRGPKAFDTFLDSLQEFPWVREKLKKAREEAM
TDLPAGD 
RAIDD ext 1-136 
MEARDKQVLRSLRLELGAEVLVEGLVLQYLYQEGILTENHIQEINAQ
TTGLRKTMLLLDILPSRGPKAFDTFLDSLQEFPWVREKLKKAREEAM
TDLPAGDRLTGIPSHILNSSPSDRQINQLAQRLGPEWEPMVL 
Iceberg 1-90 
MADQLLRKKRRIFIHSVGAGTINALLDCLLEDEVISQEDMNKVRDEN
DTVMDKARVLIDLVTGKGPKSCCKFIKHLCEEDPQLASKMGLH 
RIG-I ab 2-190 
TTEQRRSLQAFQDYIRKTLDPTYILSYMAPWFREEEVQYIQAEKNNK
GPMEAATLFLKFLLELQEEGWFRGFLDALDHAGYSGLYEAIESWDFK
KIEKLEEYRLLLKRLQPEFKTRIIPTDIISDLSECLINQECEEILQI
CSTKGMMAGAEKLVECLLRSDKENWPKTLKLALEKERNKFSELWIVE
K 
RIG-I a 2-91 
TTEQRRSLQAFQDYIRKTLDPTYILSYMAPWFREEEVQYIQAEKNNK
GPMEAATLFLKFLLELQEEGWFRGFLDALDHAGYSGLYEAIES 
RIG-I b 91-190 
SWDFKKIEKLEEYRLLLKRLQPEFKTRIIPTDIISDLSECLINQECE
EILQICSTKGMMAGAEKLVECLLRSDKENWPKTLKLALEKERNKFSE
LWIVEK  
MDA5 ab 1-201 
MSNGYSTDENFRYLISCFRARVKMYIQVEPVLDYLTFLPAEVKEQIQ
RTVATSGNMQAVELLLSTLEKGVWHLGWTREFVEALRRTGSPLAARY
MNPELTDLPSPSFENAHDEYLQLLNLLQPTLVDKLLVRDVLDKCMEE
ELLTIEDRNRIAAAENNGNESGVRELLKRIVQKENWFSAFLNVLRQT
GNNELVQELTGSD 
MDA5 a 1-100 
MSNGYSTDENFRYLISCFRARVKMYIQVEPVLDYLTFLPAEVKEQIQ
RTVATSGNMQAVELLLSTLEKGVWHLGWTREFVEALRRTGSPLAARY
MNPELT  
MDA5 b 112-201 
DEYLQLLNLLQPTLVDKLLVRDVLDKCMEEELLTIEDRNRIAAAENN
GNESGVRELLKRIVQKENWFSAFLNVLRQTGNNELVQELTGSD  
MAVS 1-95 
MPFAEDKTYKYICRNFSNFCNVDVVEILPYLPCLTARDQDRLRATCT
LSGNRDTLWHLFNTLQRRPGWVEYFIAALRGCELVDLADEVASVYQS
Y 
Caspase-4 1-95 
MAEGNHRKKPLKVLESLGKDFLTGVLDNLVEQNVLNWKEEEKKKYYD
AKTEDKVRVMADSMQEKQRMAGQMLLQTFFNIDQISPNKKAHPNMEA 
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Caspase-5 50-150 
PNTDQKSTSVKKDNHKKKTVKMLEYLGKDVLHGVFNYLAKHDVLTLK
EEEKKKYYDTKIEDKALILVDSLRKNRVAHQMFTQTLLNMDQKITSV
KPLLQIE 
Caspase-12 1-95 
MADEKPSNGVLVHMVKLLIKTFLDGIFDDLMENNVLNTDEIHLIGKC
LKFVVSNAENLVDDITETAQTAGKIFREHLWNSKKQLSSDISSD 
BCL10 10-114 
PSLTEEDLTEVKKDALENLRVYLCEKIIAERHFDHLRAKKILSREDT
EEISCRTSSRKRAGKLLDYLQENPKGLDTLVESIRREKTQNFLIQKI
TDEVLKLRNIKLEHL 
CARMA1 18-110 
EEDALWENVECNRHMLSRYINPAKLTPYLRQCKVIDEQDEDEVLNAP
MLPSKINRAGRLLDILHTKGQRGYVVFLESLEFYYPELYKLVTGKE 
CARMA2 6-111 
RRDSALTALDEETLWEMMESHRHRIVRCICPSRLTPYLRQAKVLCQL
DEEEVLHSPRLTNSAMRAGHLLDLLKTRGKNGAIAFLESLKFHNPDV
YTLVTGLQPDVD 
CARMA3 12-118 
EEAGAGSGSEAEEDALWERIEGVRHRLARALNPAKLTPYLRQCRVID
EQDEEEVLSTYRFPCRVNRTGRLMDILRCRGKRGYEAFLEALEFYYP
EHFTLLTGQEPAQ 
CARD6 1-103 
MATESTPSEIIERERKKLLEILQHDPDSILDTLTSRRLISEEEYETL
ENVTDLLKKSRKLLILVQKKGEATCQHFLKCLFSTFPQSAAICGLRH
EVLKHENTV 
COP1 1-99 
MADKVLKEKRKLFIHSMGEGTINGLLDELLQTRVLNQEEMEKVKREN
ATVMDKTRALIDSVIPKGAQACQICITYICEEDSYLAETLGLSAALQ
AVQDN 
ARC 1-95 
MGNAQERPSETIDRERKRLVETLQADSGLLLDALLARGVLTGPEYEA
LDALPDAERRVRRLLLLVQGKGEAACQELLRCAQRTAGAPDPAWDWQ
H 
BinCARD 1-116 
MTDQTYCDRLVQDTPFLTGHGRLSEQQVDRIILQLNRYYPQILTNKE
AEKFRNPKASLRVRLCDLLSHLQRSGERDCQEFYRALYIHAQPLHSR
LPSRHALRKFHITNHACLVLAR 
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A 2-3 Protein sequences of protein-tags.  
Tag aa MW [kDa] Primary Sequence 
His 20 2.2 MAHHHHHHSAALEVLFQ’GPG… 
GST 237 27.5 
MAPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDK
WRNKKFELGLEFPNLPYYIDGDVKLTQSMAIIRYIADKHN
MLGGCPKERAEISMLEGAVLDIRYGVSRIAYSKDFETLKV
DFLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFMLYDALD
VVLYMDPMCLDAFPKLVCFKKRIEAIPQIDKYLKSSKYIA
WPLQGWQATFGGGDHPPKSDLVPRHNQALEVLFQ’GPG… 
His-MBP 392 43.0 
MAHHHHHHSAAKIEEGKLVIWINGDKGYNGLAEVGKKFEK
DTGIKVTVEHPDKLEEKFPQVAATGDGPDIIFWAHDRFGG
YAQSGLLAEITPDKAFQDKLYPFTWDAVRYNGKLIAYPIA
VEALSLIYNKDLLPNPPKTWEEIPALDKELKAKGKSALMF
NLQEPYFTWPLIAADGGYAFKYENGKYDIKDVGVDNAGAK
AGLTFLVDLIKNKHMNADTDYSIAEAAFNKGETAMTINGP
WAWSNIDTSKVNYGVTVLPTFKGQPSKPFVGVLSAGINAA
SPNKELAKEFLENYLLTDEGLEAVNKDKPLGAVALKSYEE
ELVKDPRIAATMENAQKGEIMPNIPQMSAFWYAVRTAVIN
AASGRQTVDEALKDAQTNSSSAALEVLFQ’GPG… 
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A 4-1 Small scale expression and solubility screening of NOD2 tandem CARDs with 
mutations inserted in CARDa. 
 
 
 
 
 
 
 
 
 
 
 
 
A 4-2 Small scale expression and solubility screening of NOD2 tandem CARDs with 
mutations inserted in CARDb. +T: plus thrombin cleavage site, -T: original wildtype 
linker. 
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A 6-1 Sequence alignment of NOD2-CARDs with tandem DEDs. The primary 
sequences of Caspase-8 and MC159 DEDs are aligned with the two CARDs of NOD2. 
Highlighted in green are residues involved in the DED intramolecular interaction. 
Additionally, in MC159, highlighted residues are distinguished between fully buried 
(green) and partially buried (light green). S49, W59, W693 of NOD2-CARDa are shown 
in red, whereas other residues analysed via ITC but not affecting CARDb or CARDa 
binding respectively are shown in grey. Alignment was performed using ClustalW 
within the JalView application.  
 
 
